Investigating cancer cell dormancy and recurrence in the bone marrow niche by Casson, Jake
Investigating Cancer Cell Dormancy 
and Recurrence in the  
Bone Marrow Niche 
 
 
Jake Casson 
(BSc Hons) 
 
 
Submitted in fulfilment of requirements for the degree of Doctor of Philosophy (PhD) 
 
Centre for the Cellular Microenvironment 
Institute of Molecular, Cell and Systems Biology 
School of Medical Veterinary and Life Sciences 
University of Glasgow 
Glasgow, G12 8QQ 
August 2019 
 
 
  
 
 
 
 
 
 
 
‘There are no facts, only interpretations’ 
Friedrich Nietzsche 
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  Summary 
Breast cancer is the most commonly diagnosed form of cancer in 
women. The spread of metastatic cancer cells to secondary sites, such 
as the bone marrow, is the leading cause of mortality. Upon entering the 
bone marrow, disseminated breast cancer cells enter a period of cycling 
quiescence, termed dormancy. Here, cells are able to reside in the new 
environment for years before re-entering a growth phase, known as 
recurrence.  
 The relationship between these breast cancer cells and resident 
mesenchymal stem cells (MSCs) is of clinical importance. MSCs have been 
implicated in the initiation of breast cancer dormancy. The precise 
mechanism of recurrence is not known, but there is evidence to suggest 
the relationship between breast cancer and MSCs is of importance. 
Research has traditionally used two-dimensional culture techniques, 
however these models lack the complexity and three-dimensional nature 
of the bone marrow environment. 
 The project aimed to develop a novel, bio-responsive in vitro 
three-dimensional bone marrow model. Magnetic nanoparticle-loaded 
breast cancer and mesenchymal stem cells were levitated using an 
external magnetic field to form multicellular spheroids. These spheroids 
were subsequently located within a Type I collagen gel. The breast 
cancer cells within the spheroid exhibited quiescent behaviour when 
cultured in the three-dimensional environment when exposed to MSC-
derived extracellular vesicles. This quiescent behaviour was reversed 
when the breast cancer spheroids were exposed to cytokines IL-6 and 
TGFβ, associated with cellular repair.  
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CHAPTER 1 INTRODUCTION 
1 
1 Introduction 
1.1 Breast Cancer 
Breast cancer is the most commonly diagnosed form of cancer in 
women in the UK, with around 55,000 women every year being diagnosed 
(Breast Cancer Now, 2016). It is forecast that as many as 1 in 8 women in 
the UK will develop breast cancer in their lifetime. Although it primarily 
affects women, annually, 350 men are also diagnosed in the UK. Despite 
increased awareness, 1000 women still die from the disease every month, 
in the UK (Breast Cancer Now, 2016). Breast cancer commonly 
metastasises, from the original tumour site to distant organs; this is a 
major factor in disease prognosis.  It is estimated that 20-30% of those 
diagnosed will develop tumours at secondary sites (Breast Cancer Now, 
2016). This spread of metastatic tumour cells throughout the body is the 
eventual cause of the vast majority of breast cancer-related mortality 
(Cancer.net, 2018). Following mastectomy or lumpectomy many patients 
will still go on to develop secondary tumours many years later after the 
initial diagnosis and therapy, demonstrating that breast cancer cells 
(BCCs) have a prolonged dormant phase. Whilst both improved screening 
methods and an increase in the number of effective drugs will help 
patients with relapsed cancer, research into this dormancy phenomenon 
is urgently required (American Cancer Society, 2017). 
The most common form of breast cancer is a type of carcinoma, 
termed adenocarcinoma, is derived from epithelial cells and originates in 
the glandular tissue often in the milk ducts or milk-producing tissue 
(American Cancer Society, 2017). Whilst the actual causes of breast 
cancer are not fully understood, there are a range of contributing factors 
including age, family history, age during first birth and obesity (NHS, 2016; 
MacMahon et al, 1973). 
CHAPTER 1 INTRODUCTION 
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1.1.i  Breast Cancer Subtypes 
There are five major breast cancer subtypes, which can be 
determined by the expression of several markers (table 1-1), in particular 
several receptor proteins expressed on the cell surface: Oestrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2). These subtypes can be further divided into three 
classes: luminal, HER2 over-expression and triple negative phenotypic 
(TNP; tumours lacking all three previously described surface receptors) 
tumours (MacMahon et, 1973). Luminal-type carcinomas are more often 
found within older patients, with the converse being true for basal TNP-
type carcinomas (Carey et al, 2006). TNP-type carcinomas are also noted 
as being more aggressive and readily metastatic as they often derive from 
differentiated primary tumours, unlike luminal-type carcinomas, which 
are often poorly differentiated (Scully et al, 2012). 
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Table 1-1 Breast cancer cell subtypes. Five commonly recognised breast 
cancer subtypes and their immunohistochemical markers. Oestrogen 
receptor (ER), progesterone receptor (PR), human epidermal growth 
factor receptor 2 (HER2). Basal markers cytokeratin 5/14 or epidermal 
growth factor receptor (EGFR). 
  
Subtype Markers 
Luminal A [ER+|PR+] HER2-KI67- 
Luminal B ER+|PR+] HER2-KI67+ 
ER+|PR+] HER2+KI67+ 
HER2 over-expression [ER-PR-] HER2+ 
Basal [ER-PR-] HER2-, basal marker + 
Normal-like [ER+|PR+] HER2- KI67- 
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1.2 Breast Cancer Cell Lines 
1.2.i MDA-MB-231 
MDA-MD-231 is a triple negative cell line, lacking expression of the 
oestrogen and progresterone receptors (ER and PR respectively), and HER2 
on the cell surface. However epidermal growth factor receptor (EGFR) is 
expressed (Subik et al, 2010). This cell line has several surface marker 
variations that contribute to its invasive phenotype; (i) low expression of 
claudin-3 and claudin-4, proteins associated with the formation of tight 
junctions between cells, thus reducing cell-cell adhesion (Herschkowitz et 
al, 2007); (ii) increased expression of N-cadherin on the cell surface, 
associated with increased motility and invasiveness (Nieman et al, 1999). 
Unlike E-cadherin, expression of N-cadherin reduces cell-cell contact 
enabling cell motility, leading to metastasis. This metastatic phenotype 
gives cells a long, thin appearance (Figure 1-1). MDA-MB-231 is often used 
as a cell model for aggressive breast cancer in vitro, however it is poorly 
invasive unless directly introduced to the circulation in vivo (Adorno et al, 
2009). Ki67 is a marker protein for active cell cycle, expressed at all stages 
of the cell cycle except G0; MDA-MB-231 expresses this at low levels as it 
is a slower growing cell line compared with others, also expressing marker 
profiles associated with cancer stem cells, namely CD44+/CD24-/low 
(Holliday and Spiers, 2011). 
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1.2.ii MCF7 
The MCF7 cell line is derived from the pleural effusion of a patient 
by the Michigan Cancer Foundation in the 1970s.  This breast cancer cell 
line is well established and commonly used in research (Soule et al, 1973). 
It is a luminal-type cell line that expresses both ER and PR on the cell 
surface (figure 1-1), but does not express HER2 (Subik et al, 2010). This 
hormone-dependency has made this cell line ideally suited for studying 
the relationship between breast cancer and hormones since its isolation 
(Katzenellenbogen et al, 1987; Masiakowski et al, 1982; Vickers et al, 
1988; Wilder et al, 2018). 
E-cadherin is strongly expressed in MCF7 cells, causing cells to 
tightly bind together giving the cell an epithelial phenotype (figure 1-1). 
These cells are therefore not considered highly invasive. However, MCF7 
cells exhibit high expression (~ 90%) of the prognostic factor Ki67, 
indicating that the cells are readily proliferate in vitro (Subik et al, 2010). 
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Figure 1-1 Schematic of the breast cancer cell lines MCF7 and MDA-MB-
231. Luminal A type MCF7 expresses ER and PR, along with E-cadherin 
leading to a epithelial-like phenotype. Basal TNP MDA-MB-231 does not 
express ER or PR, in addition expression of N-cadherin prevents tight cell-
cell binding causing the mesenchymal-like phenotype and giving this cell 
line a more aggressive behaviour. 
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  1.3 The Bone Marrow Niche 
The bone marrow microenvironment is richly populated with a 
range of different cell types. In particular, are the mesenchymal and 
haematopoietic stem cells (MSC and HSC respectively).  
MSCs are adult stem cells that reside in many organs of the body, 
including the bone marrow (BM). MSCs are multipotent and are able to 
self-renew; producing mesenchymal lineage cells, including chondrocytes, 
adipocytes, osteoblasts, and myoblasts dependent on signalling cues from 
the environment (Baksh et al., 2007). MSCs play an important role in the 
healing and regeneration process, have immunomodulatory capacity, and 
are a key support of HSCs, the progenitors of blood and immune cells 
(Seita and Weissmann, 2010). MSCs can be obtained from multiple tissue 
sources, and several subsets exist with subtly different biological 
activities, making identification a complex process. The International 
Society for Cellular Therapy defines the minimal criteria for MSCs as 
follows: (1) cells must be plastic adherent under standard culture 
conditions; (2) cells must be positive for CD105, CD73, and CD90; negative 
for CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR surface 
molecules; and (3) cells must have the ability to differentiate into 
osteoblasts, adipocytes, and chondroblasts in vitro (Dominici et al., 2006). 
These properties can be validated by quantitative RNA analysis, functional 
analysis of relevant surface markers, and proteomic analysis (Galipeau et 
al., 2015).  
It has been widely accepted that all MSCs express STRO-1 and 
CD271 (Casado-Díaz et al., 2016); many subpopulations of MSCs can be 
identified by the presence of marker proteins (table 1-2). 
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Table 1-2 Markers used for identification of MSC subpopulations and 
their function in vivo. 
Marker Source Function Reference 
STRO-1+ BM Promote angiogenesis. 
May not support HSC 
engraftment. Also 
expressed by erythroid 
cells. 
Mo et al., 
2016; Lv et 
al., 2014 
CD271+ BM, Adipose 
tissue 
Express higher levels of 
differentiation related 
genes than cells 
isolated by plastic 
adherence. Enhanced 
chondral repair. 
Express higher levels of 
immunesuppressive 
cytokines. Enhance HSC 
engraftment ability. 
Álvarez-
Viejo, 2015; 
Mo et al., 
2016; Lv et 
al., 2014 
CD105+ BM, 
Umbilical 
cord blood, 
Wharton’s 
jelly 
Enhanced myogenic 
differentiation. 
Mo et al., 
2016 
CD146+ BM, 
Skeletal 
muscle 
pericytes 
Enhanced osteogenic 
differentiation. 
Produce 
cardiomyocytes and 
proangiogenic factors.  
Mo et al., 
2016 
CD44+ BM Increased proliferation 
and homing capacity. 
Mo et al., 
2016 
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Nestin+ BM HSC niche and cellular 
support. 
Mo et al., 
2016 
CXCR4+ BM Enhanced migration 
and engraftment. 
Mo et al., 
2016 
PDGFRα+ Fetal BM HSC supportive. 
Express nestin. 
Pinho et al., 
2013 
CD51+ Fetal BM HSC supportive. 
Express nestin. 
Pinho et al., 
2013 
CD49f+ BM Multipotent, CFU-Fs. 
Knock-down causes HSC 
differentiation. 
Lv et al., 
2014 
 
MSCs and other key cell types reside together within the bone 
marrow in two distinct niches: the endosteal niche at the edge of the bone 
marrow; lined with osteoblasts and remodelled by osteoclasts, and the 
perivascular niche situated towards the centre of the marrow where these 
cells line the vessels. CXCL12 is a chemokine highly expressed by MSCs and 
CXCL12-abundant reticular (CAR) cells within the perivascular niche 
(Mueller et al, 2001). CAR cells are located adjacent to sinusoids in the 
BM, and have been found to have a role in haematopoiesis, predominantly 
in supporting B cells (Eltoukhy et al. 2016). CXCL12 is recognised by the 
cell surface receptor CXCR4 and is required for colonisation of the bone 
marrow niche by HSCs. This receptor-ligand relationship leads to physical 
contact between HSCs and MSCs within each niche (Kiel et al, 2005). 
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1.3.i Breast Cancer Metastasis to the Bone Marrow 
Metastasis occurs when cancer cells leave the primary tumour site 
and disseminate to the lymph nodes and distant organs. To enable 
metastasis, cells within the tumour go through an epithelial-to-
mesenchymal transition (EMT) (Chaffer et al, 2016) and are able to 
circulate throughout the patient; at this point they are considered 
circulating tumour cells (CTCs). Ordinarily the immobile tumour cells at 
the primary site exhibit an adherent phenotype via proteins such as E-
cadherin, and integrin family members, but upon initiation of EMT a 
downregulation of E-cadherin in favour of N-cadherin in addition to the 
upregulation of mesenchymal markers such as vimentin and fibronectin 
(table 1-3), promotes cell migration away from the  tumour and into the 
local tissue and circulation (Poste and Fidler, 1980). Most of these cells 
will not establish secondary tumours, often being destroyed upon entry 
into the bloodstream by high shearing forces (Kumar and Weaver, 2009). 
However, cells which survive the mechanical forces present in the 
bloodstream induce a dramatic reorganisation of the cytoskeleton, 
strengthening the cell integrity; by doing so these cells persist through the 
transition stage, allowing adherence of cells to the vascular wall before 
properly exiting the blood flow (Wendt et al, 2011). 
 
 
 
 
 
 
CHAPTER 1 INTRODUCTION 
11 
Table 1-3 EMT markers. Regulation of marker genes as cells undergo 
epithelial-to-mesenchymal transition, with the reverse true of 
mesenchymal-to-epithelial transition (adapted from Logullo et al., 2010 
and Kasimir-Bauer et al., 2012). 
Marker Regulation in EMT 
E-Cadherin ↓ 
N-Cadherin ↑ 
TGFβ1 ↑ 
Snail ↑ 
Occludin ↓ 
Vimentin ↑ 
ALDH1 ↑ 
Upon successful transfer into a distant tissue, these CTCs become 
known as disseminated tumour cells (DTCs). In the case of the bone 
marrow, breast cancer DTCs have been found to home in on specific areas 
rich in E-selectin (figure 1-2; Kang et al, 2016), a protein expressed by 
endothelial cells that promotes shear-resistant adhesion. Once through 
the vessel wall, the DTCs will encounter the extracellular matrix (ECM); a 
three-dimensional network of extracellular macromolecules comprised 
largely of collagens, but additionally fibronectin, elastins and laminins. 
These structures support surrounding cells through binding focal adhesions 
– transmembrane integrins and associated protein complexes that attach 
to the internal cytoskeleton (Buck and Horwitz, 1987). Surviving the initial 
entry into this new tissue requires the DTCs to upregulate expression of 
integrin genes to adhere to the surrounding ECM (Mego et al, 2010). Simply 
binding the ECM would provide the DTC with physical support in the new 
environment, but local chemistry will cause it to home to areas where it 
might be maintained. This movement requires the DTC to degrade the ECM 
components using a family of endopeptidases known as matrix 
metalloproteinases (MMPs). Simply, these are proteins that break down 
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the amine bonds within ECM components to weaken the matrix and permit 
the cell through (Dano et al, 2005) and may be secreted or membrane-
bound (Klein and Bischoff, 2011). 
Once in situ the DTC is now able to reverse the EMT process and 
revert to a stationary epithelial-type cell; known as mesenchymal-to-
epithelial transition (MET). The DTC requires external stimuli to initiate 
MET and in the case of entry into the bone marrow, much of this comes 
from resident MSCs. In particular, the CXCR4-CXCL12 signalling axis is used 
to detect a hospitable secondary site (Ray et al, 2015). DTCs express 
CXCR4, the cognate receptor for the ligand CXCL12, on their surface 
(figure 1-2). Silencing of this removes the metastatic potential of the DTC 
as it is unable to respond to the concentration gradient of CXCL12 
produced by MSCs and cancer-associated fibroblasts  (Liang et al, 2005). 
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Figure 1-2 Breast cancer cells within the bone marrow niche. Circulating 
breast cancer cells are disseminated from the primary tumour site into 
the blood stream. These cells begin to adhere to the vessel walls in 
response to E-selectin and move between the endothelial cells, entering 
the BM. Reacting to environmental CXCL12 via surface CXCR4 receptors, 
BCCs are able to home in on MSC-maintained niches, excluding HSCs and 
taking residence in the BM. 
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Approximately 10-15% of patients are diagnosed with an aggressive 
type of breast cancer and will develop metastases within 3 years of 
detection of the primary tumour (Weigelt et al, 2005; American Cancer 
Society, 2017). Breast cancer does not successfully metastasise 
throughout the body; instead tumour cells tend to favour a suitable 
microenvironment that will protect them from the body’s immune 
response. In this regard, BCCs preferentially disseminate to the bone 
marrow, lung and liver (Lee, 1985); tissues that confer an environment 
favourable for breast cancer growth (Psaila et al, 2009). The BM is the 
most common site of BCC metastasis, with DTCs preferentially locating to 
the spine, pelvis and long bones of the limbs. This is believed to be due 
to their expression of osteomimetic genes, such as osteocalcin and 
osteopontin (Rucci and Teti, 2010) permitting the DTCs survival in the new 
environment. These factors alter the bone microenvironment, not only 
affecting the remodelling of bone through induced apoptosis of 
osteoblasts (Standal et al, 2004), but impairing the osteogenesis of MSCs 
by ectopic expression of Runx2 (Pratap et al, 2008). This allows the DTCs 
to remain in the bone marrow microenvironment, protected by MSCs 
drawn to them through the CXCR4-CXCL12 axis. Macrophages within the 
bone marrow will be polarised to an anti-inflammatory, tumour-
supporting phenotype through the secretion of cytokines (Sinha et al, 
2005; Sica et al,2006), thus will be unable to remove invading DTCs. 
Morbidity following metastasis to the bone is due to the effects the DTCs 
have on the surrounding tissue; hypercalcaemia, a condition indicated by 
an increase in the calcium levels in the blood, leads to a weakening of the 
bones as calcium leeches out into the environment (Coleman and Rubens, 
1987). 
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1.3.ii Breast Cancer Dormancy Within The Bone 
Marrow 
Once relocated in favourable tissue sites such as the bone marrow, DTCs 
can become dormant, causing no pathology. Dormancy also enables the 
cells to avoid both detection (due to their negligible size) and drug 
treatments (chemotherapy), due to their reduced proliferation and 
decreased metabolism. Cancer stem cells (CSCs) make up a proportion of 
the cells within a dormant tumour. These cells are defined as able to self-
renew and initiate new tumours (McDermott and Wicha, 2010). Similar to 
a tumour-initiating cell, a DTC that forms new tumours, these CSCs can 
develop new tumours, with the major difference being the time scale 
(Velasco-Velázquez et al, 2012). 
The phenomenon of dormancy can be described as DTCs that maintain a 
presence at a secondary site without forming into a detectable tumour. 
These dormant cells have exited the active cell cycle so do not behave 
like traditional cancer cells that are metabolically overactive, thus are 
not responsive to traditional chemotherapies (Aguirre-Ghiso, 2007). In 
addition dormant cells are often unable to initiate angiogenesis, actively 
suppressing it thereby maintaining a population by a balance of cell death 
and division (Holmgren et al, 1995). 
To achieve dormancy, cells must exit the cell cycle and enter G0 
phase (figure 1-3). Each stage in the cell cycle is regulated by cyclins and 
cyclin-dependent kinases, which in turn are regulated cyclin-dependent 
kinase inhibitors (CKIs), such as p21 and p27.  The inability for cells to 
move into G1 phase can be confirmed in breast cancer cells with an 
increase in the expression of CDK inhibitors p21 and p27 as well as 
inhibiting the expression of cyclins, checkpoint proteins required for 
successful progression of the cell cycle (Kim et al., 2010). A common 
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prognostic marker for breast cancer is the proliferative protein Ki67, 
which is present at all stages of cell cycle except for G0 (Bruno and 
Darzynkiewicz, 1992).  
Dormancy is essential for cancer cells to survive in a new 
environment, following metastasis. Once in a dormant state, breast 
cancer cells are able to resist chemotherapies. Chemotherapies, such as 
the breast cancer-specific lapatinib, work through exploiting the high 
proliferative rate of cancer cells, meaning dormant cancers are 
unaffected (Peyvandi et al., 2019). It is believed that treatment with anti-
proliferative agents can select for these resistant cells (Roesch et al, 
2013). In later stage tumours, dormancy has been shown to represent an 
important hallmark that facilitates immune evasion (Malladi et al., 2016). 
The current strategy to combat the existence of dormant cancer is to 
reawaken the cells, thereby making them vulnerable to chemotherapy and 
immune destruction. This is done by targeting dormancy-promoting 
components secreted into the microenvironment. In the case of breast 
cancer this can be done with cytokines such as IL-6 or TGFβ1 (Tivari et 
al., 2018). This is thought to recreate the conditions seen in tissue injury; 
damaged cells secrete these molecules into their environment to promote 
division of nearby cells to repair injured areas.  
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Figure 1-3 The cell cycle. The phases of cell cycle regulation; G0 indicates 
a quiescent state. A dividing cell passes through a series of stages 
described as the cell cycle. There are two gap phases (G1 and G2); S (DNA 
synthesis) phase, when the genetic material is duplicated; and M phase, 
where cellular mitosis separates the genetic material and the cell divides. 
Each stage is regulated by cyclins and cyclin-dependent kinases, which in 
turn are regulated by p21 and p27 (adapted from Yoon et al., 2012). 
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1.3.iii Breast Cancer Recurrence Within the Bone 
Marrow 
Cancer recurrence at secondary sites can occur years, on occasion 
decades, after declaration of remission. Recurrence is due to the re-entry 
into the cell cycle of the dormant micrometastases, which then 
proliferate and form tumours at the secondary site, such as the bone 
marrow. This is known as distant recurrence and is classed as stage IV 
cancer, with 34% patients living up to 5 years following this diagnosis; it 
is ultimately terminal (Susan G Komen Breast Cancer Foundation, 2018). 
Dormant DTCs that form a micrometastasis possess a balance 
between pro- (vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF)) and anti-angiogenic (thrombospondin, angiostatin) 
factors (Geleo et al., 2013). An imbalance reducing the effect of the anti-
angiogenic factors will result in the micrometasasis becoming 
vascularised, enabling growth out to tertiary sites. Tissue inhibitor of 
metalloproteinases 2 (TIMP-2) normally inhibits the effect of FGF on 
angiogenic initiation (Murphy et al., 1993). The tumour will then grow, 
initiating angiogenesis so that the inner cells can receive nutrients; it will 
continue to expand with the possibility of a secondary metastasis to a 
tertiary site. The exact cause of recurrence is unknown. There is a 
suggestion that the advancing age of the patient may play a role. For 
example, in osteoporotic patients, where a bone breakage will initiate 
release of injury signals that activate the dormant cells, causing them to 
leave G0 phase of the cell cycle and reinitiate cell division (Knupfer and 
PreiB, 2007) and migration through a downregulation of E-cadherin 
expression (Asgeirsson et al, 1998). When considering both the onset of 
breast cancer cell dormancy and recurrence, the cellular 
microenvironment and the interaction between cancer cells and resident 
cells within the bone marrow is critical.  
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1.4 Breast Cancer Cell Interaction with MSCs in The 
Bone Marrow 
There is an evolving understanding of how the bone marrow stem 
cell niche operates, with several signalling axes being identified as 
fundamental to MSC communication. MSCs use soluble factors such as stem 
cell factor (SDF), vascular cell adhesion molecule (VCAM), stem cell factor 
(SCF), angiopoietin-1 (ang1) and chemokines such as CXCL12 to enable 
cellular homing and cell-cell adhesion (Anthony et al., 2014; Tamplin et 
al., 2015). Evidence suggests that crosstalk emerges between the tumour 
cells, vascular endothelia and MSCs (Ridge et al., 2017). 
The interaction between resident MSCs and invading BCCs are 
integral to BCC long-term survival. Whilst there is a large body of 
literature on the communication between these two cell types within the 
tumour microenvironment, there is less information regarding 
communication within the marrow. This section will describe the various 
ways in which MSCs and BCCs are able to communicate and interact within 
the BM, which may ultimately be responsible for BCC dormancy and/or 
recurrence. Such communication can be indirect (eg. via cytokines, 
chemokines, growth factors and microvesicles) or direct (eg. via gap 
junctions). 
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1.4.i Direct Communication — Gap Junctional 
Intercellular Communication  
Gap junctions connect adjacent cells allowing direct cell-cell 
contact.  Gap junctions are channels, formed of a hexamer of connexin 
proteins, able to cross lipid membranes (Li et al, 2008). Typically, small 
molecules are transported through gap junctions. For example, it has been 
demonstrated that MSCs utilise gap junctions to transmit microRNAs 
(miRs) in order to influence HSC proliferation (Lim et al, 2011). These 
short miR nucleotides (19-23 bases) regulate gene expression through 
binding and subsequent degradation of intracellular mRNAs. Likewise, 
once BCCs have invaded the BM niche, they are also capable of developing 
gap junctions with MSCs (Walker et al., 2015), potentially allowing MSCs 
to transmit miRs that cause reduced BCC proliferation (figure 1-4; Gregory 
et al., 2011). For example, Lim et al (2011) demonstrated that miR-127, 
-197, -222 and -223 are increased in BCCs co-cultured with MSCs, affecting 
CXCL12 protein levels. This decrease of CXCL12 in BCCs provides an 
advantage to adapt dormancy within the bone marrow niche. The miRs 
delivered to BCCs are not limited to influencing proliferation; miR-21 has 
been documented as a strong tumour promoting miRNA (Sergina et al, 
2007) able to interfere with the expression of the apoptotic factor Bcl-2. 
In addition to this, miR-21 affects the p53 pathway (Frankel et al, 2008) 
and cellular proliferation.   
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Figure 1-4 Gap junction communication between MSCs and BCCs. The 
formation of a gap junction between MSCs and BCCs in close proximity 
allows the movement of small molecules such as miRs from one cell to 
another. In this scenario, MSC-derived miRs may be able to translocate 
into BCCs where they can prevent translation of mRNAs leading to a 
reduction in protein expressed. 
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1.4.ii Indirect Communication — Cytokines 
Cytokines are small proteins usually around 20 kDa, principally 
secreted by immune cells, which are involved in paracrine (and autocrine) 
signalling. Paracrine signalling is a form of cell-cell communication, 
whereby a cell will secrete a signal, such as a cytokine, to induce changes 
in a neighbouring or nearby cell. Inflammation or injury causes cellular 
release of cytokines such as transforming growth factor-ß (TGFß), tumour 
necrosis factor-α (TNF-α), interleukins (including IL-1, IL-6, IL-10) and the 
interferons (Yagi et al, 2012). The release of proinflammatory cytokines, 
such as IL-6, into the primary tumour environment can lead to EMT and 
metastasis (Castellana et al., 2015); conversely, the release of anti-
inflammatory cytokines can have the opposite effect upon BCCs and this 
action is key in initiating MET in metastatic BCCs, allowing them to take 
up residence in distant tissues such as the BM. 
The release of cytokines by MSCs in the BM can influence immune 
cells in close proximity and allows for maintenance of their niche, 
communicating with other cell types such as HSCs;  invading BCCs are able 
to take advantage of the immune tolerant features and chemotactic 
properties of MSCs to support cell survival (Psaila et al, 2009). MSCs 
secrete immunomodulatory molecules, such as IL-8, that inhibit the 
maturation of cytotoxic T cells and attenuate the effect of inflammatory 
macrophages by causing naïve cells to preferentially become the anti-
inflammatory M2 subtype (Caplan and Sorrell, 2015; Vasandan et al, 
2016). Where DTCs would ordinarily be cleared away from tissue by these 
immune cells, the presence of MSCs prevents this clearance and allows 
the DTCs to establish themselves within the niche.  These invading BCCss 
express high levels of CXCR4, similar to resident HSCs, and use this to 
home in on MSCs (figure 1-5). Using this signalling axis, the DTCs are able 
to outcompete many of the HSCs, preventing them from maintaining their 
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position in the niche, excluding them from the BM and forcing them to 
circulate in the bloodstream (figure 1-2). Once in the bloodstream, HSCs 
will differentiate and are unable to self-renew to maintain their 
population in the bone marrow. This affects the ability for the patient to 
generate progenitor cells, such as immune cells, worsening prognosis 
(Scheuttpelz and Link, 2013). 
Whilst the CXCL12/CXCR4 signalling axis is an important 
maintenance factor of the stem cell niche, aside from enabling BC homing 
to MSCs in the marrow, it can also aid survival once the DTCs reach their 
destination (Corcoran et al, 2008), Binding of CXCL12 to surface CXCR4 
leads to activation of downstream AKT (Zhang et al, 2009), a signalling 
pathway known to inhibit apoptosis, promoting cell survival.  
MSCs secrete cytokines, such as CXCL12, into their environment to 
maintain the stem cell niche, in particular the nearby HSCs. DTCs entering 
into the BM use these cytokines as concentration gradient to home 
towards the stem cell niche in the bone marrow (figure 1-2), where they 
can be protected from the immune response by the resident MSCs. The 
cancer cells can then alter their phenotype through the downregulation 
of cell cycle proteins and the upregulation of adhesion proteins such as E-
cadherin, resulting in cycling quiescence. 
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1.4.iii Indirect Communication — Extracellular 
Vesicles  
Another form of indirect cell-cell communication is via the release 
of extracellular vesicles (EVs). EVs are small membrane-bound packets of 
signalling molecules secreted by cells into the local environment, capable 
of influencing nearby cells (Ono et al, 2014). EVs are mainly comprised of 
microvesicles and exosomes (figure 1-5). Microvesicles are large vesicles 
(50-1000nm in diameter), which are formed through the 
compartmentalisation of the plasma membrane during cell membrane 
remodelling, thereby entrapping cytoplasmic molecules (Komalska et al, 
2015) (figure 1-6). Following release from the parent cell, the 
microvesicles can subsequently fuse with neighbouring cells, transferring 
information directly into the cytoplasm. Exosomes are smaller vesicles 
(<150nm), which are created when early endosomes form multivesiclular 
bodies. 
Both microvesicles and exosomes contain a multitude of molecules 
including miRs, cellular metabolites, cytoplasmic proteins and nucleic 
acids. These molecules are trafficked into neighbouring cells through 
endocytosis. Released in larger numbers than microvesicles, due to their 
small size, exosomes will readily enter neighbouring cells. It is possible to 
see a reduction in proliferation in BCCs as a result of MSC exosome 
exposure (Walker et al., 2015). Ono et al. (2014) have shown that 
exosomes derived from MSC-BCC co-cultures contain multiple miRNAs. 
One such miRNA is miR-23b, which when overexpressed in BCCs suppresses 
the gene MARCKS (Myristoylated alanine-rich C-kinase substrate), 
important in cell cycle. Further to this, Ota et al. (2011) report that 
accumulation of miR-21 and miR-181a cause recurrence by affecting 
PDCD4 (programmed cell death protein 4) translation, preventing cell 
death. 
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Figure 1-5 Extracellular vesicle secretion from MSCs within the bone 
marrow. MSCs transmit packets of signalling molecules through the 
formation of vesicles. Microvesicles (50-1000nm) form at the cell surface 
capturing internal cellular components (including RNAs, metabolites and 
proteins) these vesicles are excreted and fuse with neighbouring cells. 
Exosomes (<150nm) are formed through a combination of the repackaging 
of molecules brought into the cell and stored in early endosomes and 
molecules passed through the Golgi complex. Exosomes fuse with the 
parent cell membrane, exocytose and interact with neighbouring cells 
(adapted from Hessvik and Lorente, 2018). 
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1.5 Three-Dimensional Culture 
In order to determine the mechanisms that underlie BCC dormancy 
and recurrence within the bone marrow, focused studies on the 
microenvironment and cellular signals that mediate the fate of these BCCs 
are urgently required. Therefore, bioengineered, in vitro approaches to 
model the bone marrow niche are becoming important research tools. 
Advances in tissue-engineered platforms to induce, model and monitor 
BCC dormancy and recurrence may provide much needed insight into the 
regulation of these processes and potentially serve as drug testing 
platforms (Pradham et al., 2018).  
 The BM has a complex architecture; organ structures such as the 
endosteum, ECM components such as collagen, vascular structures 
including sinusoids and several different cell types.  This contributes to a 
unique physiochemistry that cannot be easily reproduced ex vivo. In vitro 
modelling of the BM niche requires consideration of matrix stiffness, 
topography and local chemistry, as alteration of these factors can affect 
MSC differentiation (Dalby et al. 2007; Kilian et al. 2010; He et al., 2016). 
Whilst there are advantages to culturing cells in two-dimensions, culturing 
on hard plastic surfaces will affect many aspects of the cell (table 1-4), 
particularly when attempting to model the BM. The stiffness of culture 
plastic is many orders of magnitude higher than the softer ECM of the BM. 
To date, there have been many attempts to recreate metastasis of 
breast cancer cells to the bone marrow. For example, Bersini and 
colleagues (2014) attempted to use microfluidics to recreate the 
extravasation of breast cancer cells as they enter the bone marrow 
environment, showing that the metastatic cells homed in to MSCs through 
sensing of cytokines secreted into the environment. MSCs resident in the 
bone marrow microenvironment have also shown to positively affect the 
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growth of incoming breast cancer cells. It is the paracrine secretions of 
MSCs that a primarily able to enhance the proliferation of oestrogen 
receptor positive breast cancers such as MCF7 (Sasser et al., 2007). 
Table 1-4 Features of 2D and 3D culture. Comparison of two and three 
dimensional cell culture with respect to cells cultured in the native bone 
marrow (adapted from Nath and Devi, 2016). 
Features 2D  3D 
Spatial restriction of cells ✓ ✗ 
Concentration gradient of O2, nutrients, and 
metabolic wastes 
✗ ✓ 
Heterogenous clonal subpopulations ✗ ✓ 
Hypoxic core ✗ ✓ 
Biological zones — proliferative, quiescent and 
necrotic zones 
✗ ✓ 
Nutrient diffusion  Low High 
Gene expression profile Different Similar 
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1.5.i Scaffold-based Cultures 
To date, there have been many studies developing 3D culture 
techniques for both MSCs and cancer cells, in an attempt to recapitulate 
the in vivo situation. These are summarised in tables 1-5. These 
techniques commonly involve the use of a matrix or scaffold to physically 
support cell growth.  Scaffolds can either be biocompatible synthetic 
materials, such as polycaprolactone and polyethylene glycol, or 
components natively found in the ECM; collagen, gelatin, or hyaluronan. 
MSCs grown in 3D environments, whether it be scaffolds, sponges or gels, 
demonstrate enhanced differentiation capacity and self-renewal, and 
have potential for scalability (Hong et al., 2015). There are limitations to 
these scaffolds, as the in vivo environment is more complicated that we 
are able to recapitulate in vitro, the whole picture is not represented. 
Whilst we may be able to recreate the stiffness of any given environment, 
the material may not be an exact match. However these 3D environments 
are stiff an improvement of the traditional 2D cell culture methods. 
 
Table 1-5 Summary of studies using 3D cell culture to model MSCs or 
cancer (adapted from Hong et al., 2015; Nath and Devi, 2016). 
Technique/ 
Material 
Cells Results Reference 
 
 
 
 
 
 
Hanging drop 
hBM-MSCs Apoptosis Model in fibrin 
hydrogel. Resistance to 
apoptosis and enhanced 
proangiogenic potential 
Murphy et 
al., 2014 
Rat MSCs Brain injury Comparison of 
MSCs derived from monolayer 
and 3D spheroids 
Guo et 
al., 2014 
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hMSCs and 
Breast 
Cancer 
BCCs cannibalise MSCs to 
enter dormancy 
Bartosh et 
al., 2016 
hBM-MSCs  Spheroids enhance anti-
inflammatory properties 
Bartosh et 
al. 2010 
 
 
 
 
 
Low adherence 
forced 
aggregation 
MSCs MSC expansion (scale up) 
Serum free media optimised 
Alimperti 
et al. 
2014 
mBM-MSCs Enhance utility of MSCs for 
therapies No necrosis, 
enhanced multilineage 
potential 
Baraniak 
& 
McDevitt 
2012 
hBM-MSCs Investigate role of the 
cytoskeleton 3D aggregation 
alters mitochondrial 
function, and induces 
functional activation, and 
cellular stress response 
Tsai et 
al., 2015 
 
 
 
 
 
 
 
 
Polydimethylsil
oxane (PDMS) 
Breast 
cancer 
3D spheroids more resistant 
than 2D-cultured cells to 
TRAIL-mediated apoptosis 
and have stem-like 
characteristics 
Chandrase
karan et 
al., 2014 
 
 
 
Prostate 
Cancer 
3D spheroids are more 
resistant to chemotherapy 
than 2D-cultured cells 
Chambers 
et al., 
2014 
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Matrigel Breast 
Cancer 
Comparative analysis of gene 
expression and signalling of 
2D and 3D cultures. 
Kenny et 
al., 2007 
Microfluidics 
micromasses 
hBM-MSCs ‘Developmental engineering’ 
for skeletal tissue 
regeneration. Exposure to 
morphogens identified 
chondrogenic concentrations 
Occhetta 
et al., 
2015 
Micropatterned 
substrates 
hMSCs Assess potential for tissue 
engineering greater 
differentiation capacity: 
downregulation of self-
renewal genes 
Wang et 
al. 2009 
Collagen/hyalu
ronic acid/ 1-
ethyl-3(3-
dimethylami- 
nopropyl) 
carbodiimide 
scaffold 
hMSCs 3D elastic modulus Human 
MSC Brain/spinal cord 
Stiffness induced 
differentiation 
Her et al., 
2013 
 
 
 
Magnetic 
Levitation in 
type 1 collagen 
gel 
hBM-MSCs 
 
Characterise MSCs in 
magnetically levitated; more 
quiescent in spheroids 
Lewis et 
al., 2017 
hBM-MSCs 
 
Probe wound healing 
response MSCs migrate from 
spheroid in response to co-
culture wounding 
Lewis et 
al., 2016 
Chambered 
slides 
Synovial 
CD105+ 
MSCs 
Chondrogenesis Chondrocytes 
were produced by spheroids 
Arufe et 
al., 2009 
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Agar Ovarian 
Cancer 
Growth and radiation 
sensitivity was measured in 
3D spheroids 
Rofstad 
and 
Sutherlan
d, 1989 
 
 
 
 
Chitosan 
hUC-MSCs Cell-matrix interaction 
Calcium signalling inside 
spheroid 
Yeh et al. 
2014 
hMSCs/ 
endothelial 
progenitors 
Angiogenesis. Sphere 
morphology influenced by 
cell-substrate interaction 
Hsu et 
al., 2014 
Adipose 
tissue MSCs 
 
Maintain stemness 
Upregulation of pluripotency 
genes, enhanced 
differentiation 
Cheng et 
al., 2012 
 
 
 1.5.ii Spheroid Culture 
More recently, 3D MSC culture techniques have involved creating 
cellular aggregates, termed spheroids. These cell spheroids facilitate cell-
cell interactions, replicate gradients of nutrients and oxygen that would 
be observed in vivo, and can generate their own ECM (Cesarz & Tamama 
2016). Traditional methods of spheroid generation include the using 
hanging drops of culture medium and non-adherent conditions, both of 
which force cells to aggregate. However further techniques have been 
recently reported, such as aggregating cells via magnetic levitation 
utilising magnetic nanoparticles. 
The use of spheroids over traditional monolayer culture allows the 
recapitulation of in vivo characteristics; growth kinetics, cellular 
heterogeneity, cell signalling and gene expression mimic that of the native 
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physiology (table 1-4). The use of spheroid culture for MSCs has gained 
attention more recently, with benefits including retention of stem cell 
markers when compared to corresponding monolayer cultured cells and 
cell quiescence (Sart et al, 2014), vastly different gene expression profiles 
(Potapova et al, 2007) and providing new targets to combat autoimmune 
disease (Bartosh et al, 2010) (table 1-6). 
 
Table 1-6 Features of different three-dimensional spheroid cell culture 
techniques (adapted from Nath and Devi, 2016). 
Technique Advantages Disadvantages 
Matrix-on-top 
and matrix-
embedded 
Cells can be recovered post 
culture if self-aggregating 
protein-based hydrogel is 
used 
Hydrogel requires 
special handling. 
Yields heterogenous 
spheroids requiring 
sorting before assay 
Challenging to stain and 
image matrix-
embedded spheroids 
Matrix 
encapsulation 
(microfluidic 
device)  
Yields homogenous 
spheroids circumventing 
sorting prior to assay 
Slower growth rate due 
to confinement. 
Capsule may burst if 
the matrix shell is thin. 
Increased occurrence of 
necrosis due to 
confinement 
Micropatterned 
plates 
Spheroids can be imaged 
with relative ease.  
Post culture recovery is 
possible 
ECM component is present 
Well needs to be 
coated to create low 
adhesion surface. 
Generates spheroids of 
variable sizes. 
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Multiple spheroids in a 
well can overwhelm 
assay chemistry. 
Hanging drop Large number of spheroids 
obtained in a limited space 
Ideal for studying invasive 
potential of cancer cells 
Reduced reagent 
consumption 
Post-culture recovery is 
possible 
Labour-intensive 
Spheroids must be 
transferred from the 
hanging drop to a 
second, higher volume 
plate for long-term 
culture 
Spheroids are 
transferred to a 
secondary plate for 
endpoint analysis. 
Ultra-low 
attachment 
plates  
Inexpensive and easy to 
handle 
Large number of spheroids 
can be obtained in a 
limited space (96 well or 
384 well) 
Endpoint analysis can be 
done on the same plate 
Post-culture recovery is 
easy 
Can be multiplexed with 
imaging and other 
biochemical assays. 
Generates spheroids of 
variable sizes 
May have a mixture of 
attached cells and 
spheroids 
Magnetic 
levitation and 
Can be multiplexed with 
imaging and other 
biochemical assays 
Limited number of 
spheroids 
Beads are expensive 
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magnetic 
bioprinting 
Endpoint analysis can be 
done on the same plate. 
Cells need to be pre-
treated with magnetic 
beads. 
 
 With respect to cancer cells, a large spheroid (>500 μm in 
diameter) will behave in the same way as micrometastases and avascular 
tumours in vivo; central cells will experience hypoxic conditions due to 
the limited diffusion of oxygen and nutrients into the mass, in addition to 
the difficulty in disposing of metabolic waste. Therefore, a large spheroid 
is ideal to study the effects of physiochemical gradients on tumour cells 
in vitro (Groebe and Muller-Kleiser, 1991; Mehta et al., 2012). Depending 
on the size of the spheroid, it will comprise a heterogeneous cell 
population arranged into layers: an innermost necrotic core where cells 
are able to exchange nutrients; a layer of viable, quiescent cells, able to 
receive nutrients from the environment, but compressed by the outermost 
cells; and a peripheral layer of proliferating cells able to migrate into the 
environment (Bell et al., 2001; Hirschhaeuser et al., 2010). Spheroid 
culture is therefore advantageous for breast cancer dormancy/recurrence 
research (Korah et al, 2004; Smith et al, 2010; Child et al, 2011; Dejardin 
et al, 2011; Marlow et al, 2013; Ono et al, 2014; Cesarz &
 
Tamama, 2015; 
Romero-Moreno et al, 2018).  
These recent studies involving multicellular spheroids have used 
many methods of forming the 3D structures (Table     1-6), of which a 
common method is the use of low-attachment culture plates. These have 
a rounded bottom that allows cells to roll as they attempt to attach 
themselves to the plastic surface. These can produce large spheroids, 
however, it can also lead to variable sizes, dependent on the number of 
cells seeded at the beginning. Another disadvantage of this method is 
analysis of the spheroids themselves. Unlike other methods, formation 
requires gravity alone, so analysis of cells within the central mass is 
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difficult without slicing the spheroids into sections to expose the central 
cells to immunohistochemical stains or similar. Another method used 
involves chitosan membranes to prevent cells from spreading on a surface, 
forcing them to form into 3D masses. However, similar to other methods, 
spheroids produced can be of variable size, making experimentation 
difficult (Cesarz & Tomama, 2015). 
Spheroid culture has been routinely used for tumour research, for 
example demonstrating how ovarian cancers become chemotherapy-
resistant through changes in metabolism (Liao et al, 2014; Sato et al, 
2015), assessing how local stress affects growth of primary breast cancer 
(Cheng et al, 2009) in addition to facilitating high-throughput screening 
of drugs (Benton et al, 2015). The formation of spheroids in the study of 
cancers can also be used to mimic circulating tumours and 
micrometastases that have broken away from the primary tumour and 
have been able to enter to circulation or a secondary site, such as the 
bone marrow (Cho et al., 2012).  
The technique used in studies herein involves using fluorescently 
labelled magnetic nanoparticles (mNPs) to label cells and subsequently 
levitating them to form multicellular spheorids. The spheroids generated 
are robust and readily visualised using the fluorescent properties 
associated with the mNPs. 
 
Although mNPs are available in a range sizes, this project will 
utilise particles of 200 nm as previously work has determined them to be 
ideally suited for spheroid generation (Lewis et al., 2016) as the cells 
readily internalise and retain them. These NPs will freely enter cells 
through multiple pathways; exposure to a magnetic source aids this 
endocytosis and generates cells that will be drawn towards a magnet. This 
phenomenon is then exploited to force the individual cells into 
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multicellular spheroids (figure 1-6). Over a period of 24 hours, cells are 
brought together under the force of a magnet and associative bonds form, 
giving robust multicellular spheroids that can be moved without damaging 
the three-dimensional structure. These can then be cultured in collagen 
gel that has a stiffness resembling the native BM. Levitating the spheroid 
through the gelation process will surround the spheroid in the three-
dimensional environment preventing adhesion to the culture plastic 
underneath (figure 1-7). 
 
 
Figure 1-6 Formation of multicellular spheroids. Cells containing 
magnetic nanoparticles are reseeded into 6-well plates containing 4 mL of 
culture medium. 350 mT magnets are placed on the lid, approximately 1 
cm from the surface of the liquid, sufficient distance from which to 
influence cells in the media. Cells are drawn towards the magnet, but 
prevented from leaving the culture medium by surface tension. This 
phenomenon forces the cells to be in close proximity with one another. 
Over a 24 hour period, cells move close enough that they may form cell-
cell contacts through mechanisms such as E-cadherin dimerisation. This is 
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similar to a method originally published by Souza et al in 2010. The 
multicellular spheroids can then be transferred from the culture medium 
into collagen gels, without damaging the 3D superstructure.  
 
 
 
Figure 1-7 Bone marrow niche in vitro model. Simplification of the bone 
marrow niche in vitro. Spheroids formed as in figure 1-7 are transferred 
into new wells and type I collagen gel solution is added. Adding a 350 mT 
magnet to the lid of the well, as the gel solidifies, causes the spheroids to 
be levitated to prevent surface adherence. The environment will now 
closely mimic the stiffness of the bone marrow causing the cell 
cytoskeleton to be remodelled changing the mechanophyscial properties 
of the cell. This cells within the spheroid will enter a quiescent state 
where division slows and can be maintained for long periods of time if no 
external stimuli are experienced. 
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1.6 Hypothesis and Project Aims 
 
In order to better understand the mechanisms involved in breast 
cancer dormancy and recurrence within the bone marrow, it is evident 
that there is a need to study the relationship between BCCs and MSCs. 
This PhD aims to study potential indirect cell-cell communication, 
including key cytokines and EVs, both of which have recently been 
identified as playing a role in dormancy and/or recurrence. This will be 
done through the creations of a functional in vitro model for metastatic 
breast cancer in the bone marrow niche, to subsequently assess how these 
BCCs may become quiescent following entry into the bone marrow 
microenvironment. The initial stage of the project will determine how 
these breast cancer cells interact with MSCs residing in this 
microenvironment. Implantation of these cells into the type I collagen gel 
will approximate the stiffness of the bone marrow to mimic any 
mechanical processes the cells might encounter that would otherwise be 
absent in a two-dimensional model. In our lab, we have recently 
developed a 3D model of the bone marrow (Lewis et al., 2016; Lewis et 
al., 2017; Lewis et al., 2018; Figure 1-7). This model will be employed in 
this project to allow the study of both individual and MSC/BCC co-
cultures.  
 
The hypothesis of this study is that culture within an in vitro BM 
niche model influences cell phenotype and behaviour in such a way as to 
more accurately represent in vivo cell phenotype and behaviour compared 
with traditional tissue culture. Primarily, the commercially available BCC 
lines, MCF7 and MDA-MB-231, will be used to form cell spheroids following 
the uptake of fluorescently labelled mNPs. This will mimic the presence 
of DTCs within the BM. In addition to the BCC spheroids, MSC spheroids 
will also be generated and co-cultured within the collagen gel. To test 
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this hypothesis and assess cell-cell communication in these two cell types, 
the aims of this project are as follows:  
• Optimisation and characterisation of BCC and MSC spheroid 
formation to produce consistent three-dimensional structures, 
using an existing magnetically levitated MSC spheroid model (figure 
1-8; Lewis et al., 2016). This part of the project is described in 
Chapter 3.  
• Study of the MSC response to cytokine IL-6, produced by local injury 
(Lewis et al., 2016). MSC migration through the collagen gel model 
will be assessed by analysing matrix metalloproteinase expression. 
This part of the project is described in Chapter 4. 
• Co-culture of MSCs and BCCs will be assessed in Chapter 5; how it 
affects the cytokine secretion profile of the cell types and how 
cytokines secreted into the BM affect BCC growth and motility. 
• Finally Chapter 6 will study the effect MSC-derived EVs have on 
BCCs in the hope of determining how incoming tumour cells enter 
dormancy.  
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2 Materials and Methods 
This chapter describes the materials and methods used to carry out 
all studies detailed in subsequent chapters.  
 
Table 2-1 List of materials, reagents and suppliers used throughout all 
experiments. 
Materials/Reagents Supplier 
1. Cells 
MSCs Promocell 
MCF7 ATCC 
MDA-MB-231 ATCC 
MG63 Sigma-Aldrich 
hTERT Clontech Labratories  
hOBs Promocell 
HUVECs Promocell 
2. Nanoparticles  
200nm mNPs coated in PEA Chemicell 
200nm mNPs coated in PEA-FITC tag Chemicell 
200nm mNPs coated in PEA-TRITC tag Chemicell 
3. Cell Culture 
DMEM Sigma-Aldrich 
FBS Sigma-Aldrich 
Penicillin-Streptomycin Sigma-Aldrich 
L-glutamine 200 mM Invitrogen 
NEAAs Life Technologies 
Sodium Pyruvate Life Technologies 
Trypsin  Sigma-Aldrich 
Versene In House  
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NaCl Fisher Scientific 
KCl Fisher Scientific 
HEPES Fisher Scientific 
EDTA Sigma-Aldrich  
DMSO Sigma-Aldrich 
Phenol Red 0.5% Sigma-Aldrich 
Rat Tail Collagen Type I, >2 mg/mL  First Link 
10x MEM First Link 
NaOH 0.1M Sigma-Aldrich 
Collagenase D Roche 
4. Electron Microscopy 
Gluteraldehyde (25% aq pure, EM Grade) Sigma-Aldrich 
Sodium cacodylate Agar Scientific 
Osmium tetroxide Agar Scientific 
Aqueous uranyl acetate Agar Scientific 
Ethanol VWR Chemicals 
Methanol VWR Chemicals 
Propylene oxide  VWR Chemicals 
Epon resin araldite (812 Kit E202) TAAB Lab Equipment 
Uranyl acetate Sigma-Aldrich 
Reynolds lead citrate Agar Scientific 
5. Cell Staining 
PBS Sigma-Aldrich 
Formaldehyde (38%) Fisher Scientific 
MgCl2 (hexahydrate) VWR Chemicals 
Triton X Sigma-Aldrich 
LIVE/DEAD® Viability/Cytotoxicity kit Invitrogen 
BSA Sigma-Aldrich 
BrdU Sigma-Aldrich 
BrdU antibody kit GE Healthcare 
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Rhodamine-phalloidin Invitrogen 
Vectashield-DAPI Vector Laboratories 
Anti-Ki67 anti-rabbit primary antibody Abcam 
Anti-ALDH1A1 anti-rabbit primary 
antibody 
Abcam 
Unbiotinylated secondary antibodies-
Texas Red 
Vector Laboratories 
CellTag® Li-Cor 
IRDye® Goat Anti-rabbit 800CW Li-Cor 
Tween 20 Sigma-Aldrich 
Cytokine array membrane kit Abcam 
6. EV Collection  
Particle-free PBS Sigma-Aldrich 
Pierce BCA Protein Assay Kit ThermoFisher Scientific 
Fluorocet Exosome Quantification kit New England Biolabs 
7. RNA Quantification 
RNeasy Mini Kit Qiagen 
Quantitect Reverse Transcription Kit  Qiagen 
Fluidigm Primers Eurofins Genomics 
2x TaqMan PreAmp Master Mix Applied Biosystems 
2x SsoFast EvaGreen Supermix Bio-Rad 
RNaseOUT Recominant RNase Inhibitor Invitrogen 
DNA Suspension Buffer  Life Technologies 
Exonuclease I Reaction Buffer New England Biolabs 
Exonuclease  New England Biolabs 
Biomark 20x DNA Binding Dye Sample 
Loading Reagent 
Fluidigm 
8. Cell Treatments 
IL-6 Abcam 
TGF-β Abcam 
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D-Erythrose Sigma-Aldrich 
L-Methionine Sigma-Aldrich 
 
2.1 Cell Culture Solutions 
Modified DMEM (Standard Growth Media) 
DMEM 400 mL 
Medium-199 100 mL 
FBS 50 mL 
Penicillin-streptomycin 10 mL 
Sodium pyruvate 5 mL 
L-glutamine 200 mM 5 mL 
 
 
Modified Alpha-MEM (Stem Cell Growth Media) 
DMEM 400 mL 
FBS 50 mL 
Penicillin-streptomycin 10 mL 
Sodium pyruvate 5 mL 
NEAA 5 mL 
 
Versene 
Water 1 L 
NaCl 8 g 
KCl 0.4 g 
Glucose 1 g 
HEPES 2.38 g 
EDTA 0.2 g 
0.5% Phenol Red 2 mL 
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Adjusted to pH 7.5   
 
Trypsin/Versene  
Versene 20 mL 
Trypsin 0.7 mL 
 
10x PBS Solution  
PBS 1 Tablet 
Water 200 mL 
 
1% PBS Solution  
10x PBS Solution 10 mL 
Water 90 mL 
 
Cell Fixation Buffer  
Formaldehyde (38%) 10 mL 
1% PBS Solution 90 mL 
Sucrose 2 g 
 
Cell Permeabilising Buffer  
 
1% PBS Solution 100 mL 
Sucrose 10.3 g 
NaCl 0.292 g 
MgCl2 hexahydrate 0.06 g 
HEPES 0.476 g 
Adjusted to pH 7.2  
Triton X 0.5 mL 
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Blocking Buffer 
1% PBS Solution 100 mL 
BSA 1 g 
 
Wash Buffer 
 
1% PBS Solution 100 mL 
Tween 20 0.5 mL 
 
Cell Freezing Solution  
FBS 50 mL 
DMEM 40 mL 
DMSO 10 mL 
  
2.2 Cell Culture 
The MSCs were cultured in T75 flask with modified alpha-MEM 
media at 37 °C with 5% CO2. Once the cells were confluent, the media 
was removed and the cells were washed with HEPES solution. Cells were 
detached from the surface using 5 mL trypsin/versene (<5 minutes at 37 
°C). 5mL Fresh media was added to the flask to neutralise the active 
trypsin, and the cell suspension was centrifuged for 4 minutes at 1400 
rpm. After centrifugation, the supernatant was removed leaving a cell 
pellet. The cells were re-suspended in 5 mL fresh media and seeded into 
appropriate wells for experiments. An appropriate volume of remaining 
cell suspension was added to new T75 flask containing 10 mL of fresh 
media to maintain cell supply. The same protocol was followed for other 
cells types including MCF7 and MDA-MB-231, where modified DMEM was 
used instead. 
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2.3 Cell Freezing/Thawing 
Cells pelleted as per section 2.1 and resuspended in 1 mL cell 
freezing solution before being frozen at -80 oC overnight then transferred 
to liquid nitrogen for storage. Cells were thawed by removing from liquid 
nitrogen and adding the cell suspension dropwise to fresh media warmed 
to 37 oC and centrifuging at 1400 rpm for 4 minutes. Cell pellet was 
resuspended in 5 mL fresh media and cells seeded in several T75 flasks 
containing 10 mL fresh media. 
 
2.4 Monolayer Culture 
Cells were removed from the surface of T75 flask as in section 2.2 
before seeding in a 24-well plate and cultured overnight at 37°C with 5% 
CO2 to allow cell adhesion.  
 
2.4.i Cell Treatments 
Fresh media doped with additional materials (such as cytokines or 
metabolites) depending on study, were added after cells had adhered to 
the surface of the well plate for 24 hours. 
 
2.5 Spheroid Synthesis 
Cells were seeded at a density of 1x104 cells/ml and incubated 
overnight (37 oC with 5% CO2). mNPs (Chemicell) were added to BCCs or 
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MSCs at a working concentration of 0.1 mg/mL and incubated for 30 
minutes (37 oC with 5% CO2) on a magnet array plate. Wells were washed 
with HEPES to remove excess mNPs and cells were then detached from 
the surface using 200 µL trypsin/versene (<5 minutes at 37 °C). 300 µL 
fresh media was then added to each well to neutralise the active trypsin. 
Cell suspension was then centrifuged at 1400 rpm for 4 minutes. The 
supernatant was discarded and cell pellet was resuspended in 500 
µL/well. 500 µL cells containing mNPs were then seeded in 6 well plate 
containing 4mL of fresh media and incubated overnight (37 oC with 5% 
CO2) under an external magnetic field (350 mT).  
 
2.6 Collagen Gel Synthesis 
0.5 mL fresh DMEM, 0.5 mL FBS and 0.5 mL 10x MEM were mixed 
on. In a separate universal tube, 2.5 mL acetic acid-stabilised type I rat 
tail collagen (2 mg/mL) was mixed with 1mL 0.1 M NaCl. The contents of 
both tubes were combined on ice and NaOH was added dropwise until the 
solution changed from yellow to pink (via phenol red indicator in media). 
500 µL of this solution was added to each well of a 24-well plate containing 
spheroids sythesised in section 2.4, to produce a gel 5mm thick. A 350 mT 
magnet was then placed on the lid of the well plate to levitate the 
spheroid within the gel before it solidified. Gels were incubated at 37oC 
until solidified. 1mL of fresh media was then applied to the gel and 
spheroids were incubated as per experiment. 
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2.6.i Gels Containing Multiple Spheroids 
Where gels contain multiple spheroids of different cell types, the 
protocol above was followed and spheroids generated separately as in 
section 2.5 were added to new wells prior to addition of collagen gel. 
 
2.7 Collagen Gel Digestion 
Media was removed from collagen gels and equal volume 2.5 
mg/mL Collagenase D in 1x PBS solution was added and incubated at 37 
˚C for 90 mins. Solution was then pipetted vigorously before the addition 
of ice cold 10 mM EDTA to quench the reaction. This solution was pelleted 
in a centrifuge and supernatant removed. Spheroid pellet could then be 
used in further experiments.  
 
2.8 RNA extraction  
RNA extractions from cell pellets were performed using a QIAGEN 
RNeasy mini kit, according to the manufacturer’s protocol. All centrifuge 
runs were at 8000 g for 15 seconds unless otherwise stated. 350 µL buffer 
RLT was added to each pellet, and the sample was homogenised by 
pipetting. 350 µL 70% ethanol was added to the lysate and mixed by 
pipetting. The sample was immediately transferred to an Rneasy MinElute 
spin column in a 2mL collection tube, and centrifuged. The flow-through 
was discarded from the collection tube. 350 µL buffer RW1 was added to 
the spin column and centrifuged. 80 µL DNase I in buffer RDD was added 
directly to the spin column membrane, and incubated at room 
temperature for 15 minutes. 350 µL buffer RW1 was added and the column 
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was centrifuged. The collection tube was discarded and replaced, 500 µL 
buffer RPE was added and the column was centrifuged again. 500 µL 80% 
ethanol was added, and the column was centrifuged for 2 minutes, after 
which the collection tube was discarded. The spin column was placed into 
a new collection tube and centrifuged at 13000 g for 5 minutes to dry the 
membrane. The flow-through and collection tube were discarded. The 
column was then placed into a 1.5 mL collection tube. 14 µL RNase-free 
water was added to the centre of the spin column membrane, and the 
RNA was eluted by centrifuging at 13000 g for 1 minute. RNA content was 
quantified using a NanoDrop 2000 spectrophotometer. The samples were 
either stored at -80 C or used immediately. 
 
2.9 Reverse Transcription 
Reverse transcription was performed using a QuantiTect® Reverse 
Transcription Kit according to the manufacturer’s protocol. Template RNA 
samples were thawed on ice. The kit reagents (gDNA Wipeout Buffer, 
Quantiscript® Reverse Transcriptase, Quantiscript RT Buffer, RT Primer 
Mix, and RNasefree water) were thawed at room temperature. The 
solutions were gently mixed and centrifuged to collect residual liquid from 
the sides of the tube. All reactions were prepared on ice. RNA content 
was normalised so all samples contained equal amounts. The genomic DNA 
elimination reaction was set up with 2 µl of gDNA Wipeout Buffer and the 
appropriate amount of template RNA, made up to 14 µl with RNase-free 
water. This reaction was incubated for 2 minutes at 42 C, and then kept 
on ice. The reverse transcription reaction was set up with 1 µl Quantiscript 
Reverse Transcriptase, 4 µl Quantiscript RT buffer, 1 µl RT primer mix, 
and 14 µl template RNA from the genomic DNA elimination reaction, to a 
total reaction volume 20 µl. This mix was incubated for 15 min at 42 C, 
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followed by an incubation for 3 min at 95 C to inactivate the Quantiscript 
Reverse Transcriptase. The resulting cDNA was then stored at -20 C.  
 
2.10 Cell Fluorescent Imaging  
After the appropriate incubation period, cell monolayers or cell spheroids 
levitated in gels were fixed for 15 minutes at room temperature, using 
cell fixative solution, before being washed three times with 1x PBS 
solution. In the case of experiments using cell monolayers under gels, a 
drop of vectashield-DAPI stain was applied to wells for 15mins at room 
temperature following fixation. Red fluorescence measured at 546nm 
excitation, 665nm emission. Green fluorescence measured at 440nm 
excitation, 540nm emission. DAPI blue fluorescence measured at 365nm 
excitation, 397nm emission. Cell imaged using a Zeiss Axio Vert A1 
fluorescent microscope. 
 
2.11 BrdU Assay 
10 mg/mL BrdU in DMSO was added to DMEM. Media over collagen gels was 
replaced with this BrdU-doped DMEM and incubated for2 6hr at 37˚C. The 
cells were then stained for immunofluorescence as described in section 
2.12. 
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2.12 Live/Dead Viability Assay 
After the appropriate incubation period the cells, in either monolayer or 
collagen gel, were assessed for cell viability, by preparing 10 mL of fresh 
DMEM media containing 5 μL 4 mM calcein AM and 20 μL 2mM ethidium 
homodimer, giving working concentrations of 2 μM and 4 μM respectively. 
This media was added to the cultures then incubated for 1 hour at 37°C. 
Subsequently, the cells or gels were washed three times with fresh media 
and analysed immediately as in section 2.12. 
 
2.13 Fluidigm Real-Time PCR  
2.13.i Specific Target Amplification  
Specific target amplification (STA) reactions were performed to 
increase the cDNA volumes. Primers for the genes listed in Table 2-2 and 
2-3 were designed using the Sigma online primer design tool. 1 µL aliquots 
of 100 µM forward and reverse primer sets were pooled and diluted in DNA 
suspension buffer to create a 500 nM (10x) primer mixture. Pre-mix 
solutions were made up for each cDNA sample: comprising 2.5 µl TaqMan 
PreAmp Master Mix (Applied Biosystems), 0.5 µl 500 nM pooled primer mix, 
and 0.75 µl water. 1.25µL cDNA sample was added to the mixture, to a 
final volume of 5 µl, mixing by vortex. The samples were then run on a 
thermocycler under the sequence outlined in Table 2.4. 
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Table 2-2 List of genes and primers tested using Fluidigm real-time PCR. 
Layout for first run; shaded cells indicate housekeeping genes. 
 Forward Primer 3’-5’ Reverse Primer 3’-5’ 
B-actin acggatttggtcgtattggg attttggagggatctgctc 
CCNA2 tcagtaccttagggaagctgaaa ccagtccaccagaatcgtg 
CCNB1 ccatacctcaagtatttgccatc tccagtctttcgtattaatgattcag 
CCNC acatggtgcactttcctcct aggtaatgttgtagagttggtgtcc 
CCND1 tttgctgagctttctgtgga aatggttgccatctcttttctc 
CCND2 tgcatctacaccgacaactcc cggatgatctgtttgttctccg 
CCND3 tacaccgacaactccatcaagc atgtgctcaatgaagtcatgagg 
CCND3 tacaccgaccacgctgtct gaaggccaggaaatcatgtg 
CCNE2 acagcttggatttgctggac tctgcttcttaccgctctgtg 
CCNT1 gccattgattcattagagttcca tgaaatactgtcccactccaaac 
CDK1 gaacatgtcatcaaggtagcaca aatgaccagatcttgaacttgttg 
ENOX-2 gagctggagggaacctgattt cactggcactaccaaactgca 
CDKN1A aactacaggtcaagtggtagcc ggaatcctgcataagcacatcc 
CDK2 gtggacctggagactctcag cctcttggagaagatcagccg 
CDK4 cctcctgggctgcaaata cagaatctccagggaataggg 
CDK5 agtgttggctgtatctttgcag atctcgaggccagtcatcc 
CDKN1A tctttttcccggcaatgat tctggcagcttggtcataga 
CDKN1B ggctaactctgaggacacgc   tgagtagaagaatcgtcggttc 
CDC7 attgtcatcaagacgcagggc gttgcgaatcccttcgctgtt 
ORC3 tcatcatcctgcttatcctt tgttatctcttacatcatcttctg 
CDC25B tgattctctgctcgtgtt cattcgttcaagtagtcatagt 
ORC4 atcaggacacaaggacatc ctctcacacttccactctc 
CCNB2 ggctaactctgaggacacgc tgagtagaagaatcgtcggttgc 
C-MYC gtggccggacatgtgtagtc gccgtaattcgagcacatgg 
CDK6 gcccttaagtgtcctgtgct tctcattggtcaagagcgca 
N-CAD ttgctgtcattattctcagtgga  gaggactcagggtggttcag 
E-CAD ggatttgtggacatcctagagagt acttgctgtacatgacgaggt 
FN1 acctgcggtcattacacatg tgctttcgagtccatgctaca 
GAS6 agaagacaccaccatcca tgtagtccaggctgtagaa 
AXL tcttatggcgtagatggag gagttgaggtggacagat 
GAS6 agcatctcaaaattctcaaca  ggtactcctgaatccactt 
GAPDH acggatttggtcgtattggg attttggagggatctgctc 
AXL aacaagaccctgcccgtgg cattcagcagaggcattccgg 
JUP ttctgcggcaagaggttcactc  gtgtttgctcaggtggtcgctt 
MER agacctgtatcgcaggcact  ccactcgtttctggtagttcttcc 
TYRO3 agctggatgaccagagtgct   tgaaattcatggctgtggaa 
KERATIN 19 gaagattgggagaaccctca tgtgggtttatggactgcaa 
TWIST 1 gcaatagcactactacactc ccaacagacctcatcaca 
PPARG gactctgaggaggaacaaga ttggcagcaggatagtcctt 
CXCL12 tgaaatgttcatgggggaac aaaaagctcctgatgccttg 
RUNX2 gaactaggcaaagacctacttctga ggtgggaatccaggttttct 
CYCR ggtgtctcttcaacggaggaa tagtgaggcatcatcagtggc 
OSX catcaacaccgagttcaag atcttattctgctgctcca 
BMP2 atctcttgacctcgtgat cagtccagcatcttgtatt 
OPN taagttgccgtctctgaa gtgtggtgcgttatgtaa 
RNF20 cctacctgaagaagaaccat cacggtcagagaatacaga 
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B2M ctgatagaagtctgaacagttgt gattggcacgacctcttg 
CYC1 ttgtctttcagcaaggactgg atgcggcatcttcaaacctcc 
 
Table 2-3 List of genes and primers tested using Fluidigm real-time PCR, 
layout for second run; shaded cells indicate housekeeping genes 
  Forward Primer 3’-5’ Reverse Primer 3’-5’  
ENOX2 gagctggagggaacctgattt cactggcactaccaaactgca  
GAPDH acggatttggtcgtattggg attttggagggatctgctc  
SNAIL1 tcggaagcctaactacagcg tcccagatgagcayyggcag  
SNAIL2 tccttcctggtcaagaagca ggtatgacaggcatggagta  
PI3K cctcaattcacctcatagtagagcaat ggagaaactattacccagatcaccac  
MAPK1 cgtgttgcagatccagacca gccagaatgcagcctacaga  
AXL tcttatggcgtagatggag gagttgaggtggacagat  
GAS6 agaagacaccaccatcca tgtagtccaggctgtagaa  
MER gcaatagcactactacactc ccaacagacctcatcaca  
JUP atctcttgacctcgtgat cagtccagcatcttgtatt  
TYRO3 taagttgccgtctctgaa gtgtggtgcgttatgtaa  
OPN agctggatgaccagagtgct   tgaaattcatggctgtggaa  
BMP agacctgtatcgcaggcact  ccactcgtttctggtagttcttcc  
RUNX2 aacaagaccctgcccgtgg cattcagcagaggcattccgg  
OSX ttctgcggcaagaggttcactc  gtgtttgctcaggtggtcgctt  
CXCL12 agcatctcaaaattctcaaca  ggtactcctgaatccactt  
Vimentin catcaacaccgagttcaag atcttattctgctgctcca  
N-Cadherin tcatcatcctgcttatcctt tgttatctcttacatcatcttctg  
E-Cadherin tgattctctgctcgtgtt cattcgttcaagtagtcatagt  
FN-1 atcaggacacaaggacatc ctctcacacttccactctc  
Keratin19 cctacctgaagaagaaccat cacggtcagagaatacaga  
TWIST1 ctgatagaagtctgaacagttgt gattggcacgacctcttg  
CCN-B2 gaagattgggagaaccctca  tgtgggtttatggactgcaa  
UBE2D2 ccatggctctgaagagaatcc gatagggactgtcatttggcc  
B-Actin gtgggccgccctaggcaccag cactttgatgtcacgcacgatttc  
CCN-C tttgctgagctttctgtgga aatggttgccatctcttttctc  
CCND2 tacaccgacaactccatcaagc atgtgctcaatgaagtcatgagg  
CCNT1 gaacatgtcatcaaggtagcaca aatgaccagatcttgaacttgttg  
CDK4 agtgttggctgtatctttgcag atctcgaggccagtcatcc  
CDK5 tctttttcccggcaatgat tctggcagcttggtcataga  
MCM9 ggctaactctgaggacacgc   tgagtagaagaatcgtcggttgc  
PPARG ttgctgtcattattctcagtgga  gaggactcagggtggttcag  
MAPK8 caggactgcaggaacgagtt ctcccatgatgcacccaact  
BCL2L2 aagtgcaggagtggatggtg gtcctcactgatgcccagtt  
BLM tccagaaaccagcacagact gcagttcgttcccacaatcc  
CCNA2 tggcggtactgaagtccgg caaggaggaacggtgacatgc  
CCNB1 cagctcttggggacattggtaac actggcaccagcataggtacc  
CDC25B ggatttgtggacatcctagagagt acttgctgtacatgacgaggt  
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CDK1 aactacaggtcaagtggtagcc ggaatcctgcataagcacatcc  
CDK2 cctcctgggctgcaaata cagaatctccagggaataggg  
CATHEPSIN D acctgcggtcattacacatg tgctttcgagtccatgctaca  
ORC4 tttccatcagcaggatgtggg ctgtgggtcttcttccatagc  
ORC3 ccagtccctttctcagcctg acttgttcgaatcactgtccca  
C-MYB gaaggtcgaacaggaaggttatct gtaacgctacagggtatggaaca  
BAX gctgacatgttttctgacgg  atgatggttctgatcagttcc  
CDK9 atggaaaacgagaaggagggg tagggggaagctttggttcg  
CYC1 actgcgggaaggtctctactt gggtgccatcgtcaaactcta  
ATP5B tccatcctgtcagggactatg atcaaactggacgtccaccac  
 
 
Table 2-4 Thermocycler program for pre-amplification of cDNA 
 
 
 
 
2.13.ii Exonuclease Treatment  
Exonuclease treatment was used to remove unincorporated primers from 
section 2.9.i. Exonuclease I was diluted to 4 U/µl to a volume of 2 µl per 
reaction (1.4 µl water, 0.2 µl Exonuclease I reaction buffer, 0.4 µl 
Exonuclease I at 20 U/µl). This mixture was added to the STA reactions, 
mixed via vortex, centrifuged briefly to collect entire volume, and run in 
a thermal cycler as described in Table 2-5. The products were then diluted 
5-fold in TE buffer to be used in further steps  
Table 2-5 Thermocycler program for exonuclease treatment of cDNA 
Temperature 37 C 80 C 4 C 
Time 30 minutes 15 minutes ∞ 
 
Cycles 1 14-22 Hold 
Temperatures 95 C 95 C 60 C 4 C 
Times 10 minutes 15 seconds 4 minutes ∞ 
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2.13.iii Sample Pre-Mix Preparation  
2x SsoFast EvaGreen Supermix was mixed with 20x DNA Binding Dye 
Sample Loading Reagent in an 11:1 ratio. 2.75 µL pre-mix was added to 
2.25 µL of the STA and exonuclease treated cDNA sample. This final 
mixture was vortexed for 20 seconds and centrifuged for 30 seconds. All 
reactions were kept on ice.  
 
2.13.iv Assay Mix Preparation  
Forward and reverse primer stocks (100 mM) were diluted to a final 
concentration of 5 µM using 2.5 µL 2x Assay Loading Reagent, 2.25 µL 1x 
DNA Suspension Buffer and 0.25 µL 100 µM mixed forward and reverse 
primers. The mixture was vortexed for 20 seconds and centrifuged for 30 
seconds. 
 
2.13.v Chip Priming and Loading  
The 48.48 Dynamic Array IFC (figure 2-1) was primed with control line 
fluid, which was injected into each accumulator on the chip. The chip was 
placed into the IFC controller MX, and the ‘Prime (136x)‘ script was run. 
Following this, 5 µL each assay mix and sample were pipetted into the 
wells of the chip. The fully loaded chip was inserted into the IFC Controller 
and the ‘Load Mix (136x)’ script was run to load the samples and assays 
into the chip. The chip was then run in the BioMark HD system using the 
protocol described in Table 2.6. 
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Figure 2-1 Fluidigm 48.48 access array chip. 48 cDNA samples are loaded 
in the left-hand wells and 48 primer pairs loaded on the right. 
 
Table 2-6 Cycling parameters for Fluidigm 48.48 dynamic array IFC 
 
 
 
 Type Temperature 
(ºC) 
Duration 
(seconds) 
BioMark HD 
Ramp Rate 
(ºC/s) 
1 Thermal mix 70 2400 5.5 
60 30 5.5 
2 Hot Start 95 60 5.5 
3 PCR (30 
cycles) 
96 5 5.5 
60 20 5.5 
4 Melting 
Curve 
60 3 1 
60-95 1 1 
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2.14 Immunofluorescent Staining 
Following a period relevant to specific tests, cells were fixed for 15 
minutes at room temperature using cell fixative solution. Fixed cells were 
incubated in cell permeablising buffer 5 min at 4 °C. Samples were 
blocked in blocking buffer and stained with primary antibody (Table 2.1), 
1:500 in blocking buffer, for 1 hour at 37 °C. After the incubation, they 
were washed three times in wash buffer. They were then incubated with 
conjugative secondary antibody (1:50 in blocking buffer) for 1 hour at 37 
°C. The samples were then washed three more times in wash buffer and 
mounted in vectashield-DAPI. Cells could then be imaged using microscope 
noted in section 2.11. 
 
2.15 In Cell Western 
All steps until addition of primary antibodies are as in 2.14. Cells are then 
washed five times in wash buffer before incubating for 1 hour at 37 °C 
with CellTag and appropriate conjugative secondary antibody (1:700 and 
1:400 respectively). Cells were then washed further using wash buffer and 
dried prior to imaging using a Li-Cor Odyssey Sa. 
 
2.16 µ-Slide Chemotaxis 2D 
The kit provided by Ibidi allows the observation and measurement of 
directional motility of a group of cells in response to a chemoattractant. 
Using the set protocol provided with the ‘3D Chemotaxis Assay Using μ-
Slide Chemotaxis - 2.2 2D Chemotaxis experiments without Gel’ slides, 
MSCs were seeded at 1x105. Once both reservoirs were filled with 60 µL 
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chemoattractant-free DMEM, 30 µL of 2 ng/mL IL-6 was aspirated into the 
left reservoir to begin the chemoattraction for the assay. The plate was 
then imaged on a 4 times objective lens at 120 second intervals over 24 
hours in a 37oC hot room. Results were then analysed using the ImageJ 
plugin ‘manual tracking’ and Ibidi’s own ‘Chemotaxis and Migration’ tool. 
 
2.17 Cytokine Array 
Following the protocol provided by the supplier samples were incubated 
overnight on array membranes shaking at 4°C. The following day, media 
samples were aspirated, membranes washed using the supplied wash 
buffers and incubated for two hours at room temperature in 1 mL of 
Biotin-Conjugated Anti-Cytokines. Membranes were then rewashed and 
incubated in 2 mL HRP-Conjugated Streptavidin shaking overnight at 4°C. 
Prior to chemiluminescence detection, streptavidin was removed and 
membranes washed for a final time. Once washed, membranes were 
transferred printed side up onto provided plastic sheets and detection 
buffers pipetted onto each sample. After two minutes of incubation, a 
second plastic sheet was placed on top and membranes were imaged via 
chemiluminescence detection using an Azure c500 Infrared Western Blot 
Imaging System. The layout of the array is shown in table 2-7. The pixel 
density of each dot on the array was recorded using ImageJ and 
normalised to the mean positive control as per manufacturer’s 
instruction.  
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Table 2-7 Abcam 23-target cytokine array layout. POS denotes positive 
control IgG and NEG denotes spots containing buffer only. 
POS POS NEG NEG G-CSF GM-CSF GRO GROα 
POS POS NEG NEG G-CSF GM-CSF GRO GROα 
IL-1α IL-2 IL-3 IL-5 IL-6 IL-7 IL-8 IL-10 
IL-1α IL-2 IL-3 IL-5 IL-6 IL-7 IL-8 IL-10 
IL-13 IL-15 IFN-γ MCP-1 MCP-2 MCP-3 MIG RANTES 
IL-13 IL-15 IFN-γ MCP-1 MCP-2 MCP-3 MIG RANTES 
TGFβ1 TNF-α TNF-β blank blank blank blank POS 
TGFβ1 TNF-α TNF-β blank blank blank blank POS 
 
2.18 Electron Microscopy Preparation 
Cell spheroids were generated before fixing in 2.5% glutaraldehyde/ 0.1 
M phosphate buffer fixative for 1 hour at room temperature before rinsing 
in buffer three times for 5 minutes. Fixed spheroids were treated in 
osmium tetroxide/ 0.1 M phosphate buffer for 1 hour and washed with 
distilled water three times for 10 minutes before being treated in uranyl 
acetate for 1 hour in the dark. Spheroids were then dehydrated in 
increasing [ethanol] for 10 minutes until absolute ethanol, which was used 
twice for 5 minutes. 
 
2.18.i SEM 
Scanning EM samples were then dried in hexamethyldisilazane before 
being mounted on SEM stubs. Mounted samples were then coated with 10 
nm gold/palladium using a polaron SCS15 SEM coating system. Samples 
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were viewed using JOEL 6400 SEM at 10kV. Images were false coloured 
with Adobe Photoshop CS4. 
 
2.18.ii TEM 
Transmission EM sample spheroids were further processed by first washing 
in propylene oxide three times for 5 minutes then a 1:1 mix of propylene 
oxide: araldite/epon 812 resin overnight. These samples were then 
embedded in fresh araldite resin and set in moulds for 48hr to allow the 
resin to polymerise. 70 nm sections were cut using a Leica Ultracut UCT 
and a Diatome diamond knife at an angle of 6o. Sections were then 
mounted on 100 mesh formvar-coated copper grids then contrast stained 
with 2% methanolic uranyl acetate for 5 minutes and Reynold’s lead 
citrate for a further 5 minutes before imaging on JOEL 1200 TEM TEM at 
accelerating velocity of 80kV. 
 
2.19 Conditioned Media Fractionation 
 Culture medium was harvested from cells following an incubation 
period to allow the secretion of signalling molecules. This was then 
filtered using a 200 micron filter to remove cells. Media was then 
sequentially ultrafiltrated using Amicon Ultra filters as per the 
manufacturer’s protocol; reservoir was filled with appropriate volume of 
media and centrifuged for time depending on rotor and molecular weight 
of desired filtrate. The runoff containing smaller molecules was then used 
in the next molecular weight cut off filter to produce filtrates of discrete 
molecular weights. The media retained in the reservoir was reconstituted 
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in a volume of fresh culture medium equal to the volume originally filtered 
to maintain the concentration. 
 
2.20 Extracellular Vesicle Isolation and 
Characterisation 
MSCs and MCF7s were cultured at scale in T150 culture flasks and the 
medium isolated every two days. Cells were grown in DMEM containing FBS 
depleted of EVs, through centrifugation at 120000 g for 18 hours. MSC or 
MCF7-derived EVs were isolated from collected medium by differential 
centrifugation: 2000 g for 20 minutes to remove cell debris and apoptotic 
bodies, 10,000 g for 30 minutes to remove micro-vesicles, 120000 g for 
70 minutes to pellet EVs. Following the final ultracentrifugation step, the 
supernatant was removed, the pellet washed in particle-free PBS and 
further centrifuged at 120,000 g. All ultracentrifugation steps were 
performed using a Sorvall WX Ultra Series Ultracentrifuge with a Fiberlite, 
F50L-8 × 39 fixed-angle rotor  
The resulting pellet was re-suspended in 200 μL of PBS and the total 
protein concentration determined using the Pierce BCA protein assay kit. 
Particle size distribution was analysed using Dynamic Light Scattering 
(DLS; Malvern Instruments, UK) and quantitated using Fluorocet assays; 
generating a protein standard then adjusting isolates to the same total 
protein and measuring fluorescence of acetecylcholinesterase, a known 
exosomal protein, present within the vesicles. Due to limited supply and 
assessment of other EV-related studies, the concentration of 
approximately 2x107 /mL was used in each experiment. 
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2.21 Statistical Testing 
Differences between the means of two independent variables in any given 
case were determined using an unpaired t-test. Where appropriate, an 
ANOVA was performed to determine differences between whole 
treatment groups. Statistical significance was determined by p<0.05 
indicating a 95% probability of the test hypothesis being correct. All 
statistical analyses were performed using Graphpad Prism 6. 
 
 
CHAPTER 3 SPHEROID CHARACTERISATION 
63 
3 Spheroid Characterisation 
3.1 Introduction 
Recently there has been interest in the study of dormant cancer 
cells within the bone marrow (BM) niche; if the factors that cause this 
phenomenon can be determined then they can be exploited to prevent an 
exit from this quiescent state (Ono et al., 2014; Zhang et al., 2013; Reddy 
et al., 2012). There is evidence that entry into the bone marrow stem cell 
niche leads BCCs to enter dormancy (Lim et al., 2011). This is not 
necessarily an immediate effect, so incoming cancer cells may begin to 
form micrometastases before becoming quiescent. Currently the norm for 
such research is to use two-dimensional environments to test a hypothesis. 
In the case of recreating a functional bone marrow stem cell niche, ECM 
proteins such as collagen and fibronectin are utilised, as well as a 
multitude of expensive growth factors to simulate the in vivo niche 
(Llopis-Hernadez, et al., 2016; Hoshiba, et al. 216; Meads et al., 2008). 
However, these models could be described as too simplistic as they lack 
the three-dimensional structure of the BM environment. Both MSCs and 
BCCs are known to express different surface receptors (Sun et al., 2006; 
Pickl and Reis, 2009) and exhibit different cell morphologies when 
cultured in two-dimensional models compared with cells grown in three-
dimensional matrices. Therefore, recently there has been a shift towards 
the use of three-dimensional culture methods, to create a more 
physiologically relevant model. 
There are various methods involved in creating three-dimensional 
MSC niche models, as described in section 1.x. However, the use of 
multicellular spheroids has been defined both as an effective and efficient 
technique. Several protocols for generating spheroids, including hanging 
drop or mechanical agitation, were summarised in section 1.4. This 
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chapter aims to utilise a previously described protocol, which causes MSCs 
to aggregate to create multicellular spheroids using magnetic 
nanoparticles (mNPs). Through the use of an external magnetic field, cells 
containing mNPs can be manipulated. Previous studies have shown mNPs 
incorporated within the MSCs do not affect the characteristic behaviour 
of these cells (Suh et al., 2009; Markides et al., 2012; Lewis et al, 2016), 
with the effects on BCCs not as clearly defined. The addition of a type I 
collagen gel matrix surrounding MSC spheroids further models the bone 
marrow by approximating the stiffness of the environment where the MSCs 
reside (Lewis et al., 2017). 
 
3.1.i Objectives 
This chapter aims to develop an in vitro three-dimensional model, 
incorporating MSCs and/or BCCs, which effectively mimics the bone 
marrow stem cell niche. The generation of a more physiologically relevant 
three-dimensional model may allow native cellular responses and will 
facilitate the further study of dormancy. If successful, the model will 
enable the study of initial dormancy signals within BCCs, in addition to 
paracrine signalling between MSCs and BCCs within the model 
environment. Understanding these processes may permit the artificial 
manipulation of BCC dormancy, providing a potential platform for 
therapy.  First, to establish the model, distinct MSC and BCC spheroids are 
initially generated and cultured in type I collagen gel. Initial assessment 
of these spheroids will include: 
• Determination of optimal cell seeding density number 
• Assessment of cell-cell contact within spheroids and spheroid morphology 
via scanning electron microscopy 
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• Assessment of internal cellular structures and distribution of mNPs within 
cells of the spheroids via transmission electron microscopy   
• Proliferation analysis of spheroids using BrdU incorporation during DNA 
synthesis 
• Co-culture of MSC and BCC spheroids to assess key gene expression 
changes  
 
3.2 Results 
3.2.i Cell Seeding Density 
All results herein used three cell types; MSCs (Promocell), MCF7 
(ATCC) or MDA-MB-231 (ATCC). The first stage in generating the in vitro 
model is to create consistently sized spheroid. As described in section 2.5, 
spheroid generation is a multistep process. The effect of initial cell 
seeding density with respect to resultant spheroid size was assessed. Each 
cell type was seeded at three different cell densities; 6x103, 1x104 and 
2x104 cells/mL (figures 3-1 to 3-3), with spheroid cross-sectional area 
measured after 24hr in collagen gel, using the fluorescent mNPs within 
the cells as fluorescent tags.   
 
MCF7 
MCF7 cells generated the largest spheroids of the cell types tested. 
As expected, spheroid size increased with increasing cell density; mean 
areas of MCF7 spheroids seeded at the higher density (2x104 cells/mL) 
were significantly different (p<0.05) from those seeded at lower densities 
(figure 3-1) and showed a large range of cross-sectional areas, likely due 
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to the epithelial phenotype of the cells, leading to tighter cell-cell 
contact. Where the areas of spheroids seeded at the lower density (6x103 
cells/mL) had the smallest range.  
 
Figure 3-1 MCF7 spheroids seeded at three cell densities. Spheroids 
cultured for 24 hours in collagen gel, representative of each cell seeding 
density. Images acquired with Zeiss Axio Vert A1. Red fluorescence 
derived from mNPs. Scale bar 10 µm. >20 spheroids measured at each cell 
seeding density across three biological replicates. Spheroid areas 
measured via pixel count using imageJ. Bars indicate range, asterisk 
indicates p<0.05. 
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MDA-MB-231 
MDA-MB-231 spheroids generated the smallest spheroids, where 
seeding at different densities showed no significant change in mean area, 
with all approxminately 200 µm2. Each seeding density presented a similar 
range (100-500 µm2). Images of these spheroids indicate a loose 
arrangement of cells, likely due to the more aggressive phenotype of this 
breast cancer cell line (figure 3-2). These cells are not as tightly bound 
with one another and appear to be comprised of fewer cells than either 
MCF7 or MSC spheroids.  
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Figure 3-2 MDA-MB-231 spheroids seeded at three cell densities. 
Spheroids cultured for 24 hours in collagen gel, representative of each cell 
seeding density. Images acquired with Zeiss Axio Vert A1. Red 
fluorescence derived from mNPs. Scale bar 10 µm. >20 spheroids 
measured at each cell seeding density across three biological replicates. 
Spheroid areas measured via pixel count using imageJ. Bars indicate min 
and max values. 
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MSC 
MSCs produced mid-range spheroids, where seeding density 
affected the size of the resulting spheroids. There was a significant 
difference between cell seeding densities of 6x103 cells/mL and the 
higher 2x104 cells/mL, with the mean area of cells seeded at the lower 
1x104 cells/mL not significantly different from either (p<0.05; figure 3-
2). This is reflected in images of these spheroids (figure 3-3). Spheroids 
derived from cells seeded at 2x104 cells/mL appear larger that spheroids 
derived from lower seeding densities, with a mean area exceeding 200 
µm2 and a larger range. Spheroids derived from lower cell seeding 
densities (6x103 cells/mL and 1x104 cells/mL) appear similar in size, both 
having a mean area under 200 µm2 and a smaller range; cells seeded at 
6x103 cells/mL having the smallest range likely due to the lower 
availability of cells.  
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Figure 3-3 MSC spheroids seeded at three cell densities. Spheroids 
cultured for 24 hours in collagen gel, representative of each cell seeding 
density. Images acquired with Zeiss Axio Vert A1. Green fluorescence 
derived from mNPs. Scale bar 10 µm. >20 spheroids measured at each cell 
seeding density across three biological replicates. Spheroid areas 
measured via pixel count using imageJ. Bars indicate min and max values 
asterisk indicates p<0.05. 
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3.2.ii Electron Microscopy 
Following cell density results, all future spheroids were derived 
from cells seeded at 1x104 cells/mL. Spheroids of each cell type were 
investigated using both scanning and transmission electron microscopy 
(SEM and TEM respectively). Spheroids were generated as in section 2.5 
and prepared for SEM as described in section 2.18.i. TEM was performed 
to confirm mNP internalisation and to identify the distribution of the mNPs 
within individual cells in spheroids. Spheroids were sectioned as described 
in 2.18.ii. 
MCF7 spheroids were generated and imaged after 24 hours at 
1500x, 2000x and 10000x magnification. The lower magnification shows 
the whole spheroid (figure 3-4A), providing gross morphology of the entire 
spheroid, with an approximate spheroid diameter of 50 µm, similar to the 
cell density study. Increasing the magnification shows the compacted 
nature of the cells within the spheroid mass (figure 3-4B,C), with 
approximate cell diameters around 10 µm, and indicates the close 
relationship between constituent cells. Outer, peripheral, cells appear 
less compacted; conversely inner cells can be seen compacted to a 
diameter of ~5 µm (figure 3-4B), suggesting peripheral cells experience 
less force from surrounding cells due to the side exposed to the 
environment. Further magnification allows the close cell-cell relationships 
to be seen where protrusions from membranes of neighbouring cells 
appear to bind to one another forming tight junctions between them. 
TEM images of MCF7 spheroids show mNPs are contained within 
endosomes (figure 3-4D), derived from internalisation via multiple 
endocytic pathways. No mNPs were detected between cells within a 
spheroid, suggesting all three cell types are able to retain the mNPs once 
internalised. Further to this, no mNPs were detected within any 
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mitochondria. The border of the nucleus can be seen as a double 
enveloped membrane containing the denser genetic material; No mNPs 
were present past the nuclear membrane. 
 
 
Figure 3-4 Electron microscopy of  multicellular MCF7 spheroids. A) 1500X 
magnification; scale bar 10 µm B) 2000X magnification; scale bar 10 µm 
C) 10000X magnification; scale bar 2 µm, arrows indicate nanoscale 
protrusions. Images captured using JEOL JSM-6400 scanning electron 
microscope at 10kV. D: Transmission electron microscopy of an individual 
cell within spheroid containing mNPs; black arrow indicates nuclear 
membrane, red arrow indicates cell membrane, white arrow indicates 
mNPs. Scale bar 1 µm. Images captured using JEOL 1200 tunnelling 
electron microscope at 80kV. Spheroids cultured for 24 hours in all cases. 
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SEM of MDA-MB-231 spheroids incorporating the whole spheroid 
indicate smaller sized spheroids comprised of fewer cells than those using 
MCF7, with approximate diameter of 30 µm (figure 3-5A), supporting the 
cell density study. The MDA-MB-231 cells are compacted, presenting a 
ball-like phenotype. In a similar fashion to MCF7 cells, these MDA-MB-231 
cells have an approximate diameter of around 5-10 µm (figure 3-5B). 
Higher magnification (figure 3-5C) shows cells within the spheroid are not 
as tightly bound as MCF7; cell membrane protrusions appear to extending 
out into the environment and each cell is distinct. 
 TEM produced images similar to those from MCF7 spheroids; mNPs 
resided within the cell in endosomes distinct from the cytoplasm and were 
not present in spaces between cells nor within the nuclei of any cells 
(figure 3-5D). 
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Figure 3-5 Electron microscopy of  multicellular MDA-MB-231 spheroids. 
A) 100X magnification; scale bar 10 µm B) 4000X magnification scale bar 
5 µm C: 10000X magnification; scale bar 2 µm, arrows indicate nanoscale 
protrusions. Images captured using JEOL JSM-6400 scanning electron 
microscope at 10kV. D: Transmission electron microscopy of an individual 
cell within spheroid containing mNPs; black arrow indicates nuclear 
membrane, red arrow indicates cell membrane, white arrow indicates 
mNPs. Scale bar 1 µm. Images captured using JEOL 1200 tunnelling 
electron microscope at 80kV. Spheroids cultured for 24 hours in all cases. 
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MSC spheroids tended to be smaller than MCF7-derived spheroids, 
despite the same cell seeding density, with spheroid diameters of 40 µm 
(figure 3-6A) and an overall area approximate to the mean determined in 
figure 3-2 at 1x104 cells/mL. Cells within the spheroid are compacted in a 
similar way to both BCC lines, with cells measuring approximately 5-10 
µm in this three-dimensional environment. Similarly to MCF7 spheroids, 
increasing the magnification shows the outer membranes of cells 
comprising the spheroid are indistinct indicating invidual cells are tightly 
associated with one another (figures 3-6B,C). 
TEM produced images similar to those from both MCF7 and MDA-
MB-231 spheroids; mNPs resided within the cell in endosomes distinct from 
the cytoplasm and were not present in spaces between cells nor within 
the nuclei of any cells (figure 3-6D). 
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Figure 3-6 Electron microscopy of multicellular MSC spheroids. False 
colour scanning electron microscopy A) 2500X magnification; scale bar 10 
µm B) 5000X magnification; scale bar 5 µm C) 10000X magnification; scale 
bar 2 µm, arrows indicate nanoscale protrusions. Images captured using 
JEOL JSM-6400 scanning electron microscope at 10kV. D) Transmission 
electron microscopy of an individual cell within spheroid containing mNPs; 
black arrow indicates nuclear membrane, red arrow indicates cell 
membrane, white arrow indicates mNPs. Scale bar 1 µm. Images captured 
using JEOL 1200 tunnelling electron microscope at 80kV. Spheroids 
cultured for 24 hours in all cases. 
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3.2.iii MCF7 Spheroid Viability 
Following the cell density and electron microscopy, all future BCC 
spheroids were constructed using MCF7 cells as they generated stable 
spheroids that remained intact over time, where those generated with 
MDA-MB-231 cells were generally smaller in size, with a large range of 
sizes. In addition, MDA cells tended to migrate away from the central 
spheroid mass into the three-dimensional environment of the collagen gel.  
The viability of the MCF7 spheroids was subsequently assessed, 
using the method described in section 2.15, across several days. After both 
1 and 7 days there was negligible cell death, indicated by the presence of 
red fluorescent ethidium (figure 3-7). The majority of the cells within the 
spheroid were alive, indicated by the presence of green fluorescent 
calcein. 
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Figure 3-7 MCF7 spheroid viability. Spheroids were cultured in collagen 
gels for A) 1 day and B) 7 days before being treated with calcein AM to 
detect live cells (green) and ethidium homodimer to detect dead cells 
(red). Images acquired with Zeiss Axio Vert A1. Scale bar 10 µm. 3 
spheroids imaged with representative spheroid shown. 
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3.2.iv BrdU Proliferation Assay 
The proliferation of MCF7 spheroids was assessed across a 10-day 
period through BrdU incorporation as described in section 2.13.  
Peripheral cells in spheroids cultured in collagen gels incorporated BrdU, 
and were therefore actively synthesising new DNA and proliferating, after 
1 and 24 hours (figure 3-8A, B). Proliferation was reduced after 72 hours 
and absent after 10 days.  The cells within the spheroid mass were still 
partially active at 1 hour (figure 3-8A indicated by the yellow overlap of 
green mNPs and red antibody-bound BrdU), with only a low level of BrdU 
fluorescence noted after 72 hours (figure 3-8C). After 10 days in collagen 
gel the spheroids possessed no red fluorescence (figure 3-8D) indicating 
no proliferation, suggesting the spheroid had become quiescent between 
7 and 10 days.   
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Figure 3-8 BrdU proliferation marker present in MCF7 spheroids. 
Spheroids cultured in collagen gel for A) 1 hour, B) 24 hours, C) 72 hours 
and D) 10 days. Images acquired with Zeiss Axio Vert A1. Green 
fluorescence indicates presence of mNPs, red fluorescence indicates the 
presence of BrdU probed for using anti-BrdU antibody. Scale bar 10 µm. 3 
spheroids imaged at each time point with representative spheroid shown. 
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3.2.v Fluidigm qPCR of Co-Cultured MSC and MCF7 
Spheroids 
Following the characterisation of individual MSC and MCF7 spheroid 
culture, spheroid co-cultures were set-up to determine the influence each 
cell type has on the other in terms of cell cycle, phenotype and 
differentiation. MCF7 and MSC spheroids were cultured in collagen gels 
individually and together; the co-culture was performed as in section 2.6.i 
and gels were digested as in section 2.7. Where two cell types were 
present, the cells had to be sorted via FACS as described in section 2.11 
to separate the MSCs from MCF7 prior to extracting RNA. Fluidigm real-
time PCR was performed as described in section 2.10 and the results 
herein show the difference in gene expression between spheroids cultured 
individually and spheroids cultured together. The genes assessed are 
described in table 2-2. 
Effects of Spheroid Co-Culture on MSC Gene Expression 
The difference in gene expression of MSC/MCF7 co-cultured 
spheroids compared with MSCs cultured alone was determined using ΔΔCt. 
This compared each gene with a housekeeping gene control (GAPDH) to 
normalise the expression value. These normalised values were then 
compared to determine how co-culture changes gene expression (figure 
3-9).  
  
CHAPTER 3 SPHEROID CHARACTERISATION 
82 
MSC Cell Cycle : Co-culture downregulated the expression of genes in each 
stage of the cell cycle several-fold after 7 days in culture. Genes 
successfully assayed included both cyclins and cyclin-dependent kinases. 
As shown n figure 1-3, these genes are active at each stage of the cell 
cycle and several, such as CCNE2 and CDK2 are checkpoints required to 
pass from G1 to S phase. The largest decreases are seen in these stages 
early in the cell cycle, preventing initiation of cell division and DNA 
synthesis. Whilst CDC7 is upregulated, it acts upon the G1/S transition 
where other genes have been downregulated; the overall downregulation 
will no doubt counter this singular gene. 
 
Figure 3-9 ΔΔCt of cell cycle gene expression in MSC spheroids in co-
culture with MCF7 spheroids compared with MSC spheroid monoculture. 
Expression normalised to GAPDH. Spheroids cultured in collagen gel for 7 
days. Error bars indicate standard error mean; n=3 with 3 technical 
replicates from each.  
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MSC Phenotype: A panel of epithelial-to-mesenchymal transition 
(EMT) genes was assessed to determine how co-culture effects the 
mesenchymal phenotype of MSCs (figure 3-10). Co-culture upregulates N-
cadherin and downregulates E-cadherin, suggesting that MSCs will reduce 
cell-cell adhesion within the spheroid. Other epithelial marker genes 
assessed such as JUP and Keratin 19 showed over a five-fold reduction 
indicating an increase in the mesenchymal nature of the MSCs. This is 
further supported with the upregulation of FN1, a marker of EMT. 
Successfully assessed genes therefore suggest that MSC/MCF7 spheroid co-
culture supported retention of MSC phenotype, with increased migration 
potential. 
 
Figure 3-10 ΔΔCt fold change of EMT marker gene expression in MSC 
spheroids in co-culture with MCF7 spheroids compared with MSC spheroid 
monoculture. Expression normalised to GAPDH. Spheroids cultured in 
collagen gel for 7 days. Error bars indicate standard error mean; n=3 with 
3 technical replicates from each.  
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MSC Differentiation: Several differentiation marker genes were 
assayed (figure 3-11). Osteopontin (OPN) was upregulated ~3-fold in MSC 
co-culture reinforcing an MSC migratory phenotype. CXCL12 expression 
was also upregulated, again indicating increased cell mobility.  
Differentiation marker genes PPARγ, RUNX2 and osterix (OSX) are all 
downregulated in co-culture compared with MSC spheroid monoculture. 
This may indicate a retention of the stem cell phenotype when co-cultured 
with MCF7 cells. 
 
Figure 3-11 ΔΔCt fold change of osteogenic differentiation marker gene 
expression in MSC spheroids in co-culture with MCF7 spheroids compared 
with MSC spheroid monoculture. Expression normalised to GAPDH. 
Spheroids cultured in collagen gel for 7 days. Error bars indicate standard 
error mean; n=3 with 3 technical replicates from each.  
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Effects of Spheroid Co-Culture on MCF7 Gene Expression 
The influence of MCF7/MSC spheroids co-culture compared to MCF7 
singular spheroid culture in terms of MCF7 gene expression was also 
assessed (figure 3-12&13).  
MCF7 Cell Cycle: BrdU data suggested that MCF7 cells were initially 
proliferative within spheroid culture, eventually becoming quiescent with 
time in culture (by day 7-10).  However, the proximity with MSCs has 
upregulated MCF7 cell cycle genes (figure 3-12); each one of the genes 
successfully assayed was upregulated in each stage of the cell cycle. This 
suggests that MSC co-culture causes MCF7 cells to either maintain their 
initial proliferation or become proliferative in the 3D collagen gels (figure 
3-12). 
 
Figure 3-12 ΔΔCt of cell cycle gene expression in MCF7 spheroids in co-
culture with MSC spheroids compared with MCF7 spheroid monoculture. 
Expression normalised to GAPDH. Spheroids cultured in collagen gel for 7 
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days. Error bars indicate standard error mean; n=3 with 3 technical 
replicates from each.  
MCF7 Phenotype: A panel of 8 EMT marker genes were successfully 
assayed (figure 3-13). Whilst N-cadherin assay was unsuccessful, the E-
cadherin gene expression increased 4-fold in co-culture suggesting cells 
become more adherent. Keratin 19, another negative marker for EMT was 
upregulated. JUP is an important marker of outgrowth and is 
downregulated here 16-fold. Vimentin and TYRO3 are both highly 
downregulated (8- and 10-fold respectively) indicating a reinforcement of 
the epithelial phenotype and a resistance to migrate into the environment 
when co-cultured with MSCs. 
 
Figure 3-13 ΔΔCt fold change of EMT marker gene expression in MCF7 
spheroids in co-culture with MSC spheroids compared with MCF7 spheroid 
monoculture. Expression normalised to GAPDH. Spheroids cultured in 
collagen gel for 7 days. Error bars indicate standard error mean; n=3 with 
3 technical replicates from each.  
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3.3 Discussion 
Within the BM niche, resident MSCs remain quiescent until they are 
required to respond to external signalling cues.  Invading BCCs are also 
able to become quiescent (or dormant) within this environment. This 
chapter aimed to determine the best BCC line to use in development of a 
simple in vitro model for the BM niche; by co-culturing MSCs and BCCs 
spheroids within a controlled three-dimensional microenvironment their 
interactions can be assessed.  
Standard two-dimensional monolayer MSC culture generates an 
artificial environment, unlike the native in vivo environment, causing 
many factors to be lost (Mueller-Klieser et al., 1997). In three-dimensional 
spheroid culture MSC morphology is vastly different from monolayer 
culture; instead of adopting a stellate morphology, MSCs will form a ball-
like phenotype (figure 3-6) and tightly adhere to neighbouring cells 
through cadherins (Lee et al., 2012). This morphological change affects 
MSC proliferation, motility, metabolism and differentiation potential 
(Bellas and Chen, 2014, McBeath et al., 2004). 
The stiffness of the environment also plays a vital role in MSC 
growth and differentiation. For example, in monolayer culture, the 
Young’s modulus of culture plastic is in the GPa range, whereas the BM 
environment is several orders of magnitude lower (Baraniak et al., 2012). 
The type of spheroid culture adopted here, where spheroids are cultured 
within a type I collagen gel, mimicking the native bone marrow 
microenvironment, with the collagen gel approximately 10kPa (Lewis et 
al., 2016). We believe that the stiffness of the environment affects the 
cell cytoskeleton, thus changing gene expression and causing the MSCs to 
quiesce (Lewis et al., 2016).  
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3.3.i MSC Spheroid Culture 
 MSC spheroid size was dependent on cell seeding density; more 
cells lead to larger spheroids, but also a greater range of sizes (figure 3-
2). It is evident that higher seeding densities permit faster spheroid 
formation as more cells are present in the same location. Furthermore, as 
there will be more small spheroids, these are able to accrete to form 
larger spheroids in the incubation period. This relationship is similar to 
that seen by Bartosh and colleagues (2010); larger numbers of cells added 
will produce larger spheroids in a linear fashion. However, the cell 
numbers are much larger, in some cases 250,000 cells/mL, producing 
spheroids much larger in size over a period of up to 4 days instead of the 
24 hour incubation used within this study. 
 The results here supported previous finding in our group where 
Lewis et al. (2016) reported that MSCs remain viable when cultured as 
spheroids in collagen gels, with increased MSC marker retention and 
reduced proliferation (i.e. MSCS become quiescent). 
 
3.3.ii MCF7 Cells Generate Stable Spheroids 
MCF7 cells form spheroids similar in size to MSCs, whilst MDA-MB-
231 cells generate much smaller spheroids.  Likewise, MCF7 spheroids 
increase in size and size range with increasing cell numbers, while MDA 
spheroids remain of a similar overall size regardless of the cell seeding 
density. As detailed in section 1.2 there are several key differences 
between MCF7 and MDA-MB-231 BCCs. MCF7 possesses a strong epithelial 
phenotype (Yin, 2011); in monolayer these cells will form colonies due to 
the high native E-cadherin expression (Hazan et al., 2004). The E-cadherin 
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expression is maintained within 3D culture, potentially enhancing 
spheroid formation (Yui et al., 2005). 
 The SEM images of the MCF7 spheroids supports their epithelial 
phenotype, demonstrating cells closely associated with one another.  The 
lamellipodia on the cells’ surfaces can be seen in figure 3-4C; 
neighbouring cells appear to be joined at these cellular protrusions, likely 
through E-cadherin (Yui et al., 2005). In the absence of any external cues 
these bonds will remain strong (Hazan et al., 2004).  MCF7 cells adopted 
a ball-like phenotype as they are compacted within the speroid (figure 3-
4)(Webster et al., 2008). MCF7 spheroids cultured alone in collagen gels 
are intially proliferative, becoming quiescent by day 7. The rounded cell 
morphology may encourage cell quiescence as it is believed the 
cytoplasm:nucleus ratio dictates whether the nucleus enters G0 or divides 
(Roca-Cusachs et al., 2004).  
Cell phenotype, therefore, appears to play a significant role in 
spheroid generation. MDA-MB-231 exhibits a mesenchymal phenotype, so 
is prone to metastasis (Charafe-Jauffret et al., 2006). This phenotype 
results in a low E-cadherin expression (Theys et al., 2011), with a higher 
N-cadherin expression increasing cell motility (Nieman et al., 1999). This 
is likely why spheroids generated using MDA-MB-231 do not aggregate into 
larger masses when more cells are available (figure 3-3).  It is for this 
reason that MCF7 cells were selected moving forward with MSC co-culture  
studies, as MCF7 spheroids are stable and appear quiescent in 3D culture. 
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3.3.iii MCF7 Cells Become Quiescent in 3D Spheroid 
Culture 
Initially the MCF7 spheroids retain their proliferative activity as 
they are transferred into the collagen gel matrix. Over time in culture this 
activity is lost and distinct zones become apparent within the cell mass.  
The core cells lose their proliferative activity, perhaps as they are 
compacted against neighbouring cells (De Sousa et al., 2013), reducing 
the availability of nutrients. Meanwhile, the peripheral cells remain 
proliferative for longer as they have access to the surrounding 
environment. This proliferation gradient is a key factor when modelling 
micrometastases, as this occurs in an in vivo setting (Mueller-Klieser, 
1987). The loss of cell proliferation by day 10 further supports the use of 
MCF7 cells in further analysis of breast cancer dormancy within the BM 
environment.  
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3.3.iv MSC and MCF7 Spheroid Co-Culture 
In order to create a 3D bone marrow model of BCC 
dormancy/recurrence, both MSC and MCF7 cell spheroids were co-
cultured together within the collagen gel.  Co-culture for 7 days clearly 
changed several aspects of gene expression within both cell types. 
MSC Spheroids are Quiescent and Retain phenotype in Co-
culture 
As previously stated, MSCs cultured as spheroids within collagen 
gels enter a quiescent state after several days (Lewis et al., 2016). Whilst 
there is much research into how MSCs might affect BCC proliferation in 3D 
co-culture, studies into the converse are much less common. It is 
interesting then that MCF7 spheroids in close proximity to MSCs enhance 
their quiescence by actively downregulating many cell cycle genes (figure 
3-9).  
Conversely the phenotype (EMT) markers expressed by MSCs in co-
culture show an upregulation in the mobile mesenchymal phenotype 
(figure 3-10), perhaps leading to cell migration in the BM environment via 
signalling axes caused by the proximal BCCs, such as CXCR4-CXCL12 (Wang 
et al., 2006). 
MCF7 spheroids appear to have a positive effect on the long-term 
stemness of MSCs (Melzer et al., 2016), where key markers are 
downregulated to prevent a movement towards either osteogenesis or 
adipogenesis (figure 3-11).  
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MCF7 Spheroids Re-enter Cell Cycle While Retaining Phenotype 
in Co-culture 
Conversely the MCF7 spheroid cells co-cultured with MSCs 
experience an upregulation of genes at each stage of the cell cycle, when 
compared to MCF7 spheroids cultured in isolation (figure 3-12). BCCs co-
cultured with MSCs have previously been shown to increase proliferation 
following both physical contact and paracrine signalling (Daverey et al., 
2015; Maffey et al., 2017). MCF7 cells cultured in 3D scaffolds as both 
multicellular spheroids or discrete cells display an increase in 
tumourigenicity and secrete pro-angiogenic factors in addition to 
becoming stem cell-like indicated by CSC markers CD44+/CD24low/- (Boo et 
al., 2016; Chen et al., 2012).  
The presence of the MSCs appears to reinforce the epithelial MCF7 
phenotype, with an increase in EMT markers present in MCF7 spheroids 
(figure 3-13); a resistance to metastasise further.  
Generating these spheroids separately causes the spheroids to 
reside within the gel distinctly, with a relatively large distance between 
them (up to 1 cm in the case of gels generated in 24-well plates). This 
does not stop the presence of one cell type affecting the other so this 
would indicate a paracrine signalling effect. This effect could be caused 
by several agents; cytokines (Karnoub et al., 2007), cellular metabolites 
(Chiarugi et al., 2016) or exosomes (Bliss et al.,2016). The effects of these 
will be assessed in future chapters. Direct contact between the two cell 
types may also be playing a role, through the formation of gap junctions 
between the cells, then can permit the passage of microRNAs (Gregory et 
al., 2011), and receptor ligand interactions (Wang et al., 2006).  
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3.4 Conclusion 
In this chapter, the previously described method of spheroid generation 
using mNPs has been successfully adopted in both MCF7 and MDA-MB-231 
BCC lines, in addition to providing further data for MSC-based spheroids. 
The seeding density of future spheroids in this thesis was determined to 
be 1x104 cells/mL. This study indicated that MDA-MB-231 spheroids were 
not suitable moving forward with the in vitro model, due to their small 
size and difficulty with maintaining them in collagen gel. Therefore, MCF7 
will be used.  
The gene expression data obtained from MSC/MCF7 spheroid co-culture 
suggested active paracrine signalling, with each cell type affecting the 
other. In subsequent chapters I will look at the type of paracrine signalling 
that may be responsible, and try to determine whether we can use these 
cell signals to control MCF7 cell behaviour in culture, with the potential 
to artificially control cell dormancy and recurrence.  
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4 Paracrine Cell Signalling in MSC/MCF7 Co-Culture  
4.1 Introduction 
The mechanism of primary metastasis is well documented (Kang et 
al., 2003; Weigelt et al., 2005; Hüsemann et al., 2008).  However, the 
mechanism of secondary metastasis within the BM is currently not well 
understood (Chaffer and Weinberg, 2011). The initiation of cancer cells, 
in particular BCCs, from dormant to a recurrent, active state has been a 
focus of much research (Paik et al., 2004; Dent et al., 2007; Korde et al., 
2018). It is believed that external environmental stimuli cause dormant 
cancer cells to re-enter the cell cycle allowing secondary metastasis to 
occur. 
The BM microenvironment contains multiple cell types, including 
resident MSCs, which secrete many soluble factors, such as cytokines and 
chemokines, which maintain cellular homeostasis in the BM (Papaccio et 
al., 2017).  On entering the BM environment, invading cancer cells are 
exposed to these soluble factors (Birbrair and Frennette, 2016). 
Therefore, paracrine signaling, facilitated by the cytokine secretion of 
cells residing in the BM, may be key when considering BCC dormancy and 
recurrence in the marrow.  
Of particular relevance are resident MSCs, which govern the 
homeostasis of the BM microenvironment. As described in chapter 1, MSCs 
respond to tissue injury via migration and differentiation by using soluble 
factors as chemical cues.   Local inflammation or injury causes immune 
cells within the BM to release cytokines such as transforming growth 
factor-β (TGFβ1), tumour necrosis factor-α (TNF-α), several interleukins 
including IL-1, IL-6, IL-10 and the interferons; all play an important role 
in controlling the immune system (Yagi et al, 2012). These cytokines also 
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stimulate the recruitment of MSCs where they are able to initiate tissue 
repair at the site of wound (Maxson et al, 2012). 
In addition to their own response to chemokines, MSCs themselves 
anchor in the BM and secrete soluble factors to influence other resident 
cells. For example, MSCs secrete cytokines such as CXCL12 that are 
integral in maintaining a population of self-renewing HSCs (Mishima et al., 
2015). In addition, MSCs secrete a range of anti-inflammatory cytokines 
such as IL-10 and VEGF, which can affect the polarisation of macrophages 
(Sridharan et al., 2015); and IL-6, which stimulates tumour growth through 
the production of tumour-stimulating factors (Spaeth et al., 2013). 
When considering BCC invasion into the marrow, the BCCs will 
therefore also be influenced by soluble factors secreted by MSCs. Indeed, 
BCCs are attracted towards MSCs via the CXCR4/CXCL12 axis.  It is well 
established that the proliferation and metastatic potential of BCCs is 
dependent on autocrine signalling of cytokines such as IL-6 and IL-8 
(Hartman et al., 2013). Thus it seems appropriate to suggest that MSCs 
are able to regulate the growth of BCCs within the BM through cytokine 
networks (Liu et al., 2011).  
The in vitro model of the BM described in Chapter 3 will provide an 
excellent platform to study paracrine signaling of MSCs and MCF7 3D co-
cultured spheroids. Through the culturing of individual spheroids 
discretely and also in co-culture, the model provides an opportunity to 
ascertain how each cell type may affect the other; MSCs may react 
differently in the presence of BCCs and vice versa. 
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4.1.i Objectives 
 This chapter aims to assess paracrine signalling in MSC/MCF7 co-
cultures. Initially, the types of cytokines secreted from both cell types 
well be determined, followed by migration studies on the cells in both 
monolayer and 3D spheroid culture. In order to achieve this, the following 
objectives will be met: 
• The identification of key cytokine secretions from MSC and MCF7 
cell spheroids, from both individual and co-cultures. 
• Assessing the effect of two main MSC-derived cytokines, IL-6 and 
TGFβ1, on MCF7 cell migration. 
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4.2 Results 
Chapter 3 described a co-culture system for MSC and MCF7 
spheroids.  These co-cultures will be used throughout this chapter to 
ascertain the influence each cell type may have on the other in terms of 
paracrine (cytokine) signalling.  The spheroids are co-cultured and imaged 
using the fluorescent properties of the mNPs.  
MCF7 and MSC Spheroid Co-cultures 
MSC and MCF7 spheroids were co-cultured in collagen gels as 
described in section 2.6.i. After 3 days’ co-culture the MSC and MCF7 
spheroids were observed in close proximity (figure 4-1A), but appear to 
retain their bulk spheroid morphology. Further time in co-culture, 
however, appears to disturb the distinct spheroid structures, where cells 
from both MCF7 and MSC spheroids appear to migrate out into the collagen 
gel environment, interacting with each other (figure 4-1B). 
 
Figure 4-1 MCF7 and MSC spheroids co-cultured in a collagen gel. A) 3 
days and B) 7 days. Images acquired using Zeiss Axio Vert A1 fluorescent 
microscope and colourised using Adobe Photoshop; (n=3, representative 
spheroid shown, scale bar 10 µm). Arrows indicate areas of yellow 
fluorescence where red and green are co-localised, indicating cell 
interaction. 
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4.2.i Cytokine Secretions  
 MSC and MCF7 spheroids were generated as described in section 2.5 
and cultured in collagen gels as in section 2.6. In the case of MSC/MCF7 
spheroid co-culture, spheroids were generated discretely and cultured in 
the same gel as described in section 2.6.i. After 3 days, the culture 
medium was removed from the gel and replaced. This was then removed 
4 days later, at day 7 post gel implantation. These conditioned media were 
then applied to individual 23-target cytokine arrays as described in section 
2.17. The targets and array layout are shown in table 2-7 below. Targets 
were selected based on a literature review to determine which cytokines 
are key in BM homeostasis. The positive control spots on each array 
contain the same amount of IgG; the mean pixel density derived from 
positive controls on each of the six arrays was similar so each array can 
be fairly compared (figure 4-2).   
Table 4-1 Abcam 23-target cytokine array layout. POS denotes positive 
control IgG and NEG denotes spots containing buffer only. 
POS POS NEG NEG G-CSF GM-CSF GRO GROα 
POS POS NEG NEG G-CSF GM-CSF GRO GROα 
IL-1α IL-2 IL-3 IL-5 IL-6 IL-7 IL-8 IL-10 
IL-1α IL-2 IL-3 IL-5 IL-6 IL-7 IL-8 IL-10 
IL-13 IL-15 IFN-γ MCP-1 MCP-2 MCP-3 MIG RANTES 
IL-13 IL-15 IFN-γ MCP-1 MCP-2 MCP-3 MIG RANTES 
TGFβ1 TNF-α TNF-β blank blank blank blank POS 
TGFβ1 TNF-α TNF-β blank blank blank blank POS 
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Figure 4-2 Cytokine secretion of MCF7 and MSC spheroids cultured alone 
or together in collagen gel. DMEM was collected from gels at day 3 and 7 
then applied to individual 23 target cytokine arrays. Antibody 
chemiluminescence detected using Azure c500 Infrared Western Blot 
Imaging System. Pink box indicates TGFβ and blue IL-6. Green squares 
indicate positive controls, red negative.  MSC Spheroid Cultures 
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Many cytokines assayed by MSC spheroid monocultures did not 
greatly change between days 3 and 7 (figures 4-3 and 4-4 respectively). 
However, longer culture did affect the levels of some cytokines secreted 
into the culture medium both positively and negatively; there was a 
significant decrease (p<0.05) in IL-8 and MCP-1, with a significant increase 
in TNFβ secretion after 7 days vs 3 days. 
When compared with MCF7 cytokine secretion levels, MSCs clearly 
secrete large levels of many interleukins (eg. IL-3, - 5, -6, -7, -8 and -10) 
at the earlier 3 day time point; however, by day 7, in almost all cases, 
whilst MSC secretion levels have not changed, MCF7 levels have increased 
to match the MSCs.  
 
  MCF7 Spheroid Cultures 
 In a similar way to MSC spheroid monoculture, MCF7 spheroids 
cultured alone do not exhibit large variations in cytokine secretions 
(figures 4-3 and 4-4 respectively). Whilst many cytokines are reduced 
after 7 days in culture, IL-8 and MCP-1 are significantly increased and 
TNFβ decreased, the converse to that seen in MSC spheroid monoculture. 
 
  MSC/MCF7 Spheroid Co-Cultures 
The co-culture environment appears to create a slightly different 
cytokine profile. Many of the cytokines present in co-culture are 
significantly different (changes both higher and lower; p<0.05), clearly 
indicating that the cells are altering their paracrine signalling secretions 
in response to each other.  
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Co-culture does not appear to greatly affect the cytokine secretion 
profile of MSCs, with many levels appearing similar at both time points 
(figures 4-3 and 4-4 respectively). However, the TNF-β level at 3 days, is 
greatly reduced when MSCs are co-cultured with MCF7 compared with MSC 
spheroids alone (figure 4-3), indicating the presence of MCF7 is directly 
affecting the MSCs. The greater change arises between MCF7 spheroids 
and MSC/MCF7 co-culture. The nature of the experiment doesn’t allow 
the two cell types to be separated, but the overall level of cytokines 
released into the environment does not appear not additive (figure 4-3); 
it is not the concentration secreted by MSC spheroids plus that of MCF7 
spheroids.  
Proliferative cytokines such as IL-6 and TGFβ1 are increased in the 
co-culture compared with MCF7 alone, which will alter the behaviour of 
the breast cancer, likely causing cell division and migration. There is a 
significant decrease (p<0.05) in the pro-inflammatory cytokines MCP-1 
(CCL2), MCP-2 (CCL8) and RANTES (CCL5) after 7 days (figure 4-3). A 
decrease will slow the recruitment of pro-inflammatory immune cells, 
protecting the BCCs from destruction. Whilst these aren’t decreased until 
after day 3, TNFα and TGFβ are reduced after 3 days in co-culture 
compared with MCF7 alone, suggesting the MSCs are conferring an 
immune-protection upon the BCCs.  
The changes seen in the interleukins after 7 days (figure 4-3) will 
contribute to maintaining the immaturity of local immune cells, further 
protecting the BCCs from destruction. In these cases, it is clear that the 
presence of MCF7 is reducing the ability of MSCs to produce these 
cytokines that would ordinarily contribute to niche maintenance.  These 
results suggest that the presence of MCF7 cells causes MSC to alter their 
secretion profile, which may protect them from the immune cells present 
in the BM. 
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4.2.ii Interleukin-6 Effects on MCF7 
During co-culture, it was observed that both MSC and MCF7 cells 
migrate in 3D spheroid co-cultures at day 7 (figure 4-1). Assuming MCF7 
migration is related to MSC-derived cytokines, the cytokine profiling 
suggested that several cytokines may be responsible for this migration. In 
this regard, based on our results and the current literature implicating 
both with increased tumour proliferation and metastasis, IL-6 and TGFB 
were selected for further study, to determine their effect on MCF7 
migration.  
 
MCF7 Cell Migration Response to IL-6 (2D Study) 
Purified IL-6 protein was added to culture medium to determine 
any migratory influence upon MCF7 cells cultured in monolayer. The 
migration of individual MCF7 cells was assessed using time lapse over a 
period of 24 hours (figure 4-5). Cell migration was analysed and plotted, 
indicating preferential migration towards IL-6 (figure 4-8B). 
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Figure 4-5 MCF7 cell migration in the presence of an IL-6 gradient over 24 
hours. A) a vector plot of individual cells tracked, and B) a rose plot 
summarising overall migration. Coordinates (0,0) reflect the origin of each 
cell. DMEM containing IL-6 1 ng/mL concentration gradient located on 
negative x-axis, with undoped DMEM present towards the positive x-axis 
(12 cells tracked across 3 wells). Cells imaged on Zeiss Axiovert 25, 
photographed every hour for 24 hours and tracked using ibidi chemotaxis 
plugin for ImageJ. 
 
MCF7 Cell Migration Response to IL-6 (3D Spheroid Study) 
 MCF7 spheroids were cultured in collagen gels and incubated with 
culture medium containing IL-6. Spheroids were imaged 3 hours after the 
addition of IL-6-doped culture medium and again after 72 hours. No 
change was noted in spheroids cultured in control culture medium. No 
MCF7 migation was noted after 3 hour culture (figure 4-6C), however 
migration was clearly evident in all directions from the spheroid mass 
after 72 hours culture (figure 4-6D).  
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Figure 4-6 MCF7 spheroids cultured within a collagen gel incubated with 
1 ng/mL IL-6. MCF7 cultured in collagen gel for A) 3 hours and B) 72 hours. 
C) MCF7 spheroid cultured for 3 hours and D) 72 hours incubated with IL-
6. Images acquired using Zeiss Axio Vert A1 fluorescent microscope and 
colourised using Adobe Photoshop; (n=3, representative spheroid shown, 
scale bar 10 µm).  
 
MCF7 spheroids were subsequently cultured in the presence of IL-6 and 
imaged hourly, up to 24 hours, to allow a closer study of cell migration 
from the spheroid. Results indicated that cell migration occurs after 
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approximately 5 hours, however, it was not until around 10 hours culture  
that the spheroid diameter significantly differs from time zero (figure 4-
7). Spheroids cultured in DMEM only do not exhibit any significant chage 
in cell migration (figure 4-7). 
 
 
Figure 4-7 Relative MCF7 spheroid diameter measurements over 24 hours 
in culture with IL-6. MCF7 spheroids cultured in DMEM containing 1 ng/mL 
IL-6 or DMEM only, imaged every hour for 24 hours. Diameter was 
measured through centre of the spheroid and normalised to hour 0 (n=4; 
error bars show standard error mean). * denotes point from which there 
was a significant change from hour 0, p<0.05. Spheroids imaged on Zeiss 
Axiovert 25, photographed every hour for 24 hours and measured using 
ImageJ. 
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4.2.iii Transforming Growth Factor β1 Effects on 
MCF7   
MCF7 Cell Migration Response to TGFβ1 (2D Study) 
 Purified TGFβ1 was added to fresh DMEM before culturing MCF7 
cells, as in 4.2.iii with IL-6. The effect of TGFβ1 on MCF7 cells in cultured 
in monolayer was performed using chemotaxis slides, allowing a 
concentration gradient to be established. Cells cultured in these slides 
were able to experience an area of TGFβ1 on one side and TGFβ1-free 
culture medium on the other. Unlike cells exposed to IL-6 (figure 4-5), 
here MCF7 cells do not preferentially migrate towards TGFβ1 (figure 4-8). 
Cells do become active, moving through the environment, but in no 
particular directionality.  
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Figure 4-8 MCF7 cell migration in the presence of an TGFβ1 gradient 
over 24 hours. A) a vector plot of individual cells tracked, and B) a rose 
plot summarising overall migration. Coordinates (0,0) reflect the origin 
of each cell. DMEM TGFβ1 2 ng/mL concentration gradient located on 
negative x-axis, with undoped DMEM present towards the positive x-axis 
(12 cells tracked across 3 wells). Cells imaged on Zeiss Axiovert 25, 
photographed every hour for 24 hours and tracked using ibidi chemotaxis 
plugin for ImageJ. 
 
MCF7 Cell Migration Response to TGFβ1 (3D Spheroid Study) 
 Spheroid expansion was measured over 24 hours using TGFβ1, 
exactly as for IL-6. Spheroids appeared relatively unreactive to the TGFβ1 
until 9 hours culture, but from this point, MCF7 cells began to react by 
migration from the spheroid mass (figure 4-9). A steady increase in 
spheroid diameter was noted until 13 hours, when it becomes significantly 
larger (p<0.05) than hour 0. There is a much steeper increase in diameter 
than that seen in the presence of IL-6 (figure 4-7). The cells in the 
periphery of the spheroid move away several cell lengths over the 24 hour 
time period. Whilst cells did not appear to move towards the source of 
CHAPTER 4 PARACRINE CELL SIGNALLING IN MSC/MCF7 CO-CULTURE 
110 
TGFβ1 in monolayer (figure 4-8), it is possible that the cytokine caused 
cells to become more active as is shown here where cells comprising the 
spheroid move further into the environment over time. The TGFβ1 is 
present everywhere in the environment, whilst the collagen gel will 
provide a concentration gradient for nutrients, over time this will 
equilibrate and that is perhaps why the effect of TGFβ1 is not seen until 
around hour 10, as a threshold concentration at the spheroid has not been 
reached until then. 
 
Figure 4-9 Relative MCF7 spheroid diameter measurements over 24 hours 
in culture with TGFβ1. MCF7 spheroids cultured in DMEM containing 2 
ng/mL TGFβ1 or DMEM only, imaged every hour for 24 hours. Diameter 
was measured through centre of the spheroid and normalised to hour 0 
(n=4; error bars show standard error mean). * denotes point from which 
there was a significant change from hour 0, p<0.05. Spheroids imaged on 
Zeiss Axiovert 25, photographed every hour for 24 hours and measured 
using ImageJ. 
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4.3 Discussion 
Paracrine signalling within the BM is essential to the maintenance 
of the cells residing there. The cytokines produced by MSCs are vital to 
the maintenance of the stem cell niche, in addition to affecting the 
maturation of other local cells such as macrophages (Waterman et al., 
2010; Li and Wu, 2011). When BCCs metastasise to the BM they are able 
to use these paracrine signals within the microenvironment to their 
advantage. This forms the seed and soil hypothesis put forth by Paget over 
a century ago; metastatic cancer will only form new populations in tissues 
where the environment is compatible.  
  
4.3.i Cytokine Secretion Changes Upon Co-Culture of 
MSC and MCF7 Spheroids 
The results presented within this chapter demonstrate that MSCs 
and MCF7 spheroids do influence each other in 3D co-culture. Cytokine 
secretions are altered after both 3 and 7 days of co-culture (figures 4-3 
and 4-4 respectively). A summary of the significantly changes (p<0.05) is 
presented in table 4-2.  
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Table 4-2 Changes in cytokine levels of spheroid co-culture compared 
with spheroid monoculture at 3 and 7 days. Red = decrease, blue = 
increase and white no change. Data derived from figures 4-3 and 4-4. 
 Co-Culture v MSC Co-Culture v MCF7 
Cytokine 3 days 7 days 3 days 7 days 
TGFB1     
IL-6     
TNFα     
RANTES     
IL-1α     
IL-2     
IL-3     
IL-5     
IL-7     
IL-8     
IL-10     
MCP-1     
MCP-2     
TNFβ     
 
Cytokine Changes May Increase MCF7 Cell Migration and 
Proliferation in Co-culture 
Many of the cytokine changes observed occurred in the MCF7 
spheroids after 3 and 7 days of co-culture; this is reflected in a study by 
Liu and colleagues (2011), who note how co-culture between BCC and MSC 
causes an increase in many of the cytokine secretions of both cell types. 
The main cytokines which are altered in MCF7 co-culture compared with 
single spheroid culture include RANTES (decreased), TNFB/TGFB1 
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(increased), a range of interleukins (increased) and MCP-1 (initially 
increased, then decreased); taken globally, this infers changes in MCF7 
cell motility and proliferation, although when individual changes are 
studied, there is a mixed response.   In particular, the co-culture 
environment sees a reduction in some of the interleukins compared with 
MSC monoculture. This reduction in vivo could lead to a reduction in the 
number of pro-inflammatory macrophages maturing in the BM through this 
immunophentoype, protecting the BCCs from removal (Kim and Hematti 
et al., 2009).  
For example, RANTES is involved in cell homing and migration 
(Khalid et al., 2015). Karnoub and colleagues illustrated how co-culture of 
MSCs with the MDA-MB-231 cell line can lead to an increase in RANTES 
signalling, leading to increased motility. However, the results of this study 
show a decrease in RANTES upon MSC co-culture, perhaps due to a less 
invasive phenotype of the MCF7 cell type (as described in chapter 1).  This 
therefore suggests a decrease in MCF7 migration potential.  Likewise, 
although MCF7 migration is supported by an initial increase in MCP-1 (day 
3), this is decreased by day 7 co-culture. MCP-1 (or CCL2 as it is also 
referred to as) can stimulate angiogenesis to occur, enabling the 
development of breast cancer (Bonapace et al., 2014). It has been 
reported that MCP-1 along with RANTES (CCL5) when expressed by cells in 
the tumour stroma in the BM, such as MSCs, will promote a more active, 
malignant phenotype (Soria et al., 2008). Thus the reduction of these 
cytokines from the environment should inhibit further migration of the 
BCCs. 
Meanwhile, other cytokine changes noted for MCF7 cells in co-
culture actually support an increase in cell proliferation and migration, 
such as the increase in interleukin secretion. In particular IL-3, 5, 7, 8, 
and 10 are all increased in co-culture at day 3. Il-10 maintained an 
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increase in secretion over the longer day 7 time point, which is 
interesting, as Il-10 is implicated in breast cancer progression (with 
increase mRNA levels in breast cancer cells) and is involved in 
angiogenesis (Sheikpour et al., 2018). Together, the increase in the 
interleukins would cause an increase in MCF7 cell proliferation and 
motility, both of which have been observed in chapter 3 (increased MCF7 
proliferation upon co-culture) and in figure 4.1 in this chapter (fluorescent 
images indicating showing MCF7 cell migration in co-culture).  
TNFβ/TGFβ1 are both increased in MCF7 cells at day 7 co-culture. 
Both are involved in cell growth and differentiation, whilst also being 
responsible for increasing cancer cell invasiveness and stimulating 
angiogenesis (Pang et al., 2016). The fact that both are increase in co-
culture again supports an increase in MCF7 cell migration. In vivo, the 
paracrine signalling to macrophages in the environment will cause them 
to mature into the immunosuppressive M2 subtype (Song et al., 2015). Rey 
and Colleagues (2018) report an increase in the aggressive phenotype of 
MCF7 cells cultured with MSCs, where co-culture induced the CSC surface 
marker CD44+/CD24low/- and surface E-cadherin was internalised leading 
to reduced cell-cell adhesion. Their study had cells seeded freely 
throughout a collagen gel so lacks the features of a spheroid culture where 
a concentration gradient can be produced across the cross-section of the 
mass. 
 
A Decrease in Cytokine Secretions in Co-culture Support 
Reduced MSC Migration 
 Several cytokines were decreased when MSCs were co-cultured 
with MCF7. The effect this has is not necessarily upon the MSCs directly, 
although the previous chapter suggested MCF7 prevent differentiation; 
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the effect is more likely to be upon cells residing in close proximity in the 
BM niche with the MSCs (Dhawan et al., 2013). In particular, the results 
showed a general decrease in interleukin secretion (IL-2, 3, 5 and 10) by 
MSCs after 7 days’ co-culture with MCF7. Reduced MSC proliferation was 
maintained in co-culture, as demonstrated by the cell cycle study in 
chapter 3; a reduction in interleukin secretion would further support this.   
When extrapolated to the BM environment, the changes in 
cytokines observed during MSCs co-culture may lead to a polarisation of 
macrophages to the M2 subtype (Tripathi et al., 2010). Where M1 
macrophages are proinflammatory cells, M2 macrophages will confer the 
opposite effect. As poor antigen presenting cells, they will prevent any 
further immune response thereby conferring an immunoprotection upon 
the BCCs. Paracrine signalling by MSCs is a major contributor to the 
polarisation of macrophages in the BM and the decrease of cytokines such 
as CCL2, 5 and 8 (MCP-2) will reduce the homing of pro-inflammatory 
immune cells to the MSCs. Therefore, if invading BCCs are in close 
proximity to MSCs, they will be protected from the immune response, 
subsequently this will allow them to remain in the BM undisturbed.  
 
4.3.ii IL-6 Stimulates MCF7 Cell Migration 
IL-6 has been identified as a key paracrine signal for MSC migration 
within the BM niche model used in this study (Lewis et al., 2016), whilst 
TGFβ1 has been shown to have an effect on breast cancer metastasis (Yin 
et al., 1999). In addition, both cytokines have been noted as important 
factors in the EMT of BCCs (Sullivan et al, 2009; Lamouille et al, 2014) in 
the BM.  Whilst the actual role of TGFβ1 in cancer cell progression is 
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ambiguous, it may positively affect the growth of hormone responsive 
cancers, such as MCF7 (Buck and Knabbe, 2006). 
There is a body of evidence that IL-6 in the environment causes 
BCCs to induce EMT and become metastatic (Kim et al., 2003; Knüpfer and 
Preiß 2007; Sullivan et al., 2009). Hence, IL-6 was assessed in our cell 
models to determine the effect it had upon MCF7 cells in 2D monolayer 
and 3D spheroid culture. In both cases MCF7 cells migrated towards [IL-
6]. Fierro and colleagues (2004) reported that IL-6 can induce MCF7 cell 
proliferation and migration. Furthermore, MSC co-culture has been shown 
to increase MCF7 cell proliferation 2-fold through IL-6-related pathways 
(Sasser et al., 2007). This suggests that MCF7 cells response to IL-6 through 
an increase in cell proliferation and migration. The presence of MSC-
derived IL-6 in the BM environment may therefore have the potential to 
stimulate dormant BCCs into recurring.  
 
4.3.iii MCF7 Migrates in The Presence of TGFβ1 
 TGFβ1 has been cited as pro-metastatic factor (Tang et al., 2003; 
Meng et al., 2016). The MSCs within the BM may play a role in secreting 
the cytokine into the environment. As demonstrated in this study, co-
culturing MCF7 spheroids with MSC spheroids exposes the BCCs to a higher 
level of TGFβ1 than when cultured alone. In a study by Xu and Colleagues 
(2012), co-culture of MCF7 and adipose-derived MSCs stimulated the MCF7 
cells to undergo EMT and establish a mesenchymal phenotype; this was 
regulated by TGFβ1 targeting the ZEB/MiR 200 regulatory loop, a crucial 
activator of EMT (Brabletz and Brabletz, 2010).  
Whilst MSCs play a role in the maintenance of dormancy, other cells 
will be present around the tumour stroma in the BM. One of these cell 
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types, cancer-associated fibroblasts (CAFs) are noted as being responsible 
for TGFβ1 signalling into the tumour environment within the BM leading 
to EMT (Yu et al., 2014); these CAFs are derived from MSCs. It is clear that 
TGFβ1 increases the activity/general migration of MCF7, likewise, this 
suggests that TGFβ1 may be able to activate dormant BCCs within the BM 
and move out into the environment as a secondary metastasis. This 
appears to be true for other ERα+ BCC lines, where the converse is true 
for triple negative lines such as MDA-MB-231 (Sasser et al., 2007). 
4.4 Conclusion 
 The seed and soil hypothesis proposed by Paget over a century ago 
is still very much relevant, as the microenvironment clearly dictates BCC 
migration and survival. The BM contains a multitude of different cells, 
each with its own paracrine signalling profile. In this chapter, taking a 
paracrine perspective, the influence of co-culturing MCF7/MSCs was 
studied through cytokine secretions. 
As BCCs enter the BM and encounter MSCs, they are exposed to MSC-
derived cytokines. Many of the cytokines secreted into the BM 
environment will lead to attenuation of the immune response preventing 
destruction of the invading cells. In addition, these secretions may lead 
to BCC dormancy, or be responsible for BCC recurrence. During co-culture, 
the MCF7 cell cytokine profiles were changed, promoting cell migration 
(and potentially proliferation). Further migration studies in both 2D and 
3D culture demonstrated that two specific cytokines, IL-6 and TGFβ1 (both 
secreted by MSCs), caused MCF7 cell activation and migration. These 
simple experiments establish how MSC co-culture and paracrine signalling 
have the potential to control BC fate and may, in this case, play a role in 
BCC recurrence.  
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5 MSC Migration with Interleukin-6 
 
5.1 Introduction 
 Stem cell-based therapies have the potential of becoming the 
future of medicine (Ullah et al., 2015); personalised to the patient 
(Quimby and Borjesson, 2018). MSCs, are of great interest when 
developing new therapies and technologies (Sohni and Verfaillie, 2013). 
As described in section 1.3, MSCs derived from the bone marrow niche are 
multipotent, capable of differentiating into osteoblasts (bone), 
chondroblasts (cartilage) and adipoblasts (fat) (Baksh et al., 2004). These 
precursor cells are essential to the formation, maintenance and repair of 
the skeleton. 
 MSCs are identified by several cell surface markers including the 
presence of CD105, CD90 and CD73 and the absence of CD45, CD34, CD14, 
CD19 and HLA-DR (table 1-2). MSCs grown in monolayer will typically begin 
to lose differentiation potential from around the 6th passage, 
demonstrating the vital role cell signalling from other supporting cell 
types within the bone marrow microenvironment plays in maintaining 
stemness (Dominici et al., 2006; Bonab et al., 2007).  Within the BM 
microenvironment, the MSC niche can be subdivided into the endosteal 
and the perivascular niches where MSC populations are maintained by, 
and communicate via cytokines, with HSCs and other later precursor cells 
such as osteoblasts and adipoblasts (DaSilva Meirelles et al., 2008; 
Frenette et al., 2013; Bara et al., 2014).  
 Upon appropriate signalling cues, MSCs mobilise and migrate out 
from the niche. MSC mobilisation is often due to either (1) homing to sites 
of injury (Hannoush et al., 2011) or (2) homing to disseminated tumour 
cells (Hu et al., 2013); both are of key interest to researchers in terms of 
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regenerative medicine (ie. replacement of lost skeletal tissue) and 
potential therapeutics for cancer.  
 Injury or inflammation cause cellular release of cytokines; 
transforming growth factor-ß (TGF-ß), tumour necrosis factor-α (TNF-α), 
several interleukins (IL) such as IL-1, IL-6, IL-10 and the interferons which 
all play an important role in controlling the immune response (Yagi et al., 
2012). These cytokines also stimulate the recruitment of MSCs where they 
initiate tissue repair at the site of wound (Maxson et al., 2012). Previously 
published work from our lab assessed migratory signals produced by 
artificial wound models; from a panel of several key cytokines (IL-1b, Il-
2, TNFα, IL-12p70 and IL-6), only IL-6 was identified as being able to 
induce MSC migration from the spheroid models (Lewis et al., 2016). Well 
known for its roles within inflammation, immune response and skeletal 
maintenance, IL-6 is also a key regulator in cell differentiation, being 
heavily associated with haematopoiesis and differentiation of both 
osteoblasts and osteoclasts (Roux and Orcel, 2000; Marriot et al., 2004; 
Grellner et al., 2000; Yoshitake et al., 2008). 
 The study carried out in chapter 4 looked at MSC-derived cytokines, 
with the belief that these can affect the metastasis of nearby BCCs; key 
cytokines included TGFβ1, TNFα and IL-6. MSCs are also under the 
influence of their own autocrine signalling via cytokines such as IL10, VEGF 
and IL-6. MCF7 was noted to migrate towards IL-6 in both 2D and 3D. The 
Berry lab has previously described how MSCs migrate towards damaged 
cells – a source of IL-6 (Lewis et al., 2016). This study sought to elucidate 
the effect of IL-6 upon MSC migration in the same conditions as previously 
seen in chapter 4. 
 As well as understanding the role of various cytokines within the 
BM niche, studies on MSC migration will help inform on potential delivery 
routes in cancer therapeutics and within the field of regenerative 
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medicine. Cell migration involves the breakdown of extracellular matrix 
(ECM); which requires the action of proteolytic enzymes such as matrix 
metalloproteinases (MMPs). There are several classes of MMPs depending 
on their substrate specificity; (1) collagenases (MP-1, -8, -13 and -18) 
which cleave fibrillar collagens type I, II and III; (2) gelatinases (MMP-2 
and -9) which cleave gelatin, but can also degrade other extracelluar 
matrix proteins including collagen and laminin; (3) stromelysins (MMP—3, 
-10 and -11), which degrade several non-collagenous proteins and (4) 
membrane-type MMPs (MMP-14, -15, -16, -17, -24 and -25) (Birkedal-
Hansen et al., 1993; Page-McCaw et al., 2007). MMP activity is regulated 
by tissue-specific inhibitors of MMPs (TIMPs). The balance between 
MMP/TIMPs is critical in ECM remodelling, cell migration, cell 
differentiation and the regeneration of any tissue (Almalki et al., 2016).  
 
5.1.i Objectives 
 IL6 was noted as being key to MSC migration in a previous study in 
our lab. This study aims to assess how MSCs respond to IL-6 in 2D 
monolayer culture and 3D spheroid model. This will be achieved by: 
• Assess monolayer MSC migration response to IL6 
• Identify the MMPs and TIMPs secreted by migrating MSC monolayers when 
exposed to IL-6 using a cytokine blot array 
• Monitor MSC spheroids and observe response to IL-6  
• Identify the MMPs and TIMPs secreted by MSC spheroids in response to IL-
6 using a cytokine blot array 
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5.2 Results 
 The presence of a panel of seven human matrix metalloproteinases 
(MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-10 and MMP-13) and three 
tissue inhibitors of metalloproteinases (TIMPs; TIMP-1, TIMP-2 and TIMP-
4) was quantified following MSC incubation with IL-6.  To complement this 
analysis, monolayer cell migration was assessed using an Ibidi cell 
migration plate assay via time lapse microscopy over a 24-hour period in 
the presence of IL-6.  Spheroids were also imaged over a series of days, 
both in the presence and absence of IL-6. 
 
 
5.2.i MSCs Migrate Towards an IL-6 Gradient in 
Monolayer Culture 
Upon IL-6 exposure, cells were tracked over 24 hours using time-
lapse microscopy. A clear directionality was observed towards the IL-6-
spiked DMEM, where large filopodia were noted extending in the direction 
of IL-6, inducing a leading edge and migration (Figure 4-1). The direction 
of cell migration was analysed and a vector plot indicated the path of cells 
incubated in the [IL-6] gradient (Figure 4-2A). A rose plot confirmed MSC 
preferential migration towards IL-6 (positive axis; figure 4-2B).  
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Figure 5-1 A selected montage of six MSC images. Taken from the 24-hour 
time-lapse following a single MSC cultured within an Ibidi μ-Slide 
Chemotaxis 2D assay plate with IL-6/DMEM (1 ng/mL) in the first reservoir 
and culture media alone in the reservoir on the right. Red arrows indicate 
presence of extending. 
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Figure 5-2 MSC cell migration in the presence of an IL-6 gradient over 24 
hours. A) a vector plot of 8 individual cells tracked, and B) a rose plot 
summarising overall migration. Coordinates (0,0) reflect the origin of each 
cell. DMEM containing IL-6 1 ng/mL concentration gradient located on 
negative x-axis, with undoped DMEM present towards the positive x-axis 
(12 cells tracked across 3 wells). Cells imaged on Zeiss Axiovert 25, 
photographed every hour for 24 hours and tracked using ibidi chemotaxis 
plugin for ImageJ. 
 
5.2.ii MMP-1 and MMP-3 Facilitate MSC IL-6-induced 
Migration in Monolayer  
MSCs were incubated in IL-6 (1 ng/mL); culture media was then 
collected after 3hr and 24hr and analysed for the presence of MMPs and 
their inhibitors, TIMPs. Changes in MMP/TIMP levels were quantified and 
expressed graphically (Figure 5-3). Collagenases MMP-1 and MMP-3 were 
increased after 24 hours’ incubation, with the corresponding inhibitor, 
TIMP-1, also upregulated to balance degradation of the local collagen. 
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Figure 5-3 MMPs and TIMPs detected in MSC monolayer culture. Mean pixel 
density, relative to control, of target proteins secreted into culture media 
by MSCs following IL-6 1 ng/mL incubation for 3hr (black) and 24hr (grey) 
hour intervals. Culture medium was analysed using Abcam human MMP 
antibody array membranes, viewed on Agilent 2100 Bioanalyzer, followed 
by quantification using imageJ; n=2 technical replicates, error bars 
indicate SEM, * indicates significant change at 24 hours (p<0.05). 
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5.2.iii MSCs Spheroids Migrate in Response to IL-6 
 Cell migration was observed in MSC spheroid culture in response to 
IL-6 over a 3-day period. Spheroids cultured in DMEM alone do not migrate 
from the central mass in the 72-hour period, as the spheroid morphology 
remained similar (figure 4-4C). Addition of IL-6 caused MSCs to begin 
migrating from the spheroid after 3 hours, with peripheral cells beginning 
to extend filopodia (figure 5-4B) as in the monolayer culture in the 
previous study (figure 5-1). After 72 hours incubation with IL-6, MSCs have 
migrated several cell lengths from the spheroid into the collagen gel 
(figure 5-4D), with migrating cells extending filopodia out into the 
environment, producing a stellate morphology.  
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Figure 5-4 MSC spheroids cultured within a collagen gel incubated with 1 
ng/mL IL-6. MSC spheroids cultured in collagen gel for 3 hours in A) 
standard culture medium and B) culture medium containing 1 ng/mL IL-6. 
MSC spheroid cultured for 72 hours in C) standard culture medium and D) 
culture medium containing IL-6. Images acquired using Zeiss Axio Vert A1 
fluorescent microscope and colourised using Adobe Photoshop. n=3, 
representative spheroid shown, white arrows indicate migrating cells 
scale bar 10 µm. 
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5.2.iv MMP-2 and MMP-8 Facilitate MSC IL-6-induced 
Migration in 3D Spheroid Culture  
MSC spheroids cultured in standard culture medium indicated an 
overall decrease in both MMP and TIMP secretion from 1 day to 3 days 
(figure 5-5A). However, the MMP secretion profile for MSC spheroids 
challenged with 1 ng/mL IL-6 is notably different, as MSCs increase the 
secretion of some MMPs. The secretion of MMP-8 (a collagenase specific 
to types I-III) significantly increased (p<0.05) over time (figure 5-5B). 
Interestingly, other collagenases specific to collagen type I, MMP-1 and 
MMP-13, showed no significant change following IL-6 treatment. The only 
significant increase in TIMP secretion was through an increase in TIMP-4 
(figure 5-5B). TIMP-1, an inhibitor of MMP-3, significantly decreased 
(p<0.05) after 72 hours culture with IL-6. 
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Figure 5-5 MSC spheroid MMP and TIMP secretion. MMPs and TIMPs 
detected in culture medium at 3hr (black) and 72hr (grey). A) Standard 
media and B) culture medium with 1 ng/mL IL-6. Culture medium was 
analysed using Abcam human MMP antibody array membranes, viewed on 
Agilent 2100 Bioanalyzer, followed by quantification using imageJ; n=2 
technical replicates, error bars indicate SEM,* indicates significant change 
at 24 hours (p<0.05), * indicates significant change at 24 hours (p<0.05). 
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5.3 Discussion 
In this chapter I aimed to assess MSC migration response to IL6 in 
both 2D and 3D culture. In addition, if cells migrate, I wanted to 
determine what changes in MMP/TIMP secretion profiles facilitated this 
migration. The initial study focused on monolayer MSC response, whilst 
the second part of the study utilised MSC spheroid culture within a 
collagen gel, to verify whether the migration repose can be translated to 
the 3D environment. 
 
 
5.3.i MSCs Migrate Towards IL-6 
MSCs are known to respond to TNFα, IFNγ, IL-1 and IL-6 
concentration gradients (Ren et al., 2008; Lewis et al., 2016) permitting 
movement towards the site of damaged cells to initiate repair (Maxson et 
al., 2012). IL-6 activates JAK/STAT and MAPK pathways to permit survival 
and proliferation of MSCs (Rattigan et al., 2010). This leads to the 
formation of actin stress fibres to facilitate migration (Menon et al., 
2007). In this way, local MSCs act as a source of fibroblasts to permit 
tumorigenesis of the neoplastic cells (Mishra et al., 2008). Therefore, the 
response of MSCs to paracrine IL-6 is of importance in understanding the 
growth patterns of disseminated cancer cells.  
 
2D Study 
The initial study to establish how MSCs responded to IL-6 in 
monolayer indicated the formation of filopodia only in the direction of the 
IL-6 as the cells attempted to migrate towards the source. There has been 
much research into the study of MSCs’ response to IL-6. An increase in 
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MSCs migration has previously been described in response to cytokines 
MCP-1 and IL-8 (Wang et al., 2002).  Pricola and colleagues (2009) showed 
how IL-6 can maintain the stemness of MSCs whilst enhancing both 
proliferation and wound-healing abilities in vitro. The migratory response 
of MSCs to IL-6 is utilised to repair epithelial damage and suppress further 
inflammation (Ke et al., 2014). IL-6 is able to induce VEGF production by 
MSCs, permitting endothelial growth and the development of vasculature 
in ischemic environments (Herrmann et al., 2011). In vivo, cells would 
migrate towards the source of IL-6 (Heinrich et al., 2003) to initiate repair 
of damaged tissues, this study showed this migratory response is 
conserved in vitro before moving forward with the 3D spheroid study. 
 
Spheroid Study 
 The MSC spheroid experienced an IL-6 gradient across the entire 
spheroid surface, which caused the peripheral cells to migrate away from 
the central mass in all directions. MSCs within the spheroid therefore 
appear to sense IL-6, most likely via the cognate cell surface receptor, 
IL6R (Yagi et al., 2012), with peripheral cells transitioning to a migratory 
cell phenotype as they lose cell-cell contacts, to move towards the IL-6 
(figure 5-4D). The culture of MSCs as 3D multicellular spheroids increases 
the secretion of immunomodulatory factors, including IL-6 (Zimmermann 
and McDevitt et al., 2018), leading to an increase in the production of 
anti-inflammatory molecules, which would support the results of Ke and 
colleagues (2014) as MSCs repair damaged tissues. The use of 3D culture 
systems over traditional monolayer culture has indicated that the 
immunomodulatory effect of MSCs is enhanced through the upregulation 
of mRNA markers. This phenomenon is beneficial for the future of cell 
therapy using ‘off-the-shelf’ MSCs (Chen et al., 2017). 
CHAPTER 5 MSC MIGRATION WITH INTERLEUKIN-6 
 
131 
The migratory response of MSCs to IL-6 in the environment did not 
change from monolayer to spheroid; in both cases MSCs migrated towards 
IL-6. MSCs in the BM will encounter elevated IL-6 secreted by macrophages 
that have been polarised to the pro-inflammatory M1 phenotype. These 
M1 macrophages are able to repress osteogenic markers, preventing MSC 
differentiation (Gong et al., 2016). Once exposed to environmental IL-6 
by M1 macrophages MSCs will begin to secrete their own IL-6 in response. 
This then prevents further M1 polarisation as MSC-derived IL-6 favours the 
maturation of naïve macrophages towards to anti-inflammatory M2 
phenotype. (Phillipp et al., 2018). The ability of ‘activated’ MSCs to 
downregulate M1 polarisation will be beneficial to any invading BCCs as 
this will prevent the inflammatory immune response from clearing them 
from the BM, allowing their continued proliferation (Weng et al., 2019). 
 
 
5.3.ii MSCs Secrete MMPs in Response to IL-6 
 The MMP profiles observed in 2D and 3D MSC culture differ notably, 
in both the types of MMP secreted and the levels in which they change. 
This is likely due to the environment surrounding the cells, as the ECM 
surrounding cells in monolayer will differ from the type I collagen, which 
the 3D spheroids are cultured within. 
 
2D Study 
MMP transcription is regulated by cytokine signalling (Brew et al., 
2000), hence as the cell senses IL-6, collagenases MMP-1 and MMP-3 
secretion are upregulated. In a 2D environment, BM-derived MSCs secrete 
large volumes of laminin, in addition to small amounts of collagen I, into 
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their environment. This ECM component is a target of MMP-3, indicating 
why this was upregulated in the this 2D study (Amable et al., 2014). 
Amable and colleagues quantified ECM and MMPs in much the same way 
as the study within this chapter, using ELISA to analyse the conditioned 
media.  
Secretion of the corresponding inhibitor (Yang et al., 2002), TIMP-
1, is also increased in response to upregulation of MMP-1 and MMP-3 to 
attenuate their effect. As the MSCs migrate they must digest the 
surrounding ECM in order to progress forward, so a balance between MMP 
and cognate TIMP allows the cell to move and stop in response to 
environment cues.  
 
Spheroid Study 
In order for MSCs to migrate, they must change from an adherent 
phenotype to a migratory phenotype. The migratory behaviour of MSCs 
involves MMP activity, with different MMP profiles depending on the 
cause of migration (Almalki et al., 2016). Within this model system, 
focusing on MSC migration in response to IL-6, an increase in collagen I-
digesting MMP-8 was seen, whereas MMP-2, able to digest collagen IV, 
decreased. This profile is different to that seen in the 2D study. In 
monolayer the cells are laying down their own ECM, in the case of BM-
derived MSCs mostly laminin (Amable et al., 2014), whereas the 3D 
spheroids are implanted within a collagen I gel, there is less need to lay 
down their own ECM. The change in the makeup of the ECM will change 
what the MSC needs to secrete in order to move through it; as the 
surrounding ECM consists of collagen I only, this finding suggests these 
MSCs are aware of the makeup of their environment.  
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There have been many recent studies into MMP secretion by MSCs. 
The ability of MMPs to digest hydrogels has been used to the advantage 
of studies where cell-mediated remodelling of the 3D structure is 
required. Fonseca and colleagues (2013) used an alginate hydrogel, 
containing MMP-sensitive peptides, to culture MSCs and through altering 
the peptide structure of the hydrogel could direct the movement of the 
cells. Leight and colleagues (2013) studied the effects of hydrogel 
stiffness upon MMP expression. The addition of TGFβ1 increased MMP 
production much in the same way IL-6 did within this study. MSCs 
cultured in collagen environments require the expression of MMP-1 to 
migrate. Blocking this results in MSCs that are unable to move through 
their environment (Lu et al., 2013). 
Without IL-6 in the environment, the MSCs remain within the 
spheroid. This correlates with previous evidence that MSCs become 
quiescent in collagen gels with time, thus do not migrate (Lewis et al., 
2015). The change in behaviour caused by the addition of IL-6 to the 
model environment is likely due to IL-6R activation by paracrine IL-6 
leading to the phosphorylation of STAT3 within the cell (Horwood et al., 
2016). This activation, in turn, leads to the expression of migration 
genes; MMPs are then upregulated by the phosphorylated STAT3 leading 
to the movement of cells towards sites of high IL-6 concentration, 
initiating cellular repair (Lukovic et al., 2015).  
 The upregulation of MMP-8, able to digest collagen type I-III 
(Nagase et al., 2006) will act upon the type I collagen used to produce 
the in vitro 3D model. TIMP-4 is known to interact with MMP-2 (Heinrich 
et al., 2003), a gelatinase, which indicates a significant decrease 
following IL-6 treatment (figure 5-5). The expression level of TIMPs act 
in a feedback loop with expression of their cognate MMP in order to 
attenuate the response when the cell needs to cease further migration 
(Birkedal-Hansen et al., 1993). The upregulation of TIMP-4 in MSC 
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spheroids cultured in IL-6 for 72 hours indicates the cell is attempting to 
attenuate the effect of its cognate protein, MMP-2. De Becker and 
colleagues (2007) found MMP-2 was required for MSC extravasation using 
endothelial cells embedded in Matrigel, consisting of laminin, collagens 
and heparan sulphate. As the components differ from the model used 
within this study, the MMPs required to migrate will also differ; MMP-2 
decreased when cells were embedded in collagen I gels. As a 
consequence of differential MMP expression, a different TIMP was 
secreted to attenuate the effects. In this case TIMP-4 was upregulated, 
but De Becker and colleagues saw an increase in TIMP-3. This evidence, 
again, suggests that MSCs are able to sense their environment and alter 
the expression of appropriate MMPs to migrate through it.  
 
5.4 Conclusion  
The response of MSCs to paracrine IL-6 is of importance in 
understanding the growth patterns of disseminated cancer cells. This 
chapter has verified that MSCs migrate towards IL-6 in 2D and 3D culture; 
a cytokine not only released by the MSCs themselves, but by macrophages 
during cellular damage, and secreted by invading cancer cells. This 
migration will both promote breast cancer proliferation and cause MSCs 
to migrate towards the tumour and become part of the tumour stroma, 
further supporting the cancerous growth.  
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6 Extracellular Vesicles Effects on MCF7 
6.1 Introduction 
There is increasing evidence that MSCs cause metastatic BCCs to 
enter a dormant state (Ono et al., 2014; Bliss et al., 2016; Walker et al., 
2016). Previous studies within this thesis have indicated that MSC 
spheroids in co-culture with MCF7 spheroids in a three-dimensional 
environment secrete a wide range of cytokines that differ from MSC 
spheroids cultured alone. This indicates a paracrine signalling effect 
emanating from the invading BCCs as they enter the environment that 
causes the MSCs to change their secretome. Paracrine signalling is not 
limited to the reception of extracellular proteins within the environment, 
but includes other agents, in particular extracellular vesicles (EVs).   
 
6.1.i Extracellular Vesicles in Cell-Cell 
Communication 
The relationship between marrow MSCs and invading BCCs has to 
date focussed on more traditional cell-to-cell communication routes, such 
as paracrine signalling via soluble proteins including cytokines (Luker et 
al., 2006; Liu et al., 2011). The studies done in chapters 4 and 5 
demonstrated that cytokines released by both cell types within the BM 
model environment can have a strong effect on the proliferation and 
migration of both MSCs and BCCs. 
 However, EVs are also key mediators in cell-cell communication. 
As described in section 1.4.iii, EVs are small extracellular membrane-
enclosed vesicles that contain a variety of molecules including proteins 
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and RNAs (Davies et al., 2014; Ono et al., 2014; Wu et al., 2017; Yáñez-
Mó et al., 2015). Increasing evidence suggests that interactions between 
MSCs and tumour cells involve the exchange of information via EVs (Ono 
et al., 2014). EV contents can potentially bypass the cell surface receptors 
that may ordinarily block their entry (Prada and Meldolesi, 2016). 
Therefore, the EV contents can enter the host cell either through 
endosome trafficking or directly into the cytoplasm if the plasma 
membrane fuses with the membrane of the EV. Once inside, these 
biomolecules can change host cell behaviour through interference with 
cellular processes or gene expression. For example, MSC-derived EVs have 
been reported to contain microRNAs such as miR23b (Vallabhaneni et al., 
2015), miR21 and miR34a (Del Fattore et al., 2015), which have been 
found to have a tumour-suppressive effect through the silencing of 
proliferative pathways. These EVs also contained tumour-supportive 
molecules, such as tissue inhibitor of metalloproteases (TIMP)-1 and -2.  
 
6.1.ii Cellular Metabolites in EVs 
In addition to microRNAs, MSC-derived EVs contain other 
biomolecules that may influence BCCs, such as cellular metabolites. These 
small molecules are products of metabolic processes occurring within the 
cell, such as sugars and amino acids, and that will exist freely within the 
cytoplasm and organelles. During the formation of EVs, these free 
molecules can then be packaged, along with microRNAs and proteins, and 
trafficked out of the cell through processes described in section 1.4.iii. 
There is some evidence to suggest that these small molecules can be 
effective in encouraging a dormant effect in cancer cells (Kim and Park, 
2003; Phang et al., 2014), although little research has been carried out to 
determine which, if any, metabolites may be responsible. 
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 6.1.iii Objectives 
There is a current lack of knowledge of the mechanistic events that 
allow BCCs to adopt a dormant phenotype in the marrow. Within this 
study, EVs derived from MSC conditioned media (MSC-CM) will be used to 
assess their influence upon MCF7 cells, both in monolayer and as 
spheroids. How these EVs impact MCF7 proliferation, migration and 
adhesion will be assessed. In order to achieve this, the following 
experiments will be performed in this study:  
• MSC-CM will be fractionated depending on molecular weight, each 
fraction will be incubated with MCF7 cells to determine effects on 
cell behaviour 
• MSC-derived EVs will be isolated form MSC-CM, quantified and 
incubated with MCF7 cells in 2D monolayer and 3D spheroid culture. 
• Metabolomics will be performed on MSC-derived EVs to profile their 
contents in terms of cellular metabolites  
• Metabolites highlighted within the MSC-derived EVs will be used in 
isolation to assess their potential to induce a dormant phenotype 
in MCF7 
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6.2 Results 
The results presented within this chapter seek to investigate the 
effects of MSC-derived EVs upon MCF7 cells, both in monolayer and in 
spheroid culture. First, MSC-CM was fractionated to contain biomolecules 
of size determined by filter pores. Of particular interest are the <30 kDa 
fraction, containing many cytokines including TGFβ and IL-6, and  the >100 
kDa fraction, containing EVs. These MSC-derived EVs contain a 
combination of biomolecules; metabolomics was performed to determine 
if any small molecules contained within the vesicles could have an effect 
upon dormancy. 
 
6.2.i Conditioned Media Fractionation 
MSC-CM contained signalling molecules secreted by MSCs into their 
environment. MSC-CM was collected as described in section 2.20 and was 
then incubated with MCF7 cells in monolayer. The cancer stem cell marker 
ALDH1A1 (Marcato et al., 2010) is important in tumour progression and 
considered a stem cell marker, it was used to determine the ‘stemness’ 
of the MCF7 cells after 24 hours in culture with MSC-CM. A dilution series 
of MSC-CM was performed to identify if there was a change in stemness 
relative to volume (figure 6-1A). This indicated that the ALDH1A1 
expression of MCF7 cells was negatively affected as higher concentrations 
of MSC-CM were present, this indicates a more stem cell-like MCF7.   
Following complete MSC-CM studies, MSC-CM was sequentially 
ultrafiltered as in section 2.20. The filtrates contained molecules of a 
particular molecular weight range (>30 kDa, 30-50 kDa, 50-100 kDa and 
>100 kDa). Through fractionating the MSC-CM, distinct effects can be 
identified. Again, ALDH1A1 fluorescence was assessed to determine 
CHAPTER 6 EXRACELLULAR VESICLES EFFECTS ON MCF7 
139 
changes in MCF7 stemness caused by the MSC-CM fractions (figure 6-1B). 
A decrease in ALDH1A1 fluorescence was noted through the MSC-CM 
fractions, with >100 kDa indicating the greatest change. This fraction, 
containing MSC-derived EVs, showed the only significant decrease (p<0.05) 
in ALDH1A1 fluorescence. 
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 Effects Upon MCF7 Spheroids 
MSC-CM was filtered to separate the molecular weights of signalling 
molecules. Each fraction was incubated with MCF7 spheroids in collagen 
gel (BM model). The mean diameter of all spheroids at zero hours was 
similar, although there was a variation in the range of sizes (figure 6-2). 
After 24 hours in culture, control spheroids cultured in DMEM alone, saw 
a significant increase in diameter, with an increase in overall range. MSC-
CM fraction containing molecules <30 kDa showed a large increase in mean 
diameter and range over 24 hours; this fraction will contain many of the 
cytokines tested in previous sections of this chapter, such as IL-6, TGFβ1 
and CCL5. Cells cultured in MSC-CM containing molecules 30-50 kDa and 
50-100 kDa exhibit a significant increase in spheroid diameter after 24 
hours (figure 6-2). The largest molecules contained in the >100 kDa 
fraction appear to maintain mean spheroid diameter over 24 hours (figure 
6-2). The range of diameters still increases, but the mean does not 
significantly increase (p<0.05).  
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Figure 6-2 MCF7 spheroids cultured in collagen gel with fractioned MSC-
conditioned media. Spheroid diameter recorded immediately following 
collagen gelation and after 24 hours. Spheroid diameter measured using 
imageJ. * denotes significant change, p<0.05, from 0hr to 24hr; n≥7 across 
3 collagen gels in each condition. Bars indicate diameter range. 
 
MSC Spheroids and MCF7-CM Fractions 
The converse experiment was also performed; MCF7 cells were 
cultured, media collected and fractionated as in section 2.20. This MCF7-
conditioned media (MCF7-CM) was then used to culture MSC spheroids in 
collagen gels. As before spheroids were measured immediately following 
collagen gelation and 24 hours later to determine if the MCF7-CM had any 
effect upon cellular outgrowth. Control spheroids, cultured in DMEM only, 
saw a significant increase (p<0.05) in diameter (figure 6-3), with no 
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difference in range. No MSC spheroids cultured in any MCF7-CM fractions 
showed a significant change in diameter over 24 hours, unlike the effects 
of MSC-CM upon MCF7 spheroids.  
 
Figure 6-3 MSC spheroids cultured in collagen gel with fractioned MCF7-
conditioned media. Spheroid diameter recorded immediately following 
collagen gelation and after 24 hours. Spheroid diameter measured using 
imageJ. * denotes significant change, p<0.05, from 0hr to 24hr; n≥7 across 
3 collagen gels in each condition. Bars indicate diameter range.   
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6.2.ii Quantification of MSC-Derived EVs from 
Conditioned Culture Medium 
In figure 6-1B it was determined that 100 kDa+ fractions, which 
contain EVs, of MSC-conditioned medium negatively affected the ALDH1A1 
expression of MCF7, leading to a more stem cell-like phenotype. This 
fraction contains EVs; these were purified to remove other large 
molecules, quantified and used to enrich further MCF7 cultures to assess 
EV influence on cell behaviour. 
EVs isolated from MSC culture medium were quantified using 
dynamic light scattering and Fluorocet assay. Dynamic light scattering 
allows the size of particles to be determined (figure 6-4A) indicating 
highest peak intensities at 91.3nm and 164nm, with a weighted average 
diameter of 174.4nm (figure 6-4C). This indicates the presence of two 
vesicle populations; exosomes and larger microvesicles. 
Acetecylcholinesterase (AChE) fluorescence, a marker for EVs, was then 
assayed to determine the number of MSC-derived EVs present, found to 
be 1.6x109/mL (figure 6-4C). The presence of MSC-derived EVs using this 
method of isolation is indicated by TEM (figure 6-4B).  
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Figure 6-4 Quantification of the size of MSC-derived EVs. A: Measured 
using dynamic light scattering and average intensities plotted (n=3). B: 
Transmission Electron Microscope image of MSC-derived EVs; arrows 
indicate the presence of vesicles. C: A table detailing key data from 
dynamic light scatter in addition to particle number acquired through 
measurement of AChE fluorescence using Fluorocet assay.   
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6.2.iii The Influence of MSC-Derived EVs on MCF7 
Migration 
The effect of MSC-derived EVs on MCF7 cell motility was assessed 
in both two- and three-dimensional culture.  
 
 Two-Dimensional Culture  
MCF7 cells were seeded into ibidi chemotaxis plates, used in 
previous studies; one side contained DMEM doped with 2x107 MSC-derived 
EVs, whereas the other contained standard DMEM. Within standard 
monolayer culture, MCF7 cells grown in control culture medium did not 
migrate preferentially in any direction (figure 6-5B), however, when 
treated with cell culture medium containing purified MSC-derived EVs 
they become more mobile. Interestingly, MCF7 cells do not move towards 
the MSC-derived EVs, but appear to migrate away from them (figure 6-
5A). This phenomenon is quite pronounced over 24 hours, with no MCF7 
cells migrating towards the MSC-derived EVs. This confirms that MCF7 cells 
react to the MSC-derived EVs and shows that they do so differently to 
cytokines, previously examined in chapter 4.     
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Figure 6-5 EV-induced migration of MCF7 cells in monolayer. MCF7 cells 
cultured over 24 hours with A) culture medium containing MSC-derived 
EVs or B) control medium, without EVs (10 cells tracked in each condition 
using ImageJ). 
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Spheroid culture 
MCF7 cells were then cultured as spheroids in collagen gels, as 
previously described, across 120 hours (5 days) and imaged at several 
intervals (figure 6-6A-C). Through tracking the same spheroid across this 
time period, a reduction in size was recorded, with no individual cells 
surrounding the spheroid, indicating that the cells were not migrating 
from the central mass. The spheroid tracked in figure 6-6A-C retains a 
similar morphology, but fluorescence becomes denser over the time 
period. This appears to mirror the phenomenon seen in monolayer culture 
as cells move away from the source of MSC-derived EVs (figure 6-5). Hourly 
measurements of spheroids over a 24 hour period indicate MSC-derived 
EVs prevent an increase in spheroid diameter (figure 6-6D). However, due 
to the range of spheroid diameters, there is no significant change (p<0.05) 
until day 5 (figure 6-6E), where the spheroids treated with MSC-derived 
EVs are significantly smaller than untreated spheroids.  
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6.2.iv Effects of MSC-derived EVs on MCF7 Stemness, 
Proliferation and Adhesion 
The influence of MSC-derived EVs on MCF7 growth was assessed via 
in cell western probing for the cancer stemness marker ALDH1A1, as in 
6.2.i, and Ki67, a proliferation marker present throughout the cell cycle 
except G0. A reduction in ALDH1A1 expression by MCF7 cells was noted 
(figure 6-7A), indicating a reduction in tumourigenicity, as cells become 
less metabolically active. This response is reflected in the Ki67 expression 
(figure 6-7B); there is a steady decline in fluorescence until 1x109 EVs/mL, 
where this decline is significantly lower (p<0.05) than the 0 EVs/mL 
treatment. These results indicate MSC-derived EVs have a negative effect 
on the growth of MCF7 cells.  
Cell adhesion following EV treatment was subsequently assessed, 
using different concentrations of MSC-derived EVs (figure 6-7C). A positive 
correlation was observed, as increased amounts of MSC-derived EVs 
present in the culture medium encourage MCF7 adhesion. In fact, 
relatively small volumes of MSC-derived EVs significantly increase this 
adhesion (12.5 x106 EVs/ mL) over 24 hours (figure 6-7C).  
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 6.2.v Metabolite Analysis of MSC-Derived EV  
The contents of MSC-derived EVs were assessed by metabolomics. 
Five samples of 2x107 EVs/mL were analysed by Glasgow Polyomics. 
Metabolites were detected within the EVs and a literature search was 
performed to determine if any of the metabolites present in high levels 
were associated with the initiation the cancer cell cycle. Table 6-1 shows 
a list of candidate metabolites that have evidence supporting their 
involvement in breast cancer growth. 
 Table 6-1: Candidate metabolites derived from MSC EV metabolomics 
Metabolite Effect Source 
D-Erythrose Toxic to breast cancer in 
high levels 
Wang and Wei, 
2010 
Pyroxidine Associated with lower ER- 
breast cancer formation 
Smith et al., 1995 
L-Proline Energy source in stress, 
blocking may slow growth  
Phang et al, 2014 
L-Phenylalanine L-PAM, a well-documented 
chemotherapeutic agent 
Fisher et al, 1975 
L-Methionine Significantly suppresses  
MCF7 growth  
Kim and Park, 
2003 
L-Valine Glutamine uptake 
inhibitor. Addition to 
lapatinib increases effect 
Maeng et al. 2014 
L-Tryptophan Deficiency leads to 
increased risk therefore 
overdose may suppress. 
Travers et al., 
2004 
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6.2.vi Viability of MCF7 Treated with D-Erythrose or 
L-Methionine  
Two candidate metabolites were taken from the literature search 
performed in section 6.2.v; D-erythrose and L-methionine. A viability 
assay was performed using a range of concentrations determined from the 
literature to have an effect on cancer cell growth. 
Monolayer Culture 
In monolayer neither erythrose nor methionine affect the viability 
of MCF7 cells over 24 hours (figure 6-8A,B). Therefore, the highest 
concentration of each was used to further test the effect on cell viability 
across 5 days (figure 6-5C). Again, these metabolites did not greatly effect 
MCF7 viability.  
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Spheroid Culture 
As it was determined neither erythrose, nor methionine affected  
the viability of MCF7 in monolayer, metabolites were tested with MCF7 
spheroids in collagen gels to determine if the three-dimensional 
environment affected viability. Spheroids cultured for 24 hours with 
erythrose or methionine resembled those cultured in DMEM alone controls 
(figure 6-9 A-C). Spheroids cultured for 72 hours in 4 mM erythrose were 
also as controls cultures (figure 6-9 D, E), however, spheroids cultured for 
72 hours in 67 mM methionine indicate large areas of cell death, reflected 
by red fluorescence (figure 6-9 F). 
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Figure 6-9 Viability assay of MCF7 spheroids cultured with D-erythrose or 
L-methionine in type I collagen gel. Control spheroids were cultured with 
DMEM only for A) 24 hr and D) 72 hr; 4 mM D-erythrose for B) 24 hr and E) 
72 hr or 67 mM L-methionine for C) 24 hr and F) 72 hr. Cells were then 
treated with calcein AM (live; green) and ethidium homodimer (dead; red) 
before imaging using Zeiss Axio Vert A1 fluorescence microscope. Scale 
bar 10 µm, n=3, representative image shown. 
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6.2.vii Effects of D-Erythrose and L-Methionine on 
MCF7 proliferation 
No changes in MCF7 cell viability were noted in spheroid culture when 
incubated with either metabolite. Here, cell cycle of MCF7 spheroids 
was assessed, using Ki67 fluorescence, in response to metabolite 
culture. 
 Monolayer culture 
The Ki67 expression of MCF7 cells treated with increasing 
concentrations of either D-erythrose or L-methionine was determined 
using in cell western (figure 6-10). Both metabolites, caused a decrease 
in proliferation after treatment; 2mM erythrose was sufficient for a 
significant decrease (p<0.05), with all concentrations of methionine 
significantly reducing (p<0.05) ki67 fluorescence over 24 hours. 
MCF7 cells were then cultured in the highest concentrations of 
metabolites, 4 mM D-erythrose or 67 mM L-methionine, for 3 and 5 days 
(figure 6-10C). Control cells showed no change in Ki67 fluorescence, L-
methionine indicated a significant decrease (p<0.05) in proliferation after 
day 3, continuing to day 5. D-erythrose treatment showed a significant 
decrease (p<0.05) after 1 day, and again after 5 days in culture (figure 6-
10C). 
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Figure 6-10 Ki67 fluorescence in MCF7 cells treated with metabolites. A) 
Increasing levels of D-erythrose at 24 hours; B): increasing levels of L-
methionine at 24 hours. C):  Cells were then incubated with metabolites 
for 1, 3 and 5 days, imaged on Odyssey SA fluorescence plate reader and 
Ki67 fluorescence normalised to cell number; n=3. Asterisks denote 
p<0.05. 
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6.2.viii Effects of Kinase Inhibitors on D-Erythrose 
and L-Methionine 
Changes seen previously may be linked to specific pathways. In 
order to determine how D-erythrose and L-methionine may be affecting 
proliferation, p38 MAP kinase inhibitor SB203580 and TGFβ receptor kinase 
inhibitor SB431542 were added to DMEM.  If either of these metabolites 
act upstream of these inhibitors then their addition will negate the effect 
of adding D-erythrose or L-methionine. These cells were then cultured in 
monolayer over 72 hours before Ki67 expression was assessed using in cell 
western. DMEM only (control) cells show an increase in Ki67 fluorescence 
across the 3 day test period (Figure 6-11). Whilst both inhibitors lower 
Ki67 fluorescence, SB203580 treated cells show an increase over time 
similar to DMEM alone. However, SB431542-treated cells steadily decrease 
Ki67 fluorescence over the test period.   
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Figure 6-11 MCF7 cells cultured with p38 inhibitor SB203580 or TGFβ 
receptor kinase inhibitor SB431542. DMEM containing 2 µM SB203580 or 10 
µM SB431542 was used to culture cells over 3 days; n=6. Bars indicate SEM. 
Cells cultured in 96-well plate and fluorescence of Ki67 measured using 
Odyssey SA, normalised to Celltag fluorescence. 
 
D-Erythrose 
Previously, D-erythrose encouraged a decrease in MCF7 cell 
proliferation over 5 days in culture. Here, by adding pathway inhibitors, 
we can determine if it is these pathways being affected. DMEM containing 
4 mM D-erythrose was used to culture MCF7 cells in addition to the 
inhibitors SB203580 or SB431542. Similar to previous results (Figure 6-10), 
MCF7 cells treated with D-erythrose alone showed a decline in Ki67 
fluorescence over time compared with the cells cultured in DMEM alone 
(red line, figure 6-12). An additional 2 µM p38 inhibitor SB203580 or 10 µM 
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TGFβ receptor kinase inhibitor was added to the D-erythrose DMEM to 
identify if the metabolite affects MCF7 cells through activation of either 
of their respective pathways. Whilst Ki67 fluorescence is higher in cells 
treated with the inhibitors, the gradient of lines generated are similar to 
that of 4 mM D-erythrose (Figure 6-12). However, SB431542 demonstrates 
a shallower decline over time, which may indicate that this inhibitor is 
potentially slowing the reduced proliferation effects of D-erythrose on the 
cell.  
Figure 6-12 MCF7 cells cultured with 4 mM D-erythrose and p38 inhibitor 
SB203580 or TGFβ receptor kinase inhibitor SB431542. DMEM containing 2 
µM SB203580 or 10 µM SB431542 was used to culture cells over 3 days; 
n=6. Bars indicate SEM. Cells cultured in 96-well plate and fluorescence 
of Ki67 measured using Odyssey SA, normalised to Celltag fluorescence.  
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L-Methionine 
Previously, L-methionine significantly reduced MCF7 cell 
proliferation over 5 days in culture. Here, the effect of the pathway 
inhibitors did not affect the metabolite’s response. Ki67 fluorescence in 
control cells appears to increase between 24 and 48 hours, but rapidly 
reduces at 72 hours (figure 6-13). Neither SB203580 nor SB431542 recover 
Ki67 fluorescence in the presence of L-methionine (figure 6-10). The line 
generated by SB431542 mirrors that of L-methionine alone, whereas 
SB203580 shows a steady decline over the time period. Results therefore 
suggest that these pathways are not affected by L-methionine. 
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Figure 6-13 MCF7 cells cultured with 67 mM L-methionine and p38 
inhibitor SB203580 or TGFβ receptor kinase inhibitor SB431542. DMEM 
containing 2 µM SB203580 or 10 µM SB431542 was used to culture cells 
over 3 days; n=6. Bars indicate SEM. Cells cultured in 96-well plate and 
fluorescence of Ki67 measured using Odyssey SA, normalised to Celltag 
fluorescence. 
 
6.2.ix Proliferative Effects of D-Erythrose and L-
Methionine on MCF7 Spheroids 
  Due to differences in the ways cells behave in two and three 
dimensions, the tests performed in 6.2.viii were repeated in MCF7 
spheroids. The fluorescence of mNPs within cells was used to compare the 
level of ki67 fluorescence in a similar fashion to CellTag used previously.   
CHAPTER 6 EXRACELLULAR VESICLES EFFECTS ON MCF7 
164 
Both SB203580 or SB431542 were added to DMEM and cultured 
spheroids were measured daily for 3 days. There was no significant 
difference between the expansion of spheroids in DMEM alone or in DMEM 
containing either of the inhibitors (figure 6-14). If either of these 
metabolites act upstream of these inhibitors then their addition will 
negate the effect of adding D-erythrose or L-methionine. 
 
Figure 6-14 MCF7 spheroids cultured with p38 inhibitor SB203580 or TGFβ 
receptor kinase inhibitor SB431542. MCF7 spheroids grown in control 
DMEM, DMEM plus 2 µM p38 inhibitor SB203580 or 10 µM TGFβ receptor 
kinase inhibitor SB431542. Spheroid measurements taken at daily intervals 
by measuring the cross-section of images using ImageJ; n≥6. Images 
captured using Axio Vert A1 fluorescent microscope, utilising green-
fluorescent mNPs to detect spheroids.  
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 D-Erythrose 
When spheroids are cultured in media containing 4 mM D-erythrose, 
there is significant reduction in spheroid expansion after 24 hours in 
culture compared with control spheroids cultured in DMEM alone (figure 
6-15). This was also noted at 72 hours. This reflects the earlier reduction 
in spheroid size noted when MCF7 spheroids were incubated with MSC-
derived EVs (figure 6-6D), which contain elevated levels of D-erythrose 
(table 6-1).This suggests D-erythrose is able to reduce cell migration. 
When 2 µM SB203580 is added to the media, the effects of the 
erythrose are reversed, and spheroid mass increases again, to significantly 
higher levels than control spheroids (figure 6-15). This suggests that D-
erythrose acts upon some part of the p38 MAPK pathway and inhibiting 
p38 phosphorylation prevents this action. The SB431542 inhibitor did not 
influence cell migration. 
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Figure 6-15 MCF7 spheroids cultured with 4 mM erythrose plus either 2 
µM p38 inhibitor SB203580 or 10 µM TGFβ receptor kinase inhibitor 
SB431542. Spheroid measurements taken at daily intervals by measuring 
the cross-section of images using ImageJ; n≥12. Images captured using 
Axio Vert A1 fluorescent microscope, utilising green-fluorescent mNPs to 
detect spheroids. * denotes p<0.05 compared with erythrose treatment, 
** denotes p<0.05 compared with control.  
 
  
 L-Methionine 
Likewise, the effects of L-methionine were assesed in MCF7 
spheroid culture. 67 mM L-methionine was added to DMEM and spheroids 
were cultured for 3 days, recording their diameter each day. In parallel, 
SB203580 or SB431542 were added to the L-methionine-doped DMEM. 
Whilst MSC-derived EVS reduced MCF7 spheroid diameter (figure 6-6C), 
here the metabolite in isolation does not affect spheroid diameter (Figure 
6-16). After 24 hours there is a slight decrease in spheroid diameter, but 
this is not a significant (p<0.05) change. Indeed, from this time point, 
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spheroids appear to rapidly expand. The addition of either inhibitor in 
combination with L-methionine reduced spheroid outgrowth, but L-
methionine alone does not reduce this so likely does not act through either 
of the pathways that have been inhibited.  
 
 
Figure 6-16 MCF7 spheroids cultured with 67 mM L-methionine plus either 
2 µM p38 inhibitor SB203580 or 10 µM TGFβ receptor kinase inhibitor 
SB431542. Spheroid measurements taken at daily intervals by measuring 
the cross-section of images using ImageJ; n≥10. Images captured using 
Axio Vert A1 fluorescent microscope, utilising green-fluorescent mNPs to 
detect spheroids. * denotes p<0.05 compared with methionine treatment.  
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6.2.x MCF7 Adhesion Assay with D-Erythrose, L-
Methionine and Kinase Inhibitors 
Previously, addition of MSC-derived EVs to MCF7 cultures caused an 
increase in adhesion (figure 6-7C), suggesting the cells become less 
migratory. Here, an adhesion assay was performed on MCF7 cells 
cultured in 4 mM D-erythrose or 67 mM L-methionine for 24 hours. 
Additionally, either SB203580 or SB431542 was added to determine any 
influence over control cells and cells incubated with the metabolites. 
D-Erythrose 
MCF7 cells were cultured for 24 hours in DMEM containing 4 mM D-
erythrose. There was no significant change in adhesion of cells compared 
with control cells in DMEM alone (figure 6-17). The addition of SB203580 
did not affect the cell adhesion.  There was a significant increase (p<0.05) 
in adhesion in cells cultured in SB431542, but this increase was also 
observed in control cells (DMEM) supplemented with SB431542, thus it is 
unlikely that the inhibitor is driving any increase in the cell adhesion. 
 
L-Methionine 
MCF7 cells were cultured for 24 hours in DMEM containing 67 mM 
L-methionine, causing a significant decrease in MCF7 cell adhesion 
(figure 6-17). Interestingly, the addition of either SB203580 or SB431542 
recovered cell adhesion and significantly increased adhesion (p<0.05) to 
almost three times the level observed in metabolite alone (figure 6-17).   
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Figure 6-17 MCF7 adhesion assay with D-erythrose and L-methionine and 
kinase inhibitors.  MCF7 monolayers cultured in DMEM alone, DMEM 
containing 4 mM D-erythrose or 67 mM L-methionine plus either plus 2 µM 
p38 MAP kinase inhibitor SB203580 or 10 µM TGFβ receptor kinase inhibitor 
SB431542. Cells cultured for 24 hours before being reseeded in a new 96-
well plate. Cells were able to attach for 30 minutes before being fixed 
and stained with Vectashield-DAPI. Images captured using Axio Vert A1 
fluorescent microscope, 10 fields in 3 wells. Cell nuclei counted using 
ImageJ cell counter plugin. * denotes p<0.05 compared with DMEM only. 
** denotes p<0.05 compared with relevant metabolite only. *** denotes 
p<0.05 compared with DMEM with relevant inhibitor.    
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6.2.xi Fluidigm Real Time PCR of MCF7 Cells Treated 
with Metabolites 
Following on from general observations regarding the influence of 
the two metabolites on MCF7 cell viability, proliferation, migration, 
‘stemness’ and adhesion, the gene expression of various sets of genes in 
MCF7 cells cultured in either 4 mM D-erythrose or 67 mM L-methionine 
was assessed using fluidigm real time PCR. Leading on from the previous 
result investigating proliferation, genes from each stage of the cell cycle 
were assessed (Figure 6-18, 6-20) to determine how D-erythrose and L-
methionine affected the MCF7 proliferation. Following observations of 
spheroid expansion, genes associated with epithelial-to-mesenchymal 
transition to determine how the metabolites affected cell adhesion and 
migration (Figure 6-19, 6-21). 
 D-Erythrose 
Cell cycle: MCF7 cells cultured in 4 mM D-erythrose showed an 
overall decrease in cell cycle related genes compared with MCF7 cells 
culture in DMEM alone (figure 6-18). There were several cyclin genes 
upregulated, however, without cognate cyclin-dependent kinases, the cell 
cycle will not progress as normal.  
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EMT markers: MCF7 cells cultured in 4 mM D-erythrose showed 
downregulation in many of the EMT marker genes  assayed, compared with 
MCF7 cells cultured in DMEM alone. The majority of genes assessed were 
markers of a mesenchymal phenotype. However several were markers of 
an epithelial phenotype; E-cadherin, Keratin 19 and JUP (figure 6-19). All 
of these markers saw a downregulation when exposed to D-erythrose in 
monolayer. Whilst many cell cycle genes were downregulated, it appears 
that these MCF7 cells did not experience a reinforcement of their 
epithelial phenotype.  
 
 
Figure 6-19 ΔΔCt of EMT marker expression in MCF7 cells cultured with 
4mM D-erythrose compared with MCF7 cells cultured without. Expression 
normalised to GAPDH. Cells cultured for 24 hours. Error bars indicate 
standard error mean; n=3 with 3 technical replicates from each. 
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L-Methionine 
Cell cycle: MCF7 cells cultured in 67 mM L-methionine indicated the 
downregulation of some genes in early cell cycle, compared with MCF7 
cultured in DMEM alone (figure 6-20). Despite the downregulation of these 
genes, many of the genes assayed were unaffected by the presence of L-
methionine throughout each stage of the cell cycle.  
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EMT markers: MCF7 cells cultured in 67 mM L-methionine indicate 
a strong decrease in many EMT marker genes such as Vimentin, TWIST1 
and Snail (figure 6-21). The large downregulation of RUNX2 will further 
prevent metastasis and migration by lowering the expression of some 
MMPs. Whilst there is a small upregulation in E-cadherin gene expression 
when cultured with L-methionine, other epithelial markers are reduced, 
such as JUP and Keratin19. This may lead to an overall reduction in the 
epithelial phenotype.  
 
Figure 6-21 ΔΔCt of EMT marker expression in MCF7 cells cultured with 
67 mM L-methionine compared with MCF7 cells cultured without. 
Expression normalised to GAPDH. Cells cultured for 24 hours. Error bars 
indicate standard error mean; n=3 with 3 technical replicates from each. 
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6.3 Discussion 
As described previously, paracrine signalling within the BM is 
essential to the maintenance of the cells residing there. The cytokines 
produced by MSCs are vital to the maintenance of their niche in addition 
to affecting the maturation of other local cells such as macrophages 
(Waterman et al., 2010; Li and Wu, 2011). However, there is increasing 
evidence to suggest that EVs also play an important role in maintaining 
the BCCs that have metastasised to the BM (Wu et al., 2017). EVs contain 
>14,000 biomolecules including nucleic acids, proteins and metabolites; 
any one of these biomolecules has the potential to affect gene expression 
and protein function. (Mathivanan et al., 2011). A summary of the results 
form this chapter are shown in table 6-2. 
Table 6-2 Summary of results. Arrows indicate increase, ↑; decrease, ↓; 
or no change, ↔ from DMEM alone. NR, not recorded. 
Media 
Supplement 
Proliferation Adhesion EMT 
markers 
Spheroid 
Migration 
Cell 
cycle 
MSC-CM ↓ NR NR ↓ NR 
MSC-derived 
EVs 
↓ ↑ NR ↔ NR 
D-eythrose ↓ ↔ ↓ ↓ ↓ 
L-
methionine 
↓ ↓ ↓ ↔ ↓ 
SB203580 ↔ ↔ NR ↔ NR 
SB431542 ↔ ↑ NR ↔ NR 
D-erythrose 
+SB203580 
↔ ↔ NR ↔ NR 
D-erythrose 
+SB431542 
↓ ↑ NR ↓ NR 
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L-
methionine 
+SB203580 
↓ ↑ NR ↓ NR 
L-
methionine 
+SB431542 
↓ ↑ NR ↓ NR 
 
6.3.i Isolation of Extracellular Vesicles  
EVs are notoriously difficult to purify and the yields are never 
substantial (Van Deun et al., 2014). MSC-derived EVs used within this study 
were acquired using ultracentrifugation, which provides a reasonably high 
yield of EVs, but is a laborious, time-consuming method that requires large 
volumes of starting material. Additionally, the high-speed centrifugation 
(in excess of 100,000 g) can damage the smaller exosomes, lowering yield. 
Purification through the precipitation of EVs requires less expensive 
equipment and can be done in a smaller time frame. The precipitation 
method is commercially available as ExoQuick and whilst it is much 
simpler, producing many orders of magnitude more particles, it may also 
purify large protein complexes due to the imprecise nature of the method 
(Thind and Wilson, 2016).  
A faster method of isolation using size-exclusion chromatography 
has been successfully used to yield EVs from the plasma of patients (Hong 
et al., 2016). This method takes around 30 minutes to complete although 
there are concerns for the purity of samples as it may also purify 
lipoproteins in the process (Welton et al., 2015). However, the overall 
advantages have to be considered against other ‘traditional’ methods. 
Advances in microfluidics has allowed the development of a method that 
isolates EVs through antibodies and analyses the resulting vesicles all 
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within the same system (He et al., 2014); purifying EVs from small volumes 
quickly, with the potential to scale up the system (Chen et al., 2010). 
Microfluidics uses a single device so eliminates many of the financial and 
time costs associated with other purification methods.  
Sequential centrifugation of MSC-CM was used to first remove cell 
debris and smaller particles until all that remained were the EVs. This 
followed by quantification of EV surface markers allowed for relatively 
large volumes to be purified. Addition of these EVs into DMEM allowed all 
the other biomolecules contained within MSC-CM to be excluded. 
 
6.3.ii MSC-Derived EVs Slows Growth of MCF7  
Previous studies showed co-culture with MSCs alters the behaviour 
of MCF7 BCCs. The preliminary study in this chapter assessed how MSC-CM 
affects the stemness of MCF7 cells. It indicated that a higher 
concentration of MSC-CM led to a more stem cell-like phenotype, through 
a reduction in ALDH1 expression (figure 6-1). High levels of ALDH1 
correlate with a tumourigenic phenotype (Resetkova et al., 2010).  
Fractionating the media by molecular weight further affects the stemness 
of MCF7 cells; only the 100 kDa+ fraction significantly lowers the ALDH1 
expression compared with fresh culture medium. These different 
signalling components explain why there is evidence indicating MSCs can 
aid growth and migration (De Luca et al., 2012) and as well as inhibiting 
(Ono et al., 2014). The 100 kDa+ fraction slows MCF7 migration out of 
spheroids in 3D (table 6-2), more than any of the other media fractions. 
Whilst this fraction may contain many components such as protein 
complexes and cellular waste, it will also contain EVs. These have been 
shown to lead to cycling quiescence in BCCs (Lim et al., 2011; Bliss et al., 
2016; Walker et al., 2016). 
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6.3.iii Metabolites from MSC-derived EVs may  
Influence BCCs 
Whilst it may not be financially practical to utilise MSC-derived EVs 
in treatment of breast cancer, due to the large volumes of cells required, 
there is great potential to use the isolated biomolecules contained within 
EVs. Multiple studies have successfully shown MSCs secrete miRNAs 
packaged into EVs which alter the behaviour of BCCs: miR-16 confers a 
silencing effect upon VEGF mRNA in BCCs reducing angiogenesis and 
therefore proliferation in BCCs (Lee et al., 2013); miR-23 inhibited 
MARCKS expression, vital to cell cycle progression through activation of 
downstream components (Ono et al., 2014); Lim and collegues (2011) 
showed multiple EV-derived miRNAs (miR-127, miR-197, miR-222, and 
miR-223) elicited a phenotype of cycling quiescence in BCCs. These are 
just a small subset of the biomolecules contained within MSC-derived EVs; 
it is clear many components of these EVs lead to a phenotype of cycling 
quiescence in BCCs. Here we focused on metabolites, where it was evident 
that one or more key metabolites appear to cause BCCs to slow 
proliferation. 
There is evidence to suggest that EVs (both exosomes and the larger 
MVs) may play a considerable role in establishing a dormant phenotype in 
invading BCCs; much of which focuses upon the study of miRNAs to bring 
about changes in gene expression (Ono et al., 2014; Bliss et al., 2016). As 
previously discussed, the EVs contain >14,000 biomolecules and whilst 
these miRNAs are abundant within EVs (Graveel et al., 2015), they are 
expensive to synthesise and use in clinic. Here we explored whether small 
cellular metabolites could have an effect upon MCF7 proliferation.  
A preliminary metabolomics assay was performed to identify  
metabolites contained within the MSC-derived EVs; a literature search 
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hoped to find evidence of dormant effects caused by any of the 
metabolites detected (table 6-1). From this list of candidates D-erythrose 
and L-methionine were selected as possible candidates because there was 
evidence of slowing growth in BCCs, where others were tested in different 
cancer types. 
From a diagnostic perspective, the presence of EVs derived from 
BCCs within the blood plasma of a patient, receptor-negative types in 
particular, could lead to early detection of tumours traditionally too small 
to notice through testing for cancer-specific miRNAs (Eichelser et al., 
2014).  EVs derived from HER2+ tumours will also express the protein on 
their surface, attenuating the effect of antibody-based treatments, such 
as Trastuzumab. These HER2-expressing EVs will bind the antibody, 
allowing further progression of the tumour (Ciravolo et al., 2012).  The 
improvement in EV purification techniques will make detection possible 
as small volumes of plasma can be extracted from the patient in a non-
invasive fashion and a diagnosis returned quickly.   
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6.3.iv Cellular Metabolites Reduce MCF7 
Proliferation  
D-Erythrose 
D-erythrose appears to affect cell cycle early on by downregulation 
of cyclin C (required for transition into G1; Giacinti and Giordano, 2006) 
and cyclin D, which pairs with CDK4 at G1. Cyclin B1 and 2 are 
upregulated, but require c-myb to transition into M phase (Nakata et al., 
2007), but this is downregulated so won’t function. The same is true for 
cyclin A2 as It requires CDK1, which is downregulated. Cathepsin D is a 
mediator of IFN and TNF-induced apoptosis via p53 so upregulation 
indicates the cell cycle is halted (Deiss et al., 1996). Cyclins require a 
cognate cyclin-dependent kinase to function and vice-versa. This would 
indicate that D-erythrose negatively affects parts of the G1/S transition of 
MCF7; the large downregulation of genes, such as CCND2, would indicate 
that this transition is not able complete as normal. The continued 
downregulation of genes in S and M phases will further prevent cell cycle 
completion (figure 6-18).Taking previous results into account, where Ki67 
is decreased, it can be seen that this metabolite slows the cell cycle in 
MCF7 (table 6-2). 
The anti-tumour mechanism of D-erythrose may be associated with 
the unique bioenergetic metabolism of cancer cells. Differing from normal 
cells, cancer cells mostly depend on glycolysis rather than mitochondrial 
oxidative phosphorylation to produce energy, even in the presence of 
ample oxygen. The increased dependency upon glycolysis is a hallmark of 
cancer cell metabolism, and gives rise to enhanced lactate production 
(Kroemer and Pouyssegur, 2008). The final products of D-erythrose 
metabolism are carbon dioxide and water (Batt et al., 1960). This excess 
carbon dioxide can then be converted to carbonic acid by carbonic 
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anhydrase (Wang and Wei, 2010). In addition, the increased lactate 
production in cancer cells leads to lactic acid-induced acidosis. Once the 
intracellular pH becomes too low the cell will die. Patra and Hay (2014) 
provide evidence that D-erythrose can markedly suppress the growth of 
colon carcinoma, inhibit tumor cell invasion and increase tumor cell 
apoptosis, without any observed toxic effects in vivo. This supports the 
findings in this study that D-erythrose inhibits MCF7 proliferation and 
migration, despite the evidence to suggest it does not appear to increase 
cellular adhesion (table 6-2). 
L-Methionine 
L-methionine appears to affect MCF7 cell cycle genes less than 
erythrose, but key genes are still downregulated: Cyclin D2, with 
corresponding CDk4 upregulated in a minor way; MAPK8 and BCL2L2 are 
downregulated showing the methionine is reducing apoptosis; ORC3 is 
required for DNA synthesis (Scholefield et al., 2011) and c-myb for G2/M 
transition with cyclin B1/2. Whilst some genes are upregulated the fold 
change from MCF7 cultured in DMEM alone is negligible. 3D Samples largely 
failed with only a few samples giving a result most likely due to the low 
RNA concentration recovered from spheroids – had to normalise to 
methionine treated cells at 3 ng/μL. 
The anti-tumour mechanism of L-methionine may be associated 
with the increased source of methyl groups for DNA methylation. L-
methionine downregulates p53 gene expression (Kim and Park, 2003). 
Mutations in the p53 gene can cause it to switch from a tumour suppressor 
to an oncogene (Muller, P.A. and Vousden, 2013). Upregulation in G1/S 
phase of the cell cycle will prevent aberrant DNA replication, but gain-of-
function mutants will allow oncogenic mutations to propagate. Through 
downregulating mutant p53, L-methionine can impede cell cycle 
progression. This can be seen in the fluidigm study (figure 6-21) as several 
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genes within G1 phase are greatly downregulated in the presence of L-
methionine, which will negatively affect progression through the cell 
cycle.   
Kim and Park (2003) show that dietary increase of L-methionine can 
protect DNA damage by carcinogenic compounds through methylation. 
PLU-1 is a H3K4 demethylase and knockdown of this protein leads to 
repression of cell proliferation in MCF7 (Yamane et al., 2007). This 
suggests that DNA methylation can negatively affect BCC proliferation. 
Providing the cell with excess L-methionine provides an excess of methyl 
donor groups, which can then be used for DNA methylation. 
 
6.4 Conclusion 
Breast cancer cell metastasis into the bone marrow niche involves 
a complex series of paracrine signalling and cell-cell interactions. 
However, here we showed that treating MFC7 cells with MSC-derived EVs 
alone slows cell migration and appears to initiate an epithelial cell 
phenotype. This suggests that MSC-derived EVs contribute to the net loss 
in tumourigenicity of invading BCCs, allowing them to engraft within the 
BM in a cycling quiescent state, ultimately resulting in anti-cancer drug 
resistance. It is evident that both EVs and microvesicles are present; these 
are trafficked out of the cell in different ways and as such their contents 
may also be different.  Whilst there is some evidence in support of the 
role of microRNAs in initiating dormancy (Vallabhaneni et al., 2015; Wu 
et al., 2017), further research into the cargo of both populations of EVs is 
necessary; namely, which proteins and small molecules/metabolites may 
be involved in BCC dormancy. It is clear that MSC-derived EVs have a 
negative effect upon MCF7 proliferation and cause an increase in 
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‘stemness’, however, it is still not clear whether there is one major 
component of those EVs having this effect, or whether it is a combination 
of all the separate biomolecules working in concert to provide the same 
result. Some small molecules contained within these MSC-derived EVs 
have separately been implicated in reducing cancer cell proliferation and 
results shown in this study suggest that both D-erythrose and L-methionine 
have a negative effect upon MCF7 proliferation. The precise mode of 
action of these small molecules remains unclear and further work would 
need to be done to elucidate this. Molecules contained within EVs are able 
to bypass the usual modes of entry into a cell so if allowed access into the 
BCCs without passing through receptors may change their effect.   
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7 Final Discussion  
7.1 Project Summary 
As outlined in chapter 1, this project aimed to model the BM 
environment in a way that allows investigation into the potential 
influences that encourage BCCs to enter into a dormant or recurrent 
state. There is a clear research and clinical need to model these states 
as the prevalence of breast cancer still remains high and metastasis to 
the bone marrow, with cancer dormancy and subsequent recurrence, 
is a major factor of breast cancer fatality. This study has made progress 
towards this goal and key achievements are described below: 
• Bone marrow 3D model. A spheroid culture system was adopted for 
3D cell culture. In order to progress through the project,  consistent 
and reproducible cell spheroids were required. Through investigating 
different cell seeding densities, spheroids were generated which 
were appropriate for use in the project. Electron microscopy was 
utilised to assess the cell-cell contacts within the 3D structure and 
allowed for the identification of strong intercellular bonds through 
filopodia. 
 
• Breast cancer cell (BCC) line: Two different BCC lines were initially 
assessed in culture, MCF7 and MDA-MB-231. Following studies in 
monolayer and 3D spheroid culture, it was determined that the cell 
line MCF7 would be better for use in this project. Spheroids 
generated using MDA-MB-231 did not remain intact once removed 
from the magnetic source, where cells migrated away from the 
central mass, so could not be reliably used over long periods of time 
to model dormancy. MCF7 cells are a well-established cell line that 
are representative of epithelial-type breast cancers, making them 
more adherent to one another, allowing the formation of spheroids 
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that could be sustained for more than a few hours as was the case 
with MDA-MB-231 spheroids.  
 
• Cytokine profile changes in MSC/BCC spheroid co-culture: Cytokines 
released into the environment during co-culture of BCC spheroids 
with MSC spheroids were analysed using antibody arrays. As reported 
in chapter 4, changes in cytokines within the co-culture environment 
will promote both migration and proliferation of cells. This 
determined that co-culturing the cells changed their cytokine profile, 
demonstrating how the presence of BCCs in the BM may react to MSC-
derived cytokines and vice versa, together altering the BM chemistry.  
 
• BCC recurrence in the BM model: The role of two specific cytokines 
secreted by MSCs during the co-culture study, IL-6 and TGFβ, were 
investigated with a view towards their influence on BCCs spheroids. 
Control 3D BCC spheroids, without cytokines, appeared less active, 
slowing the cell cycle through analysis of gene expression, but the 
addition IL-6 and TGFβ reverted this phenotype, generating a more 
active cell which migrated away for the spheroid mass into the 3D 
type I collagen environment. 
 
• Potential BCC dormancy in response to MSC-derived EVs: Cytokines 
only form part of the cell-cell communication network. In order to 
examine other candidates, fractionated  MSC-conditioned culture 
medium was used; each fraction as incubated with MCF7 cells. These 
fractions indicated how a wide range of effects can be produced by 
signalling molecules of different molecular weights. Whilst the 
smaller cytokines induced migration, the larger fractions slowed cell 
movement and allowed spheroids to remain intact over time.  
Extracellular vesicles (EVs) are within this large fraction and were 
subsequently isolated, purified and use to challenge MCF7 cells in 
both 2D and 3D culture. Results suggested the EVs can alter MCF7 cell 
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adhesion, migration and proliferation, potentially having a role in 
BCC dormancy.  
 
7.2 Potential Applications for the in vitro Bone 
Marrow Model 
The 3D collagen type I bone marrow model has been 
demonstrated to be capable of maintaining spheroid viability and 
morphology over 7 days.  It is a simple, effective model for testing the 
influence of external factors on both MSC an MCF7 cell behaviour, in 
terms of migration and activity. The study within this thesis only looked 
at a limited number of variables within the MSC-BCC relationship. 
There is much scope for further work using this model in investigation 
of BCC behaviour. For example, the model could be used to assess BCC 
migration into a BM environment, to assess mechanisms of entry and 
homing towards resident cells, such as MSCs. Alternatively, BCC 
recurrence and exit form the environment could be studies. Some of 
these applications are summarised below. 
 
7.2.i MSC-BCC Signalling and Communication 
Whilst cell-cell signalling was assessed within this study, only a 
small subset of signalling molecules were analysed. Two key cytokines 
were assessed, IL-6 ad TGFB, but as noted in chapter 4, many other 
cytokines play a role in MCS-BCC communication. The array used within 
the study in chapter 4 analysed 23 different cytokines; several of which 
were clearly altered in co-culture. RANTES, MCP-1 and many 
interleukins were present in higher volumes in co-culture. These could 
be further assessed to determine if they are altered  within the 
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MSC/BCC co-culture environment in much the same was IL-6 and TGFβ 
were assessed. . 
When considering MSC-derived EVs, this thesis focused on the 
potential that metabolites may play in BCC migration and proliferation. 
However, it would also be interesting to determine which miRs are 
present in the EVs. MiRs play an important role in MSC/BCC signalling, 
the model could be used to assess what miRs are present and what 
their role is in either dormancy or recurrence.  
The BCC line MCF7 was selected for use within this study, but 
other in vitro models have utilised different types of BCCs (Marlow et 
al., 2013; Imamura et al., 2015). There is no limitation to the cell line 
used within this in model, as such different kinds of breast cancer, 
indeed any cancer, can be modelled in the same environment to study 
how this effects interactions with MSCs in the BM.  For example, 
prostate cancer is also known to preferentially metastasise to the bone 
marrow (Taichman et al., 2002; Shiozawa et al., 2011), thus the model 
would be applicable for further investigation. 
Tests done in vivo may present a physiological environment, but 
it is equally important to remove as many factors from the native 
conditions in order to understand how BCCs affect cells in close 
proximity. This model focussed on the interaction between MSCs and 
BCCs, but could equally be used to understand the signalling effects of 
other cell types resident within the BM, such as HSCs and macrophages. 
Whilst many of these interactions may be indirect through the effects 
BCCs have upon cells such as MSCs, it is possible that invading BCCs 
directly interact with these other cell types, whether through 
paracrine signalling or cell-cell contact.  
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7.2.ii EV Isolate and Cargo 
The use of EVs within chapter 6 was limited by the ability to 
harvest them. This is a difficult process that requires large amounts of 
cells from which to obtain the EVs. There are papers emerging which 
use bioreactor cultures for EV harvesting (Guerreiro et al., 2018; 
(Palviainen et al.,2019).These use cells cultured within a 3D 
membrane, which a media collection port to allow access to cell 
secretions. One such bioreactior, the CELLine AD 1000 is currently 
being tested in our labs to assess EV generation and harvesting. The 
cells, in this case MCF7 cells, grow throughout the membrane and 
generate EV numbers well in excess of corresponding tissue culture 
flask cells (figure 7.1). Such bioreactors will be adopted for use in 
future studies in our labs. 
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Figure 7-1 Scanning electron microscopy images of MCF7 cells cultured 
within the CELLine bioreactor. A) Overview of the interaction seen 
between the cells and the cellulose membrane, B & C) Clusters of cells 
attached on the membrane. C) A cross section of the membrane 
showing cells intermingling with the membrane fibers.  
MSCs used for EV harvesting were simply cultured in monolayer, 
it s possible that  what these cells package into their EVs may differ 
from cells cultured in 3D spheroids. It would therefore be useful to use 
the 3D BM model to culture MSC spheroids and harvest any EVs secreted 
into the environment. The volume of EVs harvested from a 3D culture 
environment will be much lower than those harvested from cells 
cultured in monolayer, so better purification methods would need to 
be explored to achieve good EV yields. As previously reported in 
chapter 6, other methods for harvesting EVs exist besides the one used 
here. The use of polyethylene glycol to precipitate out EVs is widely 
used as it prevents high speed centrifugation potentially damaging 
delicate vesicles, but brings with it the possibility of a lower purity 
sample. 
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In addition, the EV cargo may differ if the MSCs are treated 
differently – for example cultured in a ‘diseased’ or injured  
environment. The 3D model can again be used to simulate such 
conditions; indeed it has been used previously to replicate an injury, 
by culturing in a Transwell over a scratched monolayer of osteoblasts 
or chondrocytes (mimicking tissue injury) (Lewis et al., 2016). 
Syn and colleagues (2016) studied EVs derived from tumour 
cells. These EVs were found to be pro-EMT and their contents will 
promote further growth of recipient tumour cells. Targeting the 
formation of these EVs will prevent this. The model could then be used 
to test agents that might block the formation or reception of EVs. If 
the contents can be elucidated and how the cells package them into 
EVs, methods to prevent this can be developed. 
 
7.2.iii Pharmaceutical Screening 
Research into breast cancer dormancy within the BM is 
increasing and in vivo studies are commonly performed to assess the 
effect of drugs on a more complex system. Bearing the 3Rs in mind, 
the use of mice is an expensive and time-consuming process, so the 
possibility of an in vitro model that appropriately mimics the BM would 
be invaluable. Although this model is simple, it presents the 
opportunity to be used as a drug testing platform, for example to be 
used to assess the effects of cancer drugs upon BCC growth and 
behaviour. The model successfully mimics the behaviour of BCCs in a 
3D environment and can be achieved in a 6, 12, 24 48 or 96-well plate, 
so a large number of tests can be done simultaneously. Wenzel and 
colleagues (2014) utilised 3D multicellular spheroids to test large drug 
libraries and target cell death pathways. This model could then be used 
to test drugs that might induce dormancy or affect already dormant 
cells as current chemotherapies are unable to affect these cells.  
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Incorporating more physiological conditions such as mimicking 
tissue vasculature using microfluidics may further enhance the 
functionality of the model. In addition, the addition of immune cells 
would more closely resemble the in vivo BM environment chemistry. 
New pharmaceuticals could then be assessed for their effects upon the 
dormant BCCs as one feature of these cells is their resistance to many 
current chemotherapies (Mitra et al., 2015). 
 
7.3 Limitations of the Model 
7.3.i Additional Bone Marrow Cells Types 
The in vitro model used within this study has many advantages, 
however, it is not without limitations. The simplicity of the model is 
advantageous, but is also a major limitation; the BM environment in 
vivo comprises many cell types, which are not included in this model. 
HSCs reside close to MSCs and will certainly be involved in and 
maintaining the BM microenvironment (Weber and Calvi, 2010; 
Morrison and Scadden, 2014). In addition, MSCs within the BM are able 
to differentiate into other cells types on demand. Tests done with this 
model are short term tissue culture tests and do not allow the MSCs 
enough time to differentiate further, which may be an outcome of co-
culture with BCCs. 
Cancer-associated fibroblasts are an important component of 
the tumour stroma in vivo, these cells are derived from MSCs (Lu et 
al., 2015). Immune cells are also a large factor in clearance of invading 
BCCs that enter the BM (Jiang and Shapiro, 2014). The absence of these 
also restricts the study of dormancy and how BCCs may affect the 
potential of local immune cells to remove threats from the 
environment.  
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When considering other cell types, such as those found in niche 
zones in the BM, both osteoblasts (endosteal niche) and endothelial 
(niche) cells were incorporated into the model, but the addition of 
each cell type made the triple-culture practically difficult; each cell 
type ideally requires a different culture medium so using DMEM alone 
affects division and impairs the physiological response expected from 
these additional cells. 
  
7.3.ii Modelling Disease Conditions 
The model used within this study only recreated one condition. Many 
patients who possess dormant BCCs within their BM may be  advanced 
in age. As such, it is reasonable to assume their BM environment is not 
‘healthy’ and likely to be osteoporotic. These conditions change the 
BM chemistry from that of a healthy patient. Osteoporosis is a disease 
characterised by systemic bone loss and destruction of the bone 
microstructure, causing fragility of the bone mass (Savopoulos et al., 
2011). Patients with osteoporosis have an increased risk of low-
traumatic fractures (Muschitz et al., 2015), which would lead to an 
increase in repair processes within the BM environment, affecting the 
growth of the invading BCCs. Osteoporosis is linked to a shift in MSC 
differentiation from osteoblasts towards adipocyte formation in the 
BM. This shift is caused by the activation of the proliferative activated 
receptor (PPAR) γ2 pathway, not the RUNX-2 pathway, in MSCs (Rosen 
and Bouxsein, 2006). The in vitro model could then be used to assess 
how these diseased MSCs interact with BCCs and adding in further cell 
types related with the disease state may provide more ‘physiologically 
relevant’ information on breast cancer dormancy and/or recurrence.  
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7.4 Conclusion 
This thesis has added several novel pieces of information to the 
body of research focusing on breast cancer dormancy. As previously 
discussed, there has been research into breast cancer utilising 3D 
spheroids, however, this thesis presents the first spheroids produced 
using mNPs. This method of creating 3D breast cancer spheroids is 
simple to reproduce on a larger scale. Whilst there are methods of 
producing spheroids that do not require the addition of an agent such 
as mNPs to form the 3D structures, their presence is beneficial when 
tracking them. As they possess a fluorescent tag, it removes the need 
for an additional immunohistochemical stain and live spheroids can be 
easily visualised over a given time period. This was of particular use in 
this thesis to monitor cell migration over several days.  
Additionally, how BCCs respond to their environment has been 
studied in this thesis. The main focus of the research was the 
relationship between incoming BCCs and MSCs residing in the bone 
marrow, however, the cytokine study chapter assessed how these BCCs 
can react to injury signals within their new environment. These 
cytokines associated with injury repair, in particular IL-6, are known 
to be released when tissue is damaged so that the remaining cells may 
repair any damaged areas by migrating into them and dividing, sealing 
any gaps that an injury might cause. This research indicated that 
quiescent BCCs were stimulated to move out into their environment, 
perhaps leading to further metastasis. 
Finally, MSC-derived EVs were assessed to determine their 
effect on BCCs. This is a growing area of research and the contents of 
these EVs are of particular interest as they are able to bypass any cell 
transport systems that may restrict access to the small molecules 
contained within. These MSC-derived EVs led to BCCs becoming 
quiescent; halting the cell cycle and reducing migration into their 
environment. Further research into these MSC-derived EVs would be of 
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interest to the study of dormancy; not only what is contained within 
the EVs, but how the environmental conditions might affect what small 
molecules MSCs package into them.  
The research carried out within this thesis attempted to further 
understand breast cancer dormancy and recurrence within the BM 
environment through the interactions of BCCs with MSCs using spheroid 
culture. It was generally noted that MSC and BCC paracrine signalling 
was affected by co-culture. This in turn resulted in changes in cell 
migration, with potential links to EMT instigation, and changes in cell 
cycle, with potential links to dormancy/recurrance.  
 
7.4.i Recommendations for Future Work 
• Further investigate BCC spheroids and how size might affect gene 
expression. 
• Create diseased BM model to assess the effect upon BCC spheroids. 
• Introduce immune cells into the model to assess how the presence of 
BCCs changes their behaviour. 
• Investigate cell signalling, quiescence, differentiation and migration 
when cultured for longer time points. 
• Characterise the levels of cytokines secreted into the environment 
during co-culture and attempt to identify the source, whether BCC 
or MSC.  
• Further examine the cell cycle, to determine whether RNA changes 
are observed downstream.  
• Further study the contents of MSC EVs – does treatment change the 
cargo? If so, use these different sources of MSC EVs to assess their 
effects upon BCCs.  
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